KR800000076B1 - Process for the preparation of polypeptides - Google Patents

Process for the preparation of polypeptides Download PDF

Info

Publication number
KR800000076B1
KR800000076B1 KR7500656A KR750000656A KR800000076B1 KR 800000076 B1 KR800000076 B1 KR 800000076B1 KR 7500656 A KR7500656 A KR 7500656A KR 750000656 A KR750000656 A KR 750000656A KR 800000076 B1 KR800000076 B1 KR 800000076B1
Authority
KR
South Korea
Prior art keywords
phe
arg
gly
added
tyr
Prior art date
Application number
KR7500656A
Other languages
Korean (ko)
Inventor
마사히꼬 후지노
미쓰히로 와끼마스
시게히사 다께도미
에이이찌로오 이시까와
Original Assignee
다쓰오까 스에오
다께다 야꾸힝고오교 가부시기가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다쓰오까 스에오, 다께다 야꾸힝고오교 가부시기가이샤 filed Critical 다쓰오까 스에오
Priority to KR7500656A priority Critical patent/KR800000076B1/en
Application granted granted Critical
Publication of KR800000076B1 publication Critical patent/KR800000076B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Polypeptides (I; R1 = H, basic or neutral amino acid residue ; R2 = neutral amino acid residue ; R3 = NH2, TyrNH2, tyrocylpeptide reidue having 1-5 amino acid residue, amide residue of tyrocylpeptide) were prepd. by condensation polymn. of one part of polypeptide consisted with amino acid residue, or arginine (R1 = H) with the remains of polypeptide or by isolation of protecting group of condensation products.

Description

[발명의 명칭][Name of invention]

폴리펩티드의 제조법Preparation of Polypeptides

[발명의 상세한 설명]Detailed description of the invention

본 발명은 의약품으로서 유용한 신규 폴리펩티드의 제조법에 관한 것이다.The present invention relates to the preparation of novel polypeptides useful as pharmaceuticals.

본 발명의 목적물은 다음식으로 표시된다.The object of the present invention is represented by the following formula.

Figure kpo00001
Figure kpo00001

상기 식에서,Where

R1은 수소 또는 염기성 또는 중성 아미노산잔기,R 1 is hydrogen or a basic or neutral amino acid residue,

R2는 중성 아미 노산잔기,R 2 is a neutral amino acid residue,

R3은 NH2, Tyr-NH2또는 1∼5개의 아미노산 잔기로 된 티로실펩티드 잔기 또는 티로실펩티드의 아미드 잔기를 나타낸다. 다만, 전술한 R1이 수소인 경우는, R2는 Pro를 나타낸다.R 3 represents NH 2 , Tyr-NH 2 or a tyrosyl peptide residue of 1 to 5 amino acid residues or an amide residue of a tyrosyl peptide. However, when R 1 mentioned above is hydrogen, R 2 represents Pro.

본 명세서 및 청구범위에 있어서, 아미노산, 펩티드 및 이들의 활성기와 보호기 및 활성화제, 보호기 도입화제는 생물학적 명명법으로 IUPAC-IUB 위원회에 의한 약호 또는 당해 분야에서 관용적으로 사용되고 있는 약호로 표시된다.In the present specification and claims, amino acids, peptides and their activators, protecting groups and activators, protecting group introducing agents are denoted by biological nomenclature by abbreviations by the IUPAC-IUB Commission or by conventions commonly used in the art.

이와 같은 약호를 이하에 예시한다.Such an abbreviation is illustrated below.

α-Abu : α-아미노부티르산α-Abu: α-aminobutyric acid

γ-Abu : γ-아미노부티르산γ-Abu: γ-aminobutyric acid

ε-Acap : ε-아미노카프론산ε-Acap: ε-aminocaproic acid

Ala : 알라닌Ala: Alanine

β-Ala : β-알라닌β-Ala: β-alanine

Arg : 아르기닌Arg: Arginine

δ-Aval : δ-아미노발레르산δ-Aval: δ-amino valeric acid

α,γ-Dab : a.r-디아미노부티르산α, γ-Dab: a.r-diaminobutyric acid

Gly : 글리신Gly: glycine

His : 히스티딘His: histidine

Leu : 로이신Leu: leucine

Lys : 리신Lys: Lysine

Nle : 노르로이신Nle: norleucine

Phe : 페닐알라닌Phe: Phenylalanine

Pro : 프롤린Pro: Proline

Sar : 사르코신Sar: sarcosine

Ser : 세린Ser: Serine

Thr : 트레오닌Thr: Threonine

Tyr : 티로신Tyr: tyrosine

Val : 발린Val: Valine

Aoc : t-아밀옥시카르보닐Aoc: t-amyloxycarbonyl

Bzl : 벤질에테르Bzl: Benzyl Ether

D.CC : N,N'-디사이클로헥실카르보디이미드D.CC: N, N'-dicyclohexylcarbodiimide

HONB : N-하이드록시-5-노르보르넨-2, 3-디카르복시이미드HONB: N-hydroxy-5-norbornene-2, 3-dicarboxyimide

OBzl : 벤질에스태르OBzl: Benzil Star

ODNP : 2, 4-디니트로페닐에스테르ODNP: 2, 4-dinitrophenyl ester

OEt : 에틸에스테르OEt: ethyl ester

ONB : HONB 에스테르ONB: HONB Ester

Opcp : 클로로페닐에스테르Opcp: Chlorophenyl Ester

Osu : N-하이드록시숙신이미드에스테르Osu: N-hydroxysuccinimide ester

OtBu : t-부틸에스테르OtBu: t-butyl ester

Tos : 토실Tos: Tossil

Z : 벤질옥시카르보닐Z: benzyloxycarbonyl

본 명세서 및 특허청구의 범위의 기재에 있어서, 아미노산에 대해서 광학 활성체가 있는 경우에는, 특별히 명기하지 않는한 그의 아미노산은 모두 광학 활성체 및 라세미체 각각을 의미하는 것으로 한다.In the description of the present specification and claims, when an optically active substance is present for an amino acid, all amino acids thereof mean an optically active substance and a racemate, unless otherwise specified.

구조식(Ⅰ)에 관해서, R1이수소인 경우, 기 R1-Arg는 다음과 같은 아르기닐기를 의미한다.When it comes to the following structural formula (Ⅰ), R 1 complete sweep, group R 1 -Arg; means a group ginil are as follows.

Figure kpo00002
Figure kpo00002

본 명세서 및 특허청구의 범위의 기재에 있어서, "아미노산 잔기"라는 용어는 펩티드 결합을 형성할 수 있는 기, 즉 아미노산의 아미노기 또는 이미노기의 수소 및 카르복실기의 수산기 중의 어느 하나 또는 양자가 없어진 기를 의미한다.In the description of the present specification and claims, the term "amino acid residue" means a group capable of forming a peptide bond, that is, a group in which one or both of the hydroxyl groups of hydrogen and carboxyl groups of the amino group or amino group of the amino acid and the imino group are missing. do.

R1로 표시되는 염기성 또는 중성 아미노산은 탄소수 2∼10개의 것이 바람직하다. 이와 같은 염기성 아미노산으로서는, 예를 들면 α-아미노산(예, α,-디아미노프로피온산, α,γ-디아미노부티르산, 아르기닌, 리신 또는 히스티딘)을 예시할 수 있다. R1로 표시되는 중성 아미노산으로서는 예를 들면 α-중성 아미노산(예, 글리신, 알라닌, 세린, 트레오닌, α-아미노부티르산, 프롤릴, 로이신, 이소로이신, 노르로이신, 페닐알라닌 또는 티로신) 및 그외의 중성 아미노산(예, β-알라닌, γ-아미노부티르산, δ-아미노발레르산 또는 ε-아미노카프론산)을 예시할 수 있다. R1로 표시되는 아미노산에 관하여, 광학 활성체가 있는 경우에는, 그의 아미노산은 모두 광학 활성체 및 라세미체 각각을 나타낸다. R1에 상당하는 아미노산 중에서, β-알라닌이 소정의 용도에 바람직하다.The basic or neutral amino acid represented by R 1 is preferably 2 to 10 carbon atoms. As such a basic amino acid, (alpha)-amino acid (for example, (alpha),-diamino propionic acid, (alpha), (gamma)-diaminobutyric acid, arginine, lysine, or histidine) can be illustrated, for example. Neutral amino acids represented by R 1 include, for example, α-neutral amino acids (e.g., glycine, alanine, serine, threonine, α-aminobutyric acid, prolyl, leucine, isoleucine, norleucine, phenylalanine or tyrosine) and other neutrals. Amino acids (eg, β-alanine, γ-aminobutyric acid, δ-aminovaleric acid or ε-aminocaproic acid) can be exemplified. With respect to the amino acid represented by R 1 , when there is an optically active substance, all of the amino acids respectively represent the optically active substance and the racemate. Among the amino acids corresponding to R 1 , β-alanine is preferred for certain applications.

R2로 표시되는 중성 아미노산은, 탄소수 2∼10개의 것이 바람직 한데, 예를 들면 글리신, 알라닌, β-알라닌, 사르코신, 세린, 프롤린, 발린, 로이신, 이소로이신, 페닐알라닌 또는 티로신을 예시할 수 있다. R2에 상당하는 아미노산 중에서, 글리신 및 프롤린이 소정의 용도에 바람직하다.The neutral amino acid represented by R 2 preferably has 2 to 10 carbon atoms, for example, glycine, alanine, β-alanine, sarcosine, serine, proline, valine, leucine, isoleucine, phenylalanine or tyrosine. have. Among the amino acids corresponding to R 2 , glycine and proline are preferred for certain applications.

R2가 프롤린 잔기의 경우, 소정의 용도는 R1이 수소일 때에도 달성된다.In the case where R 2 is a proline residue, certain uses are achieved even when R 1 is hydrogen.

R3로 표시되는 티로실펩티드 또는 그의 아미드를 구성할 수 있는 각각의 아미노산은 탄소수 2-10개인 것이 바람직하며, 예를 면들 글리신, 알라닌, 세린, 트레오닌, 발린, 프롤린, 로이신, 이소로이신, 리신, 페닐알라닌 또는 티로신을 예시할 수 있다. 이들의 아미노산은 임의의 순서로 결합하여 1-5개의 아미노산 잔기로 된 티로실펩티드 또는 그의 아미드를 구성한다. 이하에 티로실펩티드를 예시한다. 이들의 아미드는 티로실펩티드 아미드로서 예시된다.Each amino acid capable of constituting the tyrosyl peptide represented by R 3 or an amide thereof is preferably 2-10 carbon atoms, for example, glycine, alanine, serine, threonine, valine, proline, leucine, isoleucine, lysine , Phenylalanine or tyrosine can be exemplified. These amino acids combine in any order to form tyrosyl peptides or amides of 1-5 amino acid residues. A tyrosyl peptide is illustrated below. Their amides are exemplified as tyrosyl peptide amides.

Figure kpo00003
Figure kpo00003

폴리펩티드(Ⅰ)을 구성할 수 있는 R1이외의 잔기의 모든 아미노산에 관하여 광학활성체가 얻어지는 경우에는, 이들의 아미노산은 모두 광학 활성체 및 라세미체 각각을 의미하지만, L체가 저독성이기 때문에 바람직하다.When the obtained body is optically active with respect to all the amino acid residues other than R 1, which can configure the polypeptide (Ⅰ) is, these amino acids are all preferable because it means that each optically active substance and racemate, but, L body of low toxicity .

본 발명의 폴리펩티드(Ⅰ)은, R1에 해당하는 아미노산 또는 R1이 수소인 아르기닌, 또는 N-말단 아미노산으로서 아미노산잔기 R1또는 R1이 수소인 아르기 닐기를 갖는 폴리펩티드(Ⅰ)을 형성하는 펩티드 구성 성분의 일부를, 폴리펩티드(Ⅰ)의 잔여부분과 펩티드 축합시킴으로써 제조된다. 펩티드 축합시키는 2종의 원료는, 그의 아미노기, 카르복실기 중 소정의 축합반응에 관여하지 않는 기는 적당히 보호해도 좋고, 또 소정의 축합반응에 관여하는 기는 적당히 활성화시켜도 좋다. 따라서, 축합 생성물이 보호기를 갖는 경우에는 그 보호기를 적절히 제거시킨다.Polypeptide (Ⅰ) of the present invention, to form a polypeptide (Ⅰ) the amino acid or the R 1 corresponding to R 1 which is hydrogen-arginine, or as an N- terminal amino acid of amino acid residues R 1 or R 1 is a hydrogen group are carbonyl groups A part of the peptide component to be prepared is prepared by peptide condensation with the rest of the polypeptide (I). The two kinds of raw materials for peptide condensation may be appropriately protected from the amino group and the carboxyl group that do not participate in the predetermined condensation reaction, and the group involved in the predetermined condensation reaction may be appropriately activated. Therefore, when the condensation product has a protecting group, the protecting group is appropriately removed.

본 발명의 축합반응은 펩티드 결합을 형성할 수 있는 통상법에 따라서 실시할 수 있다.The condensation reaction of the present invention can be carried out according to a conventional method capable of forming a peptide bond.

본 발명의 축합반응은 폴리펩티드(Ⅰ)의 임의의 위치에서 행할 수가 있다. R2에 상당하는 3번째의 아미노산과 4번째의 페닐알라닌과의 사이에서 본 발명의 축합반응을 행하면 공업적으로 유리하게 폴리펩티드(Ⅰ)을 제조할 수 있다.The condensation reaction of the present invention can be carried out at any position of the polypeptide (I). When the condensation reaction of the present invention is carried out between the third amino acid and the fourth phenylalanine corresponding to R 2 , the polypeptide (I) can be produced industrially advantageously.

공지의 폴리펩티드와 동일하게 본 발명의 폴리펩티드(Ⅰ)은 이것을 구성할 수 있는 각각의 아미노산을 그의 아미노산 배열에 따라서 순차적으로 축합시킴으로써 제조된다. 통상, 그의 최종 축합 공정은, 2종의 구성 성분, 즉 펩티드와 말단 아미노산 또는 2종의 펩티드의 사이에서 행해진다. 이들 2종의 구성 성분은 본 발명의 폴리펩티드(Ⅰ)를 제조하는 원료이다. 이들의 원료 또는 최종 중간체는 그 자체공지의 펩티드 합성 수단에 의해 제조된다.Similarly to known polypeptides, the polypeptide (I) of the present invention is prepared by sequentially condensing each of the amino acids that can constitute it according to its amino acid sequence. Usually, the final condensation step is performed between two constituents, namely, a peptide and a terminal amino acid or two peptides. These two components are raw materials for producing the polypeptide (I) of the present invention. Their raw materials or final intermediates are prepared by known peptide synthesis means.

본 발명에 사용할 수 있는 원료중의 일예, 예를 들면 폴리펩티드(Ⅰ)의 N-말단 아미노산, 또는 그의 N-말단아미노산에 폴리펩티드(Ⅰ)을 구성하는 아미 노산의 각각이 그의 아미노산 배열에 따라서 순차적으로 결합한 것을 예시할 수 있다. 여기에 대응하는 다른 원료는 상기 원료를 제외한 폴리펩티드(Ⅰ)의 잔여 부분이다. 이와 같은 원료의 기본적 조합에는 다음표에 계재한다.One of the raw materials which can be used for this invention, for example, the N-terminal amino acid of polypeptide (I), or each of the amino acids which comprise polypeptide (I) in the N-terminal amino acid thereof is sequentially according to the amino acid sequence. The combined thing can be illustrated. Another raw material corresponding thereto is the remainder of the polypeptide (I) except the above raw material. The basic combination of such raw materials is listed in the following table.

[표 1]TABLE 1

Figure kpo00004
Figure kpo00004

본 발명에 있어서 축합반응은 펩티드 결합형성을 위하여 사용할 수 있는 공지의 축합방법에 의해 실시될 수 있다. 이와 같은 축합방법으로서는, DCC/HONB법(벨기에 특히 제763.399호), 아지드법, 클로라이드법, 산무수물법, 혼합산 무수물법, DCC법 활성 에스테르법, 우드위어드(Woodward)시약 K를 사용하는 방법, 카르보디이미다졸법, 산화환원법 ["The peptides". Vol.1(1966), Sch

Figure kpo00005
rder and Lubke, Academic press, New 4York, U.S.A.]을 들 수가 있다.In the present invention, the condensation reaction can be carried out by a known condensation method that can be used for peptide bond formation. As the condensation method, DCC / HONB method (especially in Belgium 763.399), azide method, chloride method, acid anhydride method, mixed acid anhydride method, DCC method active ester method, Woodward reagent K is used. Carbodiimidazole method, redox method ["The peptides"). Vol. 1 (1966), Sch
Figure kpo00005
rder and Lubke, Academic press, New 4York, USA.

축합반응 전에, 공지 방법에 의해, 소정의 축합반응에 관여하지 않을 카르복실기 또는 아미노기를 보호해도 좋으며, 또는 소정의 축합반응에 관여할 카르복실기 또는(및) 아미노기를 활성화시켜도 좋다. 소정의 축합반응에 관여하지 않는 카르복실기는 금속염(예, 나트륨, 칼륨염) 또는 에스테르(예, 메틸, 에틸, 벤질, p-니트로벤질, t-부틸 또는 t-아밀 등의 에스테르)의 형으로 보호해도 좋다.Prior to the condensation reaction, a known method may protect the carboxyl group or amino group which will not be involved in the predetermined condensation reaction, or may activate the carboxyl group or (and) amino group which will be involved in the predetermined condensation reaction. Carboxyl groups not involved in certain condensation reactions are protected in the form of metal salts (eg sodium, potassium salts) or esters (eg esters such as methyl, ethyl, benzyl, p-nitrobenzyl, t-butyl or t-amyl) You may also

원료의 아미노기의 보호기로서는 공지의 펩티드 합성에 있어서, 아미노 보호기가 사용되는데, 예를들면 벤질옥시 카르보닐, t-부톡시카르보닐, t-아밀옥시카르보닐, 이소보르닐옥시카르보닐 등을 들 수가 있다. 이들의 보호기는 프롤린의 이미노기의 보호에도 사용할 수 있다. 히스티딘의 이미다졸 관능기는 공지의 보호기, 예를 들면 벤질, 토실, 2,4-디니트로페놀, t-부톡시카르보닐, 또는 카르보벤족시 등으로 보호해도 좋다. 세린, 티로신 또는 트레오닌의 수산기는 공지의보호기, 예를 들면 벤질, t-부틸 등의 에테르 형으로 보호해도 좋다. 아르기닌의 구아니디노기는 예를 들면 니트로, 토신, 카르보벤족시, 이소보르닐옥시카르보닐 또는 아다만틸옥시카르보닐기로 보호해도 좋다. 원료의 활성화된 카르복실기의 예로서, 대응하는 산무수물, 아지드, 활성 에스테르(예를들면, 펜타클로로페닐, 2,4,5-트리클로로페닐, 2,4-디니트로페닐, 시아노메틸알코올, p-니트로페놀, N-하이드록시-5-노르보넨 -2,3-디카르복시이미드, N-하이드록시숙신이미드 N-하이드록시프탈이미드 또는 N-하이드록시벤즈트리아졸 등의 알코올과의 에스테르)등을 들 수 있다. 원료의 활성화된 아미노기로서, 예를 들면 대응하는 인산아미드를 들수 있다.As a protecting group of the raw amino group, an amino protecting group is used in known peptide synthesis. Examples thereof include benzyloxy carbonyl, t-butoxycarbonyl, t-amyloxycarbonyl, isobornyloxycarbonyl, and the like. There is a number. These protecting groups can also be used for protecting the imino group of proline. The imidazole functional group of histidine may be protected with a known protecting group, for example benzyl, tosyl, 2,4-dinitrophenol, t-butoxycarbonyl, or carbobenzox. The hydroxyl group of serine, tyrosine or threonine may be protected by a known protecting group, for example, ether type such as benzyl and t-butyl. The guanidino group of arginine may be protected with, for example, a nitro, toxin, carbobenzoxyl, isobornyloxycarbonyl or adamantyloxycarbonyl group. Examples of activated carboxyl groups of the raw materials include the corresponding acid anhydrides, azides, active esters (eg pentachlorophenyl, 2,4,5-trichlorophenyl, 2,4-dinitrophenyl, cyanomethyl alcohol and alcohols such as p-nitrophenol, N-hydroxy-5-norbornene-2,3-dicarboxyimide, N-hydroxysuccinimide N-hydroxyphthalimide or N-hydroxybenztriazole Esters). As an activated amino group of a raw material, the corresponding phosphate amide is mentioned, for example.

2종의 원료 A 및 원료 B의 카르복실 및 아미노기의 상기와 같은 상태의 조합예를 다음 표에 게재한다The combination example of the above state of the carboxyl and amino group of two raw materials A and the raw material B is shown in the following table.

[표 2]TABLE 2

Figure kpo00006
Figure kpo00006

주 :*의 경우, 반응계에 탈수제(예, 디사이클로헥실-카르보디이미드와 같은 카르보디이미드 시약)를 존재시키는 것이 바람직하다.Note: In the case of * , it is preferred to have a dehydrating agent (eg a carbodiimide reagent such as dicyclohexyl-carbodiimide) in the reaction system.

본 반응은 용메의 존재하에 행할 수 있다. 용메로서는, 펩티드 축합반응에 사용할 수 있는 것으로 알려진 것들로 부터 적당하게 선택될 수 있다. 예를 들면, 무수 또는 함수디메틸포름아미드, 디메틸술폭사이드, 피리딘, 클로로포름, 디옥산, 디클로로메탄, 테트라하이드로푸란 또는 이들의 적당한 혼합물 등을 들수 있다.This reaction can be carried out in the presence of a solvent. The solvent may be appropriately selected from those known to be used for the peptide condensation reaction. For example, anhydrous or hydrous dimethylformamide, dimethyl sulfoxide, pyridine, chloroform, dioxane, dichloromethane, tetrahydrofuran or a suitable mixture thereof can be mentioned.

반응 온도는, 펩티드 결합 형성반응에 사용될 수 있는 것으로 알려져 있는 범위로부터 적당하게 선택되며, 통상 약 -20℃∼약 30℃의 범위에서 적당하게 선택된다. 또, 본 발명 화합물의 전구물질 : 보호 펩티드)은 고상 합성법에 의해서도 용이하게 제조할 수 있다.The reaction temperature is appropriately selected from the ranges known to be used for the peptide bond formation reaction, and is usually appropriately selected in the range of about -20 ° C to about 30 ° C. In addition, the precursor of the compound of the present invention: a protective peptide) can be easily produced by solid phase synthesis.

본 축합반응 종료 후, 생성물이 보호기를 갖고 있는 경우, 이것은 통상법에 의해 이탈시킬 수 있다. 이러한 상법으로서는 예를 들면 팔라듐블랙, 팔라듐-탄소, 백금 등을 촉매로서 사용하는 접촉환원, 불화수소, 트리플루오로초산 등에 의한 가수분해, 액체암모니아 중에서의 금속 나트륨에 의한 환원 등을 사용할 수 있다.After the completion of the condensation reaction, when the product has a protecting group, it can be separated by a conventional method. As such a conventional method, for example, catalytic reduction using palladium black, palladium-carbon, platinum, or the like as a catalyst, hydrolysis by hydrogen fluoride, trifluoroacetic acid or the like, reduction by metal sodium in liquid ammonia, or the like can be used.

이와 같이하여 제조된 폴리펩티드(Ⅰ)은 반응 종료 후 혼합물로부터 펩티드의 분리수단, 예를 들면, 추출, 분배컬럼크로마토그라피 등에 의해 회수할 수 있다.The polypeptide (I) thus prepared can be recovered by means of separation of the peptide from the mixture after the reaction is completed, for example, extraction, chromatography, chromatography and the like.

폴리펩티드(Ⅰ)는 염 또는 금속 착화합물로서도 회수할 수 있다.Polypeptide (I) can also be recovered as a salt or a metal complex.

폴리펩티드(Ⅰ)의 염을 형성할 수 있는 산으로서는, 예를들면 염산, 취화수소산, 과염소산, 초산, 티오시안산, 황산, 인산 등의 무기산, 또는 예를 들면 의산, 초산, 프로피온산, 글리콜산, 젖산, 피루빈산, 옥살산, 말론산, 구연산, 호박산, 말레인산, 푸마르산, 안트라닐산, 신남산, 나프탈렌술폰산, 술파닐산등의 유기산 등을 들 수 있다.As the acid capable of forming a salt of the polypeptide (I), for example, inorganic acids such as hydrochloric acid, hydrochloric acid, perchloric acid, acetic acid, thiocyanic acid, sulfuric acid, phosphoric acid, or for example, acid, acetic acid, propionic acid, glycolic acid, Organic acids such as lactic acid, pyruvic acid, oxalic acid, malonic acid, citric acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalenesulfonic acid, sulfanilic acid, and the like.

폴리펩티드(Ⅰ)의 금속 착화합물을 형성할 수 있는 금속으로서는, 예를 들면 아연, 니켈, 코발트, 구리철 등을 들 수 있다. 이와 같은 금속 착화합물은 공지의 수단, 예를 들면 폴리펩티드(Ⅰ)을 상기 금속의 수산화물 또는 산화물과 pH 약 6∼8로 반응시킴으로써 제조될 수 있다.As a metal which can form the metal complex compound of polypeptide (I), zinc, nickel, cobalt, copper iron, etc. are mentioned, for example. Such metal complexes can be prepared by known means, for example by reacting polypeptide (I) with a hydroxide or oxide of the metal at a pH of about 6-8.

본 발명의 폴리펩티드(Ⅰ)은 비구경 뿐만 아니라 경구 투여에 의해서도 혈중 및 뇨증의 고농도의 당(글루코오스)을 정상치까지 저하시키는 작용을 갖는다. 폴리펩티드(Ⅰ)은 혈중 또는 뇨중의 당량(糖量)이 정상치의 경우에는, 그 이하로 저하시키지 않는 예상 외의 특유한 작용을 가지며, 이 작용은 저혈당을 야기하는 인슐린에 비하여 현저히 우수한 성상이다. 폴리펩티드(Ⅰ)은 저독성으로 안전하게 투여 된다. 폴리펩티드(Ⅰ)은 지방대사를 촉진하는 작용도 갖는다. 전술한 바와 같은 특유의 작용을 가지므로, 폴리펩티드(Ⅰ)은 사람 혹은 그 외의 동물(예, 쥐 또는 새앙쥐)의 당대사부전증 혹은 지방대사부전증의 치료, 특히 당뇨병 또는 하이퍼 콜레스테린 혈증(hypercholestemia)의 치료에 부작용을 일으키지 않고 유효하게 투여된다. 폴리펩티드(Ⅰ)은 그 자체만으로 투여해도 좋으며, 또는 통상법으로 제조되는 제형(예, 정제, 펠릿트, 과립, 산제, 액제, 주사제)으로서 투여해도 좋다.Polypeptide (I) of the present invention has the effect of lowering high concentrations of glucose (glucose) in blood and urinary tract to normal levels not only by parenteral but also by oral administration. Polypeptide (I) has an unexpected and distinctive action that does not lower the blood or urine equivalent to normal levels, and this action is remarkably superior to insulin causing hypoglycemia. Polypeptide (I) is safely administered with low toxicity. Polypeptide (I) also has an action of promoting fat metabolism. Due to the peculiar action as described above, polypeptide (I) is used for the treatment of glucose metabolism or fat metabolism in humans or other animals (eg rats or birds), in particular in the treatment of diabetes mellitus or hypercholesteremia. It is administered effectively without causing side effects. Polypeptide (I) may be administered by itself, or may be administered as a formulation (e.g., tablet, pellet, granule, powder, liquid, injection) prepared by a conventional method.

각 제형의 처방예는 다음에 열거한다.Prescription examples of each formulation are listed below.

주사제Injection

Figure kpo00007
Figure kpo00007

산제Powder

Figure kpo00008
Figure kpo00008

폴리펩티드(Ⅰ)의 1일 투여량은 병의 종류. 증상, 대상동물의 연령 등에 의해 변화되지만, 통상 약 체중 1kg당 50㎍∼약 100㎎의 범위로부터 적당히 선택된다.The daily dose of polypeptide (I) is the type of disease. Although it changes with a symptom, the age of a target animal, etc., it normally selects suitably from the range of 50 micrograms-about 100 mg per kilogram of body weight.

폴리펩티드(Ⅰ)에 의한 당뇨병 치료 효과의 약리실험 인공당뇨병 새앙쥐(KKAy즉 황색 KK 새앙쥐. 8주령, 스컷)를 1마리 씩 금속제 케이지에 넣고 뇨(urine)를 채취한다.Pharmacological Experiment of Diabetes Treatment Effect by Polypeptide (I) Artificial diabetic rats (KKA y, yellow KK rats, 8 weeks old, cut) are placed in metal cages one by one and urine is collected.

3 그룹의 새앙쥐에 식(β-Ala-L-Arg-Gly-L-Phe-L-Phe-L-Tyr-NH2(화합물A)의 폴리펩티드 (Ⅰ)을 3종류의 양(1.10 및 100㎎/㎏/일)으로 경구 투여한다. 처리법은 표 3에 기재한 것과 같다. 대조군에는 생리식염수를 투여한다. 4일마다 혈당 및 뇨당을 글루코오스산화법[Huggett, A.St.G. and Nixon, D.A.,"Lamcet" Volume Ⅱ. 368∼370페이지(1957)]에 의해 측정했다.Three groups of polypeptides (I) of formula (β-Ala-L-Arg-Gly-L-Phe-L-Phe-L-Tyr-NH 2 (Compound A) were used in three different amounts (1.10 and 100 mg). / Kg / day) The treatment is as described in Table 3. The control group is administered with saline, and blood glucose and urine glucose are treated every four days (Huggett, A. St. G. and Nixon, DA). , "Lamcet" Volume II. 368 to 370 pages (1957)].

그 결과를 표 3에 나타낸다. 대조군에 있어서는, 혈당 및 뇨당은 24시간 후에 대단히 높아진다. 이것과 대조적으로 폴리펩티드 투여군으로는 혈당 및 뇨당은 점차로 저하한다. 그리하여, 항당뇨병 효과에 있어서 약품 의존성이 관찰된다. 투여 후의 단계로, 혈당 및 뇨당치가 함께 3군의 처지군으로 증대하고 있지만 투여후에 있어서도 항당뇨병 효과의 지속성에 있어서 약품 의존성이 인지된다.The results are shown in Table 3. In the control group, blood glucose and urine glucose are very high after 24 hours. In contrast, blood glucose and urine glucose are gradually decreased in the polypeptide-administered group. Thus, drug dependence is observed in the antidiabetic effect. At the post-administration stage, blood glucose and urine glucose levels are increased to the three groups, but drug dependence is recognized in the persistence of the antidiabetic effect even after administration.

상기 발견으로부터, 폴리펩티드는 새앙쥐의 당뇨병을 치료할 수 있는 결론을 내릴 수 있다.From the findings, the polypeptide can be concluded to be able to treat diabetic rats.

Figure kpo00009
Figure kpo00009

[표 3]TABLE 3

Figure kpo00010
Figure kpo00010

Figure kpo00011
Figure kpo00011

[실시예 1]Example 1

Arg-Pro-Phe-Phe-Tyr-NH2의 제조.Preparation of Arg-Pro-Phe-Phe-Tyr-NH 2 .

a) Z-Arg(NO2)-Pro-Phe-Phe-Tyr-NH2의 제조.a) Preparation of Z-Arg (NO 2 ) -Pro-Phe-Phe-Tyr-NH 2 .

DMF (디메틸포름아미드) 50㎖에 Z-Phe-Phe-Tyr-NH210.0g을 용해시키고 Pd 블랙을 촉매로 여하 10시간 동안접촉환원을 행하였다. 촉매를 여거하여 여액을 빙냉하고 Z-Arg(NO2)-Pro-OH 7.37g과 HONB 3.53g을 첨가했다.10.0 g of Z-Phe-Phe-Tyr-NH 2 was dissolved in 50 ml of DMF (dimethylformamide), and catalytic reduction was performed for 10 hours with Pd black as a catalyst. The catalyst was filtered off, and the filtrate was ice-cooled, and 7.37 g of Z-Arg (NO 2 ) -Pro-OH and 3.53 g of HONB were added.

또한, DCC4.60g을 첨가한 다음에 이 혼합물을 16시간 동안 교반했다. 형성된 DC(디사이클로헥실)우레아를 여거하고 DMF를 감압하에서 유거했다. 잔사물에 초산에틸 200㎖를 가하여 생성되는 분말을 여과하여 수집하였다. 이 분말을 DMF-메타놀-물로부터 재침전시켜 정제했다. 수량 14.5g(95.6)Also, after adding 4.60 g of DCC, the mixture was stirred for 16 hours. The formed DC (dicyclohexyl) urea was filtered off and the DMF was distilled off under reduced pressure. 200 ml of ethyl acetate was added to the residue, and the resulting powder was collected by filtration. This powder was purified by reprecipitation from DMF-Methanol-water. Quantity 14.5 g (95.6)

Figure kpo00012
Figure kpo00012

Figure kpo00013
Figure kpo00013

초산 30㎖에 Z-Arg(NO2)-Pro-Phe-Phe-Tyr-NH2500㎎을 용해시키고 Pd-블랙을 촉매로 하여 20시간동안 촉매환원을 행한다.500 mg of Z-Arg (NO 2 ) -Pro-Phe-Phe-Tyr-NH 2 was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 20 hours using Pd-black as a catalyst.

촉매를 여거하여 여액을 감압하에서 건고시키고 잔사를 물 50㎖에 용해시켜서, 소량의 불용물을 여거한후 여액을 동결건조한다. 생성물을 물 5㎖에 용해시키고, 이 용액을 카르복시메틸-세파덱스의 컬럼(1.8×9㎝)에 사용하여 0.1M 초산암모늄 수용액(400㎖)과 1M 초산암모늄 수용액(400㎖)으로 경사용리법(gradient elution)을 행하였다. 250∼370㎖의 용출분류물을 모아 동결건조하여 백색우모상 물질 (whitef luffy product) 250㎎(52.3%)을 얻었다.

Figure kpo00014
The catalyst is filtered off and the filtrate is dried under reduced pressure, and the residue is dissolved in 50 ml of water. After a small amount of insolubles are filtered off, the filtrate is lyophilized. The product was dissolved in 5 ml of water, and this solution was used for a column of carboxymethyl-sepadex (1.8 × 9 cm) in a gradient elution with 0.1 M aqueous ammonium acetate solution (400 ml) and 1 M aqueous ammonium acetate solution (400 ml). (gradient elution) was performed. 250-370 mL of the eluate was collected and lyophilized to give 250 mg (52.3%) of whitef luffy product.
Figure kpo00014

Figure kpo00015
Figure kpo00015

[실시예 2]Example 2

Gly-Arg-Pro-Phe-Phe-Tyr-NH2의 제조.Preparation of Gly-Arg-Pro-Phe-Phe-Tyr-NH 2 .

a) Z-Gly-Arg-Pro-Phe-Phe-Tyr-NH2의 제조.a) Preparation of Z-Gly-Arg-Pro-Phe-Phe-Tyr-NH 2 .

초산 30㎖에 Z-Arg(NO2)-Pro-Phe-Phe-Tyr-NH2800㎎을 용해시키고 Pd 블랙을 촉매로 하여 8시간 동안 접촉환원을 행한다. 촉매를 여거하고, 이 여액을 감압하에서 건고한다. 잔사를 물 ㎖에 용해시키고 동결 건조한다.800 mg of Z-Arg (NO 2 ) -Pro-Phe-Phe-Tyr-NH 2 was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 8 hours using Pd black as a catalyst. The catalyst is filtered off and the filtrate is dried under reduced pressure. The residue is dissolved in ml of water and freeze dried.

생성되는 분말을 DMF 10㎖에 용해시키고 여기에 p-톨루엔술폰산모노하이드레이트 147㎎을 가했다. 이 혼합물에 A-Gly-ONB 349㎎을 첨가한 뒤 10시간 동안 교반했다. DMF를 감압하에서 유거하고 초산에틸 50㎖를 첨가하였다. 생성되는 분말을 여과하여 수집했다. 수량 858㎎ (89.5%)The resulting powder was dissolved in 10 ml of DMF, and 147 mg of p-toluenesulfonic acid monohydrate was added thereto. 349 mg of A-Gly-ONB was added to the mixture, followed by stirring for 10 hours. DMF was distilled off under reduced pressure and 50 ml of ethyl acetate was added. The resulting powder was collected by filtration. Yield 858mg (89.5%)

Figure kpo00016
Figure kpo00016

b) Gly-Arg-Pro-Phe-Phe-Tyr-NH2의 제조.b) Preparation of Gly-Arg-Pro-Phe-Phe-Tyr-NH 2 .

초산 30㎖에 Z-Gly-Argo-Phe-Tyr-NH2의 p-톨루엔술포네이트 500㎎을 용해시키고 Pd 블랙을 촉매로 하여 5시간 동안 촉매환원을 행하였다. 이 촉매를 여거하고 용매를 감압하에서 유거하였다. 잔사를 물 20㎖에 용해시키고 이 용액을 암벌라이트(Amberlite) IRA 410 (초산형) (미국 톰 앤드하아즈회사의 강염기성 음이온 교환수지)의 컬럼으로 이온 교환크로마토그라피를 행했다. 용출물을 동결건조하여 생성되는 분말을 물 5㎖에 용해시켰다. 이 용액을 카르복시메틸셀룰로오즈의 컬럼(2.6×23㎝)에 통과시키고 0.005M∼0.2M 초산암모늄 수용액(각 700㎖)을 사용하여 경사법에 의해 용출을 행했다. 840∼970㎖의 획분을 모아서 동결건조했다. 수량 270㎎(63.6%),

Figure kpo00017
500 mg of p-toluenesulfonate of Z-Gly-Argo-Phe-Tyr-NH 2 was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 5 hours using Pd black as a catalyst. This catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was dissolved in 20 ml of water and the solution was subjected to ion exchange chromatography on a column of Amberlite IRA 410 (acetic acid type) (strong base anion exchange resin from Tom & Haaz Corporation, USA). The eluate was lyophilized to dissolve the resulting powder in 5 ml of water. This solution was passed through a column of carboxymethyl cellulose (2.6 x 23 cm) and eluted by a decanting method using 0.005 M to 0.2 M ammonium acetate aqueous solution (700 ml each). 840-970 ml of fractions were collected and lyophilized. Yield 270 mg (63.6%),
Figure kpo00017

Figure kpo00018
Figure kpo00018

[실시예 3]Example 3

γ-Abu-Arg-Pro-Phe-Phe-Tyr-NH2의 제조.Preparation of γ-Abu-Arg-Pro-Phe-Phe-Tyr-NH 2 .

Z-Gly-ONB 대신에 Z-γ-Abu-ONB를 사용하여 실시예 2의 방법을 행하여 상기의 목적물 324㎎을 얻었다.

Figure kpo00019
The target object 324 mg was obtained by performing the method of Example 2 using Z-γ-Abu-ONB instead of Z-Gly-ONB.
Figure kpo00019

Figure kpo00020
Figure kpo00020

[실시예 4]Example 4

ε-Acap-Arg-Pro-Phe-Phe-Tyr-NH2의 제조.Preparation of ε-Acap-Arg-Pro-Phe-Phe-Tyr-NH 2 .

a) Z-ε-Acap-Arg-Pro-Phe-Phe-Tyr-NH2의 제조.a) Preparation of Z-ε-Acap-Arg-Pro-Phe-Phe-Tyr-NH 2 .

DMF 10㎖에 빙냉하에 Z-ε-Acap-OH 250㎎을 용해시키고, 여기에 HONB186㎎ 및 DCC214㎎을 첨가했다. 이 혼합물을 16시간 동안 교반하고 형성된 DC-우레아를 여거했다. 이 여액을 실시예 2一a)에 기재한 것과 동일한 방법으로 제조된 H-Arg- Pro-Phe-Phe-Tyr-NH2의 p-톨루엔술포네이트의 DMF 용액에 첨가했다. 이 혼합물을 12시간 동안 교반하고 DMF를 감압하에서 유거했다. 잔사에 초산에 틸 30㎖를 첨가하여 생성되는 분말을 여과수집하였다. 수량 810㎎(79.1%). 융점 (90∼92℃).250 mg of Z-ε-Acap-OH was dissolved in 10 ml of DMF under ice-cooling, and HONB186 mg and DCC214 mg were added thereto. The mixture was stirred for 16 hours and the DC-urea formed was filtered off. This filtrate was added to a DMF solution of p-toluenesulfonate of H-Arg-Pro-Phe-Phe-Tyr-NH 2 prepared in the same manner as described in Example 2a). The mixture was stirred for 12 hours and the DMF was distilled off under reduced pressure. 30 ml of ethyl acetate was added to the residue, and the resulting powder was collected by filtration. Yield 810 mg (79.1%). Melting point (90-92 캜).

Figure kpo00021
Figure kpo00021

b) ε-Acap-Arg-Pro-Phe-Phe-Tyr-NH2의 제조.b) Preparation of ε-Acap-Arg-Pro-Phe-Phe-Tyr-NH 2 .

a) 에서 제조한 Z-유도체 500㎎을 실시예 2-b)와 동일한 방법으로 처리하여 상기의 목적물 316㎎을 수득했다.

Figure kpo00022
500 mg of the Z-derivative prepared in a) was treated in the same manner as in Example 2-b) to obtain 316 mg of the target compound.
Figure kpo00022

아미노산분석 : Arg,1.02; Pro,1.03Tyr,0.9;h.13; ε-Acap(측정불능) (펩티드함량 : 81.5%)Amino acid analysis: Arg, 1.02; Pro, 1.03 Tyr, 0.9; h. 13; ε-Acap (Measured) (peptide content: 81.5%)

[실시예 5]Example 5

Lys-Arg-Pro-Phe-Phe-Tyr-NH2의 제조.Preparation of Lys-Arg-Pro-Phe-Phe-Tyr-NH 2 .

a) di-Z-Lys-Arg-Pro-Phe-Phe-Tyr-NH2의 제조.a) Preparation of di-Z-Lys-Arg-Pro-Phe-Phe-Tyr-NH 2 .

Z-ε-Acap-OH 대신에 di-Z-Lys-OH 390㎎을 사용하고 실시예 4-a) 방법을 행하여 상기 목적물 932㎎을 수득했다. 융점 103~105℃

Figure kpo00023
390 mg of di-Z-Lys-OH was used instead of Z-ε-Acap-OH and Example 4-a) was carried out to obtain 932 mg of the target substance. Melting Point 103 ~ 105 ℃
Figure kpo00023

Figure kpo00024
Figure kpo00024

b) Lys-Arg-Pro-Phe-Phe-Tyr-NH2의 제조.b) Preparation of Lys-Arg-Pro-Phe-Phe-Tyr-NH 2 .

a)에서 제조한 di-Z-유도체 500㎎을 실시예 2-b)와 동일한 방법으로 처리하여 상기 목적물 336㎎을 수득했다.

Figure kpo00025
500 mg of the di-Z-derivative prepared in a) was treated in the same manner as in Example 2-b) to obtain 336 mg of the target compound.
Figure kpo00025

아미노산 분석 : Lys, 1.02; Arg, 0.98; Pro, 1.00; Tyr, 0.94; Phe, 2.04 (펩티드 함량 : 91%)Amino acid analysis: Lys, 1.02; Arg, 0.98; Pro, 1.00; Tyr, 0.94; Phe, 2.04 (peptide content: 91%)

[실시예 6]Example 6

α,γ-Cab-Arg-Pro-Phe-Phe-Tyr-NH2의 제조.Preparation of α, γ-Cab-Arg-Pro-Phe-Phe-Tyr-NH 2 .

실시예 4 및 5의 방법과 정확히 동일하게 하여, 상기 목적물을 di-Z-α,γ-Dab-디사이클로헥실아민염 535㎎을 합성했다. 수량 325㎎.In exactly the same manner as in Examples 4 and 5, 535 mg of di-Z-α, γ-Dab-dicyclohexylamine salt was synthesized as the target product. Yield 325 mg.

Figure kpo00026
Figure kpo00026

아미노산 분석; α,γ-Dab, 1.00; Arg, 0.98; Pro,1.00; Tyr, 0.87; Phe, 1.96 (펩티드 함량 : 84.2%)Amino acid analysis; α, γ-Dab, 1.00; Arg, 0.98; Pro, 1.00; Tyr, 0.87; Phe, 1.96 (peptide content: 84.2%)

[실시예 7]Example 7

β-Ala-Arg-Pro-Phe-Tyr-NH2의 제조.Preparation of β-Ala-Arg-Pro-Phe-Tyr-NH 2 .

a) Z-β-Ala-Arg(NO2)-Pro-OMe의 제조.a) Preparation of Z-β-Ala-Arg (NO 2 ) -Pro-OMe.

Z-Arg(NO2)-Pro-OMe 3.50g에 25% HBr-초산 35㎖를 첨가하고 이 혼합물을 실온에서 35분간진탕 시켰다. 이 혼합물에 에틸에테르 300㎖를 첨가하여 생성되는 침전물을 여과수집하여 에테르로 세척하여 건조시켰다.To 3.50 g of Z-Arg (NO 2 ) -Pro-OMe, 35 ml of 25% HBr-acetic acid was added and the mixture was shaken for 35 minutes at room temperature. 300 ml of ethyl ether was added to the mixture, and the resulting precipitate was collected by filtration, washed with ether and dried.

이 분말을 DMF 20㎖에 용해시키고, 빙냉하에 이 용액을 트리에틸아민으로 중화시켰다. 다음에 Z-Ala-ONB 2.9g을 첨가하여 이 혼합물을 16시간 동안 교반했다.This powder was dissolved in 20 mL of DMF and the solution was neutralized with triethylamine under ice cooling. Then 2.9 g of Z-Ala-ONB was added and the mixture was stirred for 16 hours.

DMF를 감압하에서 유거하고 잔사를 초산에틸 300㎖에 용해시켰다. 이 용액을 4%탄산수소나트륨 수용액을 1회 100㎖씩 사용하여 3회 세척했다. 물로 세척한 후에 이 용액을 무수황산나트륨으로 건조시켰다. 용매를 감압하에서 유거하고 그 잔사에에 틸에테르를 첨가했다. 생성되는 분말을 여과수집했다. 수량 3.05g(74.3%(. 융점 62∼65℃

Figure kpo00027
DMF was distilled off under reduced pressure and the residue was dissolved in 300 ml of ethyl acetate. The solution was washed three times using 100 ml of 4% aqueous sodium hydrogen carbonate solution once. After washing with water the solution was dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and ethyl ether was added to the residue. The resulting powder was collected by filtration. Yield 3.05 g (74.3% (. Melting point 62-65 ℃)
Figure kpo00027

Figure kpo00028
Figure kpo00028

b) Z-β-Ala-Arg(NO2)-Pro-OH의 제조b) Preparation of Z-β-Ala-Arg (NO 2 ) -Pro-OH

아세톤 30㎖에 Z-β-Ala-Arg(NO2)-Pro-OMe 2.82g을 용해시키고, 빙냉하에, 1N 수산화나트륨 수용액 10.7㎖를 첨가했다. 이 혼합물을 실온에서 2시간 동안 교반했다. 이 혼합물을 1N 염산 11㎖로 중화시키고, 아세톤을 감합하에서 유거했다. 유상 잔사에 냉수 30㎖를 첨가하고 이 물을 경사법으로 제거했다. 잔사를 냉수로 1회 세척한 뒤 건조시켰다. 그 다음에 초산에틸-피리딘-초산-물(60 : 20 : 6 : 11)을 전개용매로 사용하여 실리카 겔(90g)의 컬럼으로 크로마토그라피했다. 목적물 중에 다량 함유된 획분을 모아 감압하에서 건조시켰다. 잔사를 에테르로 세척한 뒤 여과 수집했다. 수량 2.62g, 융점 65∼67℃2.82 g of Z-β-Ala-Arg (NO 2 ) -Pro-OMe was dissolved in 30 ml of acetone, and 10.7 ml of 1N aqueous sodium hydroxide solution was added under ice-cooling. The mixture was stirred at rt for 2 h. The mixture was neutralized with 11 mL of 1N hydrochloric acid, and acetone was distilled off under fitting. 30 ml of cold water was added to the oily residue, and this water was removed by decantation. The residue was washed once with cold water and dried. Then ethyl acetate-pyridine-acetic acid-water (60: 20: 6: 11) was chromatographed on a column of silica gel (90 g) using a developing solvent. Fractions contained in a large amount in the target were collected and dried under reduced pressure. The residue was washed with ether and collected by filtration. Quantity 2.62g, melting point 65-67 degreeC

Figure kpo00029
Figure kpo00029

c) Z-β-Ala-Arg(NO2)-Pro-Phe-Phe-Tyr-NH2의 제조 DMF 15㎖에 Z-Phe-Phe-Tyr-NH21.50g을 용해시키고 Pd 블랙을 촉매로 하여 4시간 동안 접촉 환원을 행하였다. 촉매를 여거하여 여액을 빙냉시키고, Z-β-Ala-Arg(NO2)-Pro-OH 1.21g, HONB 0.53g 및 DCC 0.61g을 첨가했다. 이 혼합물을 18시간 동안 교반했다. 형성된 DC-우레아를 여거하고 DMF를 감압하에서 증류 증발시켰다. 잔사에 물 50㎖를 첨가하여 생성되는 분말을 여과 수집한 다음 건조시켰다. 이 분말을 DMF-초산에틸로 재침전시켰다. 수량 1.99g(80.9%), 융점 135∼138℃,

Figure kpo00030
c) Preparation of Z-β-Ala-Arg (NO 2 ) -Pro-Phe-Phe-Tyr-NH 2 Dissolve 1.50 g of Z-Phe-Phe-Tyr-NH 2 in 15 ml of DMF and catalyze Pd black as a catalyst. Contact reduction was carried out for 4 hours. The catalyst was filtered off and the filtrate was ice-cooled, and 1.21 g of Z-β-Ala-Arg (NO 2 ) -Pro-OH, 0.53 g of HONB and 0.61 g of DCC were added. This mixture was stirred for 18 hours. The formed DC-urea was filtered off and the DMF was distilled off under reduced pressure. 50 ml of water was added to the residue, and the resulting powder was collected by filtration and dried. This powder was reprecipitated with DMF-ethyl acetate. Yield 1.99 g (80.9%), melting point 135-138 ° C,
Figure kpo00030

Figure kpo00031
Figure kpo00031

d) β-Ala-Arg-Pro-Phe-Phe-Tyr-NH2의 제조d) Preparation of β-Ala-Arg-Pro-Phe-Phe-Tyr-NH 2

빙초산 40㎖에 Z-β-Ala-Arg(NO2)-Pro-Phe-Phe-Tyr-NH21.50g을 용해시키고 Pd 블랙을 촉매로 하여 8시간 동안 접촉환원을 행하였다. 촉매를 여과하여 제거하고 용매를 감압유거하였다. 잔사를 물 50㎖에 용해시키고 소량의 불용물을 여거한 뒤 이 여액을 동결건조시켰다. 생성물을 물 20㎖에 더 용해시키고 카르복시메틸-셀룰로오즈의 컬럼(3.0×28㎝)에 통과시킨 뒤 이것을 경사법에 의하여 0.005M 및 0.2M 초산암모늄 수용액(각 1.5ℓ)으로 용출시켰다. 1,490∼1,840㎖의 용출 분획을 모아서 동결건조시켰다.1.50 g of Z-β-Ala-Arg (NO 2 ) -Pro-Phe-Phe-Tyr-NH 2 was dissolved in 40 ml of glacial acetic acid, and catalytic reduction was performed for 8 hours using Pd black as a catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was dissolved in 50 ml of water, a small amount of insoluble material was filtered off and the filtrate was lyophilized. The product was further dissolved in 20 ml of water and passed through a column of carboxymethyl-cellulose (3.0 × 28 cm), which was eluted with 0.005 M and 0.2 M aqueous ammonium acetate solution (1.5 L each) by gradient method. Elution fractions of 1490-1840 ml were collected and lyophilized.

Figure kpo00032
Figure kpo00032

상기 c) 및 d)와 동일한 방법에 의하여, 다음과 같은 반응식에 따라 동일한 목적물을 제조할 수 있다.By the same method as c) and d), it is possible to produce the same object according to the following reaction scheme.

Figure kpo00033
Figure kpo00033

Figure kpo00034
Figure kpo00034

[실시예 8]Example 8

β-Ala-Arg-Pro-Phe-Phe-NH2의 제조Preparation of β-Ala-Arg-Pro-Phe-Phe-NH 2

실시예 7-c)의 방법에 있이서, Z-Phe-Phe-Tyr-NH2대신에 Z-Phe-Phe-NH2를 사용하고, 실시예 7-c)내지 d)에서 설명한 바와 동일한 방법을 행하여 백색 우모상 물질로서 상기 목적물 1.24g을 얻었다.In the method of Example 7-c), Z-Phe-Phe-NH 2 is used instead of Z-Phe-Phe-Tyr-NH 2 and the same method as described in Examples 7-c) to d). 1.24 g of the target substance was obtained as a white feather material.

Figure kpo00035
Figure kpo00035

[실시예 9]Example 9

β-Ala-Arg-β-Ala-Phe-Phe-Tyr-NH2의 제조Preparation of β-Ala-Arg-β-Ala-Phe-Phe-Tyr-NH 2

a) Z-β-Ala-Phe-Phe-Tyr-NH2의 제조a) Preparation of Z-β-Ala-Phe-Phe-Tyr-NH 2

DMF 40㎖에 Z-Phe-Phe-Tyr-NH22.00g을 용해시키고 Pd 블랙을 촉매로 하여 5시간 동안 접촉환원을 행하였다. 이 촉매를 여거하고 여액에 Z-β-Ala-ONB 1.39g을 첨가했다. 이 혼합물을 9시간 동안 교반하고 DMF를 감압유거했다. 잔사에 물 50㎖를 첨가하고 생성되는 분말을 여과하여 수집한 다음 건조시켰다. 이 생성물을 DMF-초산에틸로 재침전시켰다. 수량 2.02g(88.0%), 융점 232℃,

Figure kpo00036
Figure kpo00037
2.00 g of Z-Phe-Phe-Tyr-NH 2 was dissolved in 40 mL of DMF, and catalytic reduction was performed for 5 hours using Pd black as a catalyst. The catalyst was filtered off and 1.39 g of Z-β-Ala-ONB was added to the filtrate. The mixture was stirred for 9 hours and the DMF was distilled off under reduced pressure. 50 ml of water was added to the residue, and the resulting powder was collected by filtration and dried. This product was reprecipitated with DMF-ethyl acetate. Yield 2.02 g (88.0%), melting point 232 ° C,
Figure kpo00036
Figure kpo00037

Figure kpo00038
Figure kpo00038

b) Z-Arg(NO2)-β-Ala-Phe-Phe-Tyr-NH2의 제조b) Preparation of Z-Arg (NO 2 ) -β-Ala-Phe-Phe-Tyr-NH 2

DMF 30㎖에 Z-β-Ala-Phe-Phe-Tyr-NH21.0g을 용해시키고 Pd 블랙을 촉매로 사용하여 접촉 환원을 6시간 동안 행했다. 촉매를 여거하고 여액에 테트라하이드라이드로푸란 중에 용해시킨 Z-Arg(NO2)-ODNP의 용액(DCC방법에 의해 테트라히드로푸란 10㎖중의 Z-Arg(NO2)-OH 0.52g및 2,4-디니트로페놀 0.30g으로부터 제조한 디니트로페닐에스테르). 이 혼합물을 13시간 동안 교반하고 용매를 유거했다. 잔사에 물 50㎖를 첨가하여 생성되는 분말을 여과수집하여 건조했다. 수량 1.01g(74.9%), 융점 192∼194℃,1.0 g of Z-β-Ala-Phe-Phe-Tyr-NH 2 was dissolved in 30 mL of DMF, and catalytic reduction was performed for 6 hours using Pd black as a catalyst. A solution of Z-Arg (NO 2 ) -ODNP dissolved in a tetrahydride lofuran by filtration of the catalyst (0.52 g of Z-Arg (NO 2 ) -OH in 10 ml of tetrahydrofuran by the DCC method and 2, Dinitrophenyl ester prepared from 0.30 g of 4-dinitrophenol). The mixture was stirred for 13 hours and the solvent was distilled off. 50 ml of water was added to the residue, and the resulting powder was collected by filtration and dried. Yield 1.01 g (74.9%), melting point 192-194 degreeC,

Figure kpo00039
Figure kpo00039

Figure kpo00040
Figure kpo00040

c) Z-β-Ala-Arg(NO2)-β-Ala-Phe-Phe-Tyr-NH2의 제조c) Preparation of Z-β-Ala-Arg (NO 2 ) -β-Ala-Phe-Phe-Tyr-NH 2

Z-Arg(NO2)-β-Ala-Phe-Phe-Tyr-NH2700㎎에 아니졸 0.2㎖를 부가한 다음에 25% HBr-초산 7㎖를 첨가했다. 이 혼합물을 실온에서 40분간 진탕시켰다. 이 반응 혼합물에 에틸에테르 100㎖를 첨가하여 생성되는 침전물을 여과 수집하고 에틸에테르로 세척했다. 양호하게 건조시킨 후 이 침전물을 DMF 100㎖에 용해시키고, 빙냉하에 이 용액을 트리에틸아민으로 중화시켰다. Z-β-Ala-ONB 336㎎을 첨가한 다음에, 이 용액을 18시간 동안 교반했다. DMF를 감압하에서 유거하고 잔사에 물 50㎖를 첨가했다. 생성되는 침전을 여과 수집하여, 건조시킨 다음 DMF와 초산에틸로 재침전시켰다. 수량 560㎎(77%), 융점 200∼202℃(분해),

Figure kpo00041
To 700 mg of Z-Arg (NO 2 ) -β-Ala-Phe-Phe-Tyr-NH 2 0.2 ml of anizol was added followed by 7 ml of 25% HBr-acetic acid. This mixture was shaken for 40 minutes at room temperature. 100 ml of ethyl ether was added to the reaction mixture, and the resulting precipitate was collected by filtration and washed with ethyl ether. After drying well, the precipitate was dissolved in 100 mL of DMF and the solution was neutralized with triethylamine under ice cooling. 336 mg of Z-β-Ala-ONB was added and then the solution was stirred for 18 hours. DMF was distilled off under reduced pressure and 50 ml of water was added to the residue. The resulting precipitate was collected by filtration, dried and then reprecipitated with DMF and ethyl acetate. Yield 560 mg (77%), melting point 200-202 ° C (decomposition),
Figure kpo00041

Figure kpo00042
Figure kpo00042

d) β-Ala-Arg-β-Ala-Phe-Phe-Tyr-NH2의 제조d) Preparation of β-Ala-Arg-β-Ala-Phe-Phe-Tyr-NH 2

빙초산 30㎖에 Z-β-Ala-Arg(NO2)-β-Ala-Phe-Phe-Tyr-NH2400㎎을 용해시키고 Pb 블랙을 촉매로 하여 8시간 동안 촉매환원을 행했다. 촉매를 여거하고 용매를 감압하에 유거했다. 잔사를 물 5㎖에 용해시키고 이 용액을 카아복시메틸-셀룰로오즈의 컬럼(2.6×22㎝)에 통과시켰다. 0.005M 및 0.2M 초산암모늄 수용액(각 700㎖)을 사용하여 경사용출시켰다. 720∼870㎖의 분획을 모아서 동결건조하여 백색우모상 물질로서 목적물 270㎎(69.1%)을 얻었다.

Figure kpo00043
400 mg of Z-β-Ala-Arg (NO 2 ) -β-Ala-Phe-Phe-Tyr-NH 2 was dissolved in 30 ml of glacial acetic acid, and catalytic reduction was performed for 8 hours using Pb black as a catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was dissolved in 5 ml of water and the solution passed through a column of carboxymethyl-cellulose (2.6 x 22 cm). The solution was decanted using 0.005 M and 0.2 M ammonium acetate aqueous solutions (700 mL each). Fractions of 720 to 870 ml were collected and lyophilized to obtain 270 mg (69.1%) of the title compound as a white wool material.
Figure kpo00043

Figure kpo00044
Figure kpo00044

[실시예 10]Example 10

Ala-Arg-β-Ala-Phe-Phe-Tyr-NH2의 제조Preparation of Ala-Arg-β-Ala-Phe-Phe-Tyr-NH 2

실시예 9-c)의 방법에 있어서, Z-β-Ala-ONB를 Z-Ala-ONB 340㎎으로 대체하고, 실시예 9-c) 내지 d)에 기재한 것과 동일한 방법을 행하여 백색우모상 물질로서 상기의 목적물 297㎎을 얻었다.In the method of Example 9-c), Z-β-Ala-ONB was replaced with 340 mg of Z-Ala-ONB, and the same method as described in Examples 9-c) to d) was carried out to give a white feathery appearance. 297 mg of the target substance was obtained as a substance.

Figure kpo00045
Figure kpo00045

[실시예 11]Example 11

β-Ala-Arg-Sar-Phe-Phe-Tyr-NH2의 제조Preparation of β-Ala-Arg-Sar-Phe-Phe-Tyr-NH 2

a) Z-Sar-Phe-Phe-Pyr-NH2의 제조a) Preparation of Z-Sar-Phe-Phe-Pyr-NH 2

DMF 30㎖에 Z-Phe-Phe-Tyr-NH22.02g을 용해시키고 Pd 블랙을 촉매로 하여 5시간 동안 접촉 환원을 행했다. 촉매를 여거하고 여액을 냉각시켰다. 한편, Z-Sar-OH 810㎎을 테트라하이드로푸란 10㎖에 용해시키고, 그 다음에 HONB 0.71g을 첨가했다. 이 혼합물을 0℃로 냉각하고, DCC 0.82g을 첨가했다. 이 혼합물을 3시간 동안 교반했다. 형성된 DC-우레아를 여거하고 이 여액을 상기 DMF 용액에 첨가했다. 이 혼합물을 20분간 교반한 다음에 용매를 감압하에서 유거하고, 그 잔사에 물 50㎖를 첨가했다. 생성되는 분말을 여과수집하고 DMF-초산에틸로 재침전시켰다. 수량 1.90g(83.8%), 융점 246∼248℃(분해 ),2.02 g of Z-Phe-Phe-Tyr-NH 2 was dissolved in 30 ml of DMF, and catalytic reduction was performed for 5 hours using Pd black as a catalyst. The catalyst was filtered off and the filtrate was cooled. On the other hand, 810 mg of Z-Sar-OH was dissolved in 10 ml of tetrahydrofuran, and then 0.71 g of HONB was added. The mixture was cooled to 0 ° C. and 0.82 g of DCC was added. This mixture was stirred for 3 hours. The DC-urea formed was filtered off and this filtrate was added to the DMF solution. After the mixture was stirred for 20 minutes, the solvent was distilled off under reduced pressure, and 50 ml of water was added to the residue. The resulting powder was collected by filtration and reprecipitated with DMF-ethyl acetate. Yield 1.90 g (83.8%), melting point 246 to 248 ° C (decomposition),

Figure kpo00046
Figure kpo00046

Figure kpo00047
Figure kpo00047

b) Z-Arg(NO2)-Sar-Phe-Phe-Tyr-NH2의 제조.b) Preparation of Z-Arg (NO 2 ) -Sar-Phe-Phe-Tyr-NH 2 .

DMF 10㎖에 Z-Sar-Phe-Phe-Tyr-NH21.0g을 용해시키고, Pd 블랙을 촉매로 하여 7시간 동안 접촉 환원을 행했다. 촉매를 여거하고 여액을 냉각했다.1.0 g of Z-Sar-Phe-Phe-Tyr-NH 2 was dissolved in 10 mL of DMF, and catalytic reduction was performed for 7 hours using Pd black as a catalyst. The catalyst was filtered off and the filtrate was cooled.

한편, Z-Arg(NO2)-OH0.52g을 테트라하이드로푸란 10㎖에 용해시키고, 빙냉하에 2,4-디니트로페놀 0.3g 및 DCC-0.33g을 첨가했다. 이 혼합물을 3시간동안 교반하여 형성된 DC-우레아를 여거하고, 이 여액을 상기의 DMF용액에 첨가했다. 이 혼합물을 20시간 교반하고 용매를 감압하에서 유거했다. 잔사에 물 50㎖를 첨가하고 생성되는 분말을 여과 수집했다. 건조 후에, 분말을 DMF-초산에틸-에틸에테르로 재침전시켰다. 수량 1.04g(77.2%), 융점 96-98℃.On the other hand, 0.52 g of Z-Arg (NO 2 ) -OH was dissolved in 10 ml of tetrahydrofuran, and 0.3 g of 2,4-dinitrophenol and DCC-0.33 g were added under ice cooling. The mixture was stirred for 3 hours to filter off the DC-urea formed, and the filtrate was added to the above DMF solution. The mixture was stirred for 20 hours and the solvent was distilled off under reduced pressure. 50 ml of water was added to the residue, and the resulting powder was collected by filtration. After drying, the powder was reprecipitated with DMF-ethyl acetate-ethyl ether. Yield 1.04 g (77.2%), melting point 96-98 degreeC.

Figure kpo00048
Figure kpo00048

c) Z-β-Ala-Arg-(NO2)-Sar-Phe-Phe-Tyr-NH2의 제조c) Preparation of Z-β-Ala-Arg- (NO 2 ) -Sar-Phe-Phe-Tyr-NH 2

25% HBr-초산 7㎖에 Z-Arg(NO2)-Sar-Phe-Phe-Tyr-NH2700㎎과 아니졸 0.2㎖를 용해시키고 이 용액을 실온에서 40분간 교반했다. 이 반응혼합물에 에틸에테르 100㎖를 첨가하여 생성되는 침전물을 여과수집한 다음, 에테르로 세척하고 수산화나트륨 펠릿트로 2시간 동안 건조시켰다.700 mg of Z-Arg (NO 2 ) -Sar-Phe-Phe-Tyr-NH 2 and 0.2 ml of anisole were dissolved in 7 ml of 25% HBr-acetic acid, and the solution was stirred at room temperature for 40 minutes. 100 ml of ethyl ether was added to the reaction mixture, and the resulting precipitate was collected by filtration, washed with ether, and dried over sodium hydroxide pellets for 2 hours.

건조된 침전물을 DMF 10㎖에 용해시키고, 빙냉하에 이 용액을, 트리에틸아민으로 중화시켰다. Z-β-Ala-ONB 335㎎을 첨가한 다음에, 이 용액을 20분간 교반했다. DMF를 감압하에서 유거하고 물 50㎖를 첨가했다. 생성되는 분말을 여과수집하여 건조시킨 다음, DMF-초산에틸로 재침전시켰다. 수량 500㎎(76.5%), 융점 135∼138℃.The dried precipitate was dissolved in 10 ml of DMF and the solution was neutralized with triethylamine under ice cooling. After adding 335 mg of Z-β-Ala-ONB, the solution was stirred for 20 minutes. DMF was distilled off under reduced pressure and 50 ml of water was added. The resulting powder was collected by filtration, dried and then reprecipitated with DMF-ethyl acetate. Yield 500 mg (76.5%) and melting | fusing point 135-138 degreeC.

Figure kpo00049
Figure kpo00049

d) β-Ala-Arg-Sar-Phe-Phe-Tyr-NH2의 제조d) Preparation of β-Ala-Arg-Sar-Phe-Phe-Tyr-NH 2

초산 30㎖에 Z-β-Ala-Arg(NO2)-Sar-Phe-Pre-Tyr-NH2450㎎을 용해시키고 Pd블랙을 촉매로 사용하여 8시간동안 접촉환원을 행했다. 촉매를 여거하고, 여액을 감압하에서 견고시켰다. 잔사를 물 5㎖에 용해시키고 카아복시메틸-셀룰로오즈의 컬럼(2.6×22㎝)으로 크로마토그라피했다. 0.005M 및 0.2M 초산암모늄수용액(각 700㎖)으로 경사 용출시킨 다음 770-880㎖의 용출분획을 모아서 동결 건조시켜 백색 우모상 물질인 목적물 309㎎(70.4%)을 얻었다.450 mg of Z-β-Ala-Arg (NO 2 ) -Sar-Phe-Pre-Tyr-NH 2 was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 8 hours using Pd black as a catalyst. The catalyst was filtered off and the filtrate was solid under reduced pressure. The residue was dissolved in 5 ml of water and chromatographed with a column of carboxymethyl-cellulose (2.6 x 22 cm). After eluting with 0.005 M and 0.2 M ammonium acetate solutions (700 ml each), 770-880 ml of the elution fractions were collected and freeze-dried to obtain 309 mg (70.4%) of the target product as a white feather.

Figure kpo00050
Figure kpo00050

[실시예 12]Example 12

Leu-Arg-Pro-Phe-Phe-Tyr-NH2의 제조Preparation of Leu-Arg-Pro-Phe-Phe-Tyr-NH 2

a) Z-Leu-Arg(NO2)-Pro-Phe-Phe-Tyr-NH2의 제조a) Preparation of Z-Leu-Arg (NO 2 ) -Pro-Phe-Phe-Tyr-NH 2

DMF20㎖이 Z-Phe-Phe-Tyr-NH2700㎎을 용해시키고 Pd블랙을 촉매로 하여 6시간동안 접촉환원을 행했다. 촉매를 여거하고 여액을 냉각했다. 이 여액에 Z-Leu- Arg(NO2)-Pro-OH 648㎎을 첨가한 다음, HONB247㎎과 DCC285㎎을 첨가했다. 이 혼합물을 20시간동안 교반하여 형성된 DC-우레아를 여거하고, DMF를 감압하에서 유거했다. 잔사에 물 50㎖를 첨가하고 생성되는 분말을 여과수집하여 건조한 다음, DMF-초산에틸-에테르로 재침전시켰다. 수량 1.05g(86.5%), 융점 101∼111℃.20 mL of DMF dissolved 700 mg of Z-Phe-Phe-Tyr-NH 2 and catalytic reduction was performed for 6 hours using Pd black as a catalyst. The catalyst was filtered off and the filtrate was cooled. Z-Leu-Arg (NO 2 ) -Pro-OH was added to the filtrate, followed by HONB247 mg and DCC 285 mg. The mixture was stirred for 20 hours to filter off the DC-urea formed, and the DMF was distilled off under reduced pressure. 50 ml of water was added to the residue, the resulting powder was collected by filtration, dried, and reprecipitated with DMF-ethyl acetate-ether. Yield 1.05 g (86.5%), melting point 101-111 degreeC.

Figure kpo00051
Figure kpo00051

b) Leu-Arg-Pro-Phe-Phe-Tyr-NH2의 제조b) preparation of Leu-Arg-Pro-Phe-Phe-Tyr-NH 2

초산 20㎖에 Z-Leu-Arg(NO2)-Pro-Phe-Phe-Tyr-NH2500㎎을 용해시키고, Pd블랙을 촉매로하여 10시간동안 접촉환원을 행했다. 촉매를 여거하여 이 여액을 감압하에서 건고했다. 잔사를 물 5㎖에 용해시키고 카아복시메틸-셀룰로오즈의 컬럼(2.6×20㎝)으로 크로마토그라피했다. 0.005M 및 0.2M 초산암모늄수용액(각 700㎖)으로 경사용출을 행한 다음 700-790㎖의 용출분획을 모아 동결건조하여 백색 우모상 물질인 목적물 300㎎(63.6%)을 얻었다.500 mg of Z-Leu-Arg (NO 2 ) -Pro-Phe-Phe-Tyr-NH 2 was dissolved in 20 ml of acetic acid, and catalytic reduction was performed for 10 hours using Pd black as a catalyst. The catalyst was filtered off and the filtrate was dried under reduced pressure. The residue was dissolved in 5 ml of water and chromatographed with a column of carboxymethyl-cellulose (2.6 x 20 cm). After eluting with 0.005 M and 0.2 M ammonium acetate solutions (700 ml each), 700-790 ml of the elution fractions were collected and lyophilized to obtain 300 mg (63.6%) of the target product as a white feather.

Figure kpo00052
Figure kpo00052

[실시예 13]Example 13

β-Ala-Arg-Phe-Phe-Phe-Tyr-NH2의 제조Preparation of β-Ala-Arg-Phe-Phe-Phe-Tyr-NH 2

a) Z-β-Ala-Arg(NO2)-Phe-Phe-Phe-Tyr(Bzl)-수지의 제조a) Preparation of Z-β-Ala-Arg (NO 2 ) -Phe-Phe-Phe-Tyr (Bzl) -resin

고상펩티드합성장치(시마주 APS-800, 일본 시마주세이사꾸쇼제)의 반응조에 BOC-Tyr(Bzl)-수지(Tyr함량, 2.18mM) 4.33g을 넣고, 디클로로메탄으로 팽윤시킨 후 메리피일드(Merrifield)법[J.A.C.S.86,304(1964)참조]에 따른 DCC법에 의하여 BOC-Phe-OH, BOC-Phe, OH, BOC-Phe-OH, BOC-Arg(NO2) 및 Z-β-Ala-OH,를 순서에 따라 도입했다. 모든 반응의 종료 후, 수지를 디클로로메탄, DMF 에탄올, 빙초산 및 메타놀로 세척하여 건조시켰다. 상기의 방법으로 펩티드수지 6.55g을 얻었다.4.33 g of BOC-Tyr (Bzl) -resin (Tyr content, 2.18 mM) was added to a reaction tank of a solid peptide synthesis apparatus (Shimazu APS-800, manufactured by Shimazu Seisakusho, Japan), and swelled with dichloromethane. BOC-Phe-OH, BOC-Phe, OH, BOC-Phe-OH, BOC-Arg (NO 2 ) and Z-β-Ala by DCC method according to Merrifield method (see JACS 86,304 (1964)) -OH, was introduced in order. After completion of all reactions, the resin was washed with dichloromethane, DMF ethanol, glacial acetic acid and methanolol and dried. 6.55 g of a peptide resin was obtained by the above method.

b) Z-β-Ala-Arg(NO2)-Phe-Phe-Phe-Tyr(Bzl)-NH2의 제조b) Preparation of Z-β-Ala-Arg (NO 2 ) -Phe-Phe-Phe-Tyr (Bzl) -NH 2

17% 암모니아-메타놀 50㎖에 상기의 a)에서 얻은 수지 6.04g을 현탁시키고, 이 현탁액을 실온에서 48시간동안 교반했다. 수지를 여거하고 여액을 감압하에서 건고시켰다. 잔사에 에테르를 첨가하여 생성되는 분말을 여과 수집한 뒤 건조시켰다. 수량 2.43g.6.04 g of the resin obtained in a) was suspended in 50 ml of 17% ammonia-methanol, and the suspension was stirred at room temperature for 48 hours. The resin was filtered off and the filtrate was dried under reduced pressure. The powder produced by adding ether to the residue was collected by filtration and dried. Quantity 2.43 g.

c) β-Ala-Arg-Phe-Phe-Phe-Tyr-NH2의 제조c) Preparation of β-Ala-Arg-Phe-Phe-Phe-Tyr-NH 2

빙초산 30㎖에 상기 b)에서 얻은 보호 펩티드-아미드조품 509㎎을 용해시키고 Pd블랙을 촉매로 사용하여 10시간동안 접촉환원을 행했다. 촉매를 여거하고 여액을 감압하에서 건고시켰다. 잔사를 물 5㎖에 용해시키고, 이 용액을 카아복시메틸-셀룰로오즈의 컬럼(2.6×24.5㎝)에 통과시켰다. 0.005M 및 0.2M초산암모늄 수용액(각 800㎖)으로 경사용출을 행하고, 1,180∼1,545㎖의 용출분획을 모아 동결 건조시켰다. 수량 237㎎(64%).509 mg of the protective peptide-amide preparation obtained in b) was dissolved in 30 ml of glacial acetic acid, and catalytic reduction was performed for 10 hours using Pd black as a catalyst. The catalyst was filtered off and the filtrate was dried under reduced pressure. The residue was dissolved in 5 ml of water and the solution passed through a column of carboxymethyl-cellulose (2.6 x 24.5 cm). The solution was decanted with an aqueous solution of 0.005 M and 0.2 M ammonium acetate (800 ml each), and 1,180-1,545 ml of elution fractions were collected and freeze-dried. Yield 237 mg (64%).

Figure kpo00053
Figure kpo00053

[실시예 14]Example 14

β-Ala-Arg-Leu-Phe-Phe-Tyr-Gly-NH2의 제조Preparation of β-Ala-Arg-Leu-Phe-Phe-Tyr-Gly-NH 2

a) Z-β-Ala-Arg(Tos)-Leu-Phe-Phe-Tyr(Bzl)-Gly-수지의 제조a) Preparation of Z-β-Ala-Arg (Tos) -Leu-Phe-Phe-Tyr (Bzl) -Gly-resin

고상 펩티드 합성장치(시마주 APS-800)의 반응조에 BOC-Gly-수지(1.7mM상당의 Gly함유) 4.0g을 넣은 다음에 이것을 디클로로메탄으로 20시간동안 팽윤시켰다. 이 반응조에 BOC-Phe-OH, BOC-Phe-OH, BOC-Leu-OH, Aoc-Arg(Tos)-OH 및 Z-β-Ala-OH를 순서에 따라 도입하고, 축합제로서 DCC와 BOC탈리제로서 트리플루오로초산-디클로로메탄(1 : 1)을 도입했다. 모든 반응의 종료 후, 이 수지를 디클로로메탄, DMF, 메타놀, 빙초산 및 메타놀로 세척한 다음 건조시켰다. 수량 5.09g.4.0 g of BOC-Gly-resin (containing Gly of 1.7 mM equivalent) was added to a reaction vessel of a solid phase peptide synthesizer (Shimazu APS-800), followed by swelling with dichloromethane for 20 hours. BOC-Phe-OH, BOC-Phe-OH, BOC-Leu-OH, Aoc-Arg (Tos) -OH and Z-β-Ala-OH were introduced in this reactor in order, and DCC and BOC as condensing agents. Trifluoroacetic acid-dichloromethane (1: 1) was introduced as a releasing agent. After completion of all reactions, the resin was washed with dichloromethane, DMF, methanol, glacial acetic acid and methanol and then dried. Quantity 5.09 g.

b) Z-β-Ala-Arg(Tos)-Leu-Phe-Phe-Tyr(Bzl)-Gly-NH2의 제조b) Preparation of Z-β-Ala-Arg (Tos) -Leu-Phe-Phe-Tyr (Bzl) -Gly-NH 2

17% 암모니아-메타놀 50㎖에 상기 a)에서 제조한 수지 4.4g을 현탁시키고, 용기를 견고하게 밀폐한후에, 이 현탁액을 실온에서 48시간동안 교반했다.4.4 g of the resin prepared in a) was suspended in 50 ml of 17% ammonia-methanol, and the vessel was tightly sealed, and then the suspension was stirred at room temperature for 48 hours.

수지를 여거하고 DMF로 세척했다. 이 여액을 혼화시켜 감압하에서 건고했다. 잔류오일에 에테르를 첨가하고 생성되는 분말을 여과 수집했다. 수량 950㎎.The resin was filtered off and washed with DMF. The filtrate was mixed and dried under reduced pressure. Ether was added to the residual oil and the resulting powder was collected by filtration. Yield 950 mg.

c) β-Ala-Arg-Leu-Phe-Phe-Tyr-Gly-NH2의 제조c) Preparation of β-Ala-Arg-Leu-Phe-Phe-Tyr-Gly-NH 2

상기 b(에서 제조한 보호 펩티드-아미드 조품 500㎎에 아니졸 0.5㎖를 첨가한 다음에, 이 혼합물을 불화수소 10㎖에 첨가했다. 이 혼합물을 0℃에서 60분가 교반하고 불화수소를 감압하에서 유거했다. 잔사를 물 50㎖에 용해시키고 이 용액을 에테르 20㎖로 2회 세척하고, 암벌라이트 IRA-410(초산형)의 컬럼(1×10cm)에 유입시킨 다음 동결 건조했다. 생성물을 물 20㎖에 용해시키고 이 용액을 카아복시메틸-셀룰로오즈의 컬럼(2.6×25㎝)에 통과시켰다. 0.005M 및 0.2M 초산 암모늄 수용액(각 800㎖)을 사용하여 경사용출을 행하여 1,200∼1,530㎖의 용출분획을 모아서 동결 건조했다. 이 방법으로 백색 우모상 물질 167㎎을 얻었다.0.5 ml of aniazole was added to 500 mg of the protective peptide-amide prepared in b (b), and the mixture was added to 10 ml of hydrogen fluoride. The mixture was stirred at 0 ° C. for 60 minutes and hydrogen fluoride was reduced under reduced pressure. The residue was dissolved in 50 ml of water and the solution was washed twice with 20 ml of ether, introduced into a column (1 × 10 cm) of Amberlite IRA-410 (acetic acid type) and lyophilized. Dissolved in 20 mL and passed through a column of carboxymethyl-cellulose (2.6 x 25 cm) in a gradient elution using 0.005 M and 0.2 M ammonium acetate aqueous solutions (800 mL each) to produce 1,200-1,530 mL. The elution fractions were collected and freeze-dried to give 167 mg of a white feather material.

Figure kpo00054
Figure kpo00054

[실시예 15]Example 15

β-Ala-Arg-Ser-Phe-Phe-Tyr-Gly-NH2의 제조Preparation of β-Ala-Arg-Ser-Phe-Phe-Tyr-Gly-NH 2

a) Z-β-Ala-Arg(Tos)-Ser(Bzl)-Phe-Phe-Tyr(Bzl)-Gly-수지a) Z-β-Ala-Arg (Tos) -Ser (Bzl) -Phe-Phe-Tyr (Bzl) -Gly-resin

고상 펩티드 합성장치(모델 APS-800, 일본 시마주 세이사꾸쇼제) 의반응조에 BOC-Gly-수지(2.17mM의 Gly함유) 4.02g을 유입하고, 메리피일드법에 의하여 BOC-Tyr(Bzl)-OH, BOC-Phe-OH, BOC-Phe-OH, BOC-Ser(Bzl)-OH, Aoc-Arg(Tos)-OH 및 Z-β-Ala-OH를 순서에 따라 도입했다. 모든 반응의 종료 후, 이 수지를 디클로로메탄, 메타놀, DMF, 빙초산 및 메타놀로 세척한 다음에 건조시켰다. 수량 6.4g.4.02 g of BOC-Gly-resin (containing 2.17 mM Gly) was introduced into a reaction tank of a solid peptide synthesis apparatus (model APS-800, manufactured by Seisakusho, Shimazu, Japan), and BOC-Tyr (Bzl) was obtained by the Mary Feid method. ) -OH, BOC-Phe-OH, BOC-Phe-OH, BOC-Ser (Bzl) -OH, Aoc-Arg (Tos) -OH and Z-β-Ala-OH were introduced in order. After completion of all reactions, the resin was washed with dichloromethane, methanol, DMF, glacial acetic acid and methanol and then dried. Quantity 6.4g.

b) Z-β-Ala-Arg(Tos)-Ser(Bzl)-Phe-Phe-Tyr(Bzl)-Gly-NH2의 제조b) Preparation of Z-β-Ala-Arg (Tos) -Ser (Bzl) -Phe-Phe-Tyr (Bzl) -Gly-NH 2

17% 암모니아-메타놀 50ml에 상기 a)에서 제조한 수지 5.9g을 현탁시키고, 이 현탁액을 실온에서 48시간동안 교반했다. 수지를 여거하고 DMF로 세척했다. 세척물을 여액과 혼화하고, 이 혼화시킨 용액을 감압 건고시켰다. 잔사에 에테르를 첨가하여 생성되는 분말을 여과 수집했다. 수량 2.02g.5.9 g of the resin prepared in a) was suspended in 50 ml of 17% ammonia-methanol, and the suspension was stirred at room temperature for 48 hours. The resin was filtered off and washed with DMF. The wash was mixed with the filtrate and the mixed solution was dried under reduced pressure. The powder produced by adding ether to the residue was collected by filtration. Quantity 2.02 g.

c) β-Ala-Arg-Ser-Phe-Phe-Tyr-Gly-NH2의 제조c) Preparation of β-Ala-Arg-Ser-Phe-Phe-Tyr-Gly-NH 2

무수 불화수소 10㎖에 상기 b)에서 제조한 보호펩티드-아미드 조품 1.0g과 아니졸 1㎖를 용해시키고, 이 용액을 0℃에서 60분간 교반했다. 불화수소를 감압하에서 유거하여 잔사를 물 20㎖에 용해시켰다. 이 용액을 에테르 10㎖로 2회 세척하고 암벌라이트 IRA-410의 컬럼(1.0×15㎝)에 유입시킨 다음 동결 건조시켰다. 생성물을 물 10㎖에 용해시킨 용액을 카아복시메틸-셀룰로오즈의 컬럼(2.5×25㎝)에 통과시켰다, 0.005M 및 0.2M 초산암모늄 수용액(각 800㎖)으로 경사용출을 행하고 800~950㎖의 용출분류물을 모아 동결 건조했다. 이 생성물을 암벌라이트 XAD-2(미국, 톰 앤드 하아즈회사제, 폴리스티렌수지)의 컬럼(2×10㎝)을 통과시켜 동결 건조했다. 이 방법으로 백색 우모상 물질인 상기 표제화합물 55㎎을 얻었다.1.0 g of the protective peptide-amide preparation prepared in b) and 1 ml of anisole were dissolved in 10 ml of anhydrous hydrogen fluoride, and the solution was stirred at 0 ° C. for 60 minutes. Hydrogen fluoride was distilled off under reduced pressure and the residue was dissolved in 20 ml of water. The solution was washed twice with 10 ml ether and introduced into a column of Amberlite IRA-410 (1.0 × 15 cm) and then freeze dried. The solution in which the product was dissolved in 10 ml of water was passed through a column of carboxymethyl-cellulose (2.5 × 25 cm), followed by decanting with 0.005 M and 0.2 M aqueous ammonium acetate solution (800 ml each), followed by 800-950 ml. The eluate was collected and freeze dried. The product was lyophilized by passing through a column (2 × 10 cm) of Ambolite XAD-2 (polystyrene resin, manufactured by Tom & Haars, USA). In this way, 55 mg of the title compound was obtained as a white, feathery material.

Figure kpo00055
Figure kpo00055

[실시예 16]Example 16

β-Ala-Arg-Pro-Phe-Phe-Thr-Thr-Pro-Lys-Ala-OH의 제조Preparation of β-Ala-Arg-Pro-Phe-Phe-Thr-Thr-Pro-Lys-Ala-OH

메타놀 30㎖에 Z-Phe-Phe-Tyr-Tyr-Pro-Lys(BOC)-Ala-OtBU1.16g을 용해시키고 Pd 블랙을 촉매로 하여 4시간동안 접촉환원을 행했다. 촉매를 여거하고 여액을 감압하에서 건고했다. 잔사를 DMF15㎖에 용해시키고, 이 용액에 Z-β-Ala-Arg(NO2)-Pro-OH492㎎과 HONB200㎎을 가하고, 냉각하에 DCC250㎎을 첨가한 다음 이 혼합물을 18시간동안 교반했다.The Z-Phe-Phe-Tyr- Tyr-Pro-Lys (BOC) -Ala-O t BU1.16g dissolved in methanol 30㎖ and was subjected to catalytic reduction for 4 hours by the Pd black as the catalyst. The catalyst was filtered off and the filtrate was dried under reduced pressure. The residue was dissolved in 15 mL of DMF, and Z-β-Ala-Arg (NO 2 ) -Pro-OH492 mg and HONB 200 mg were added to the solution, DCC 250 mg was added under cooling, and the mixture was stirred for 18 hours.

불용물을 여거하고 DMF를 감압하에서 유거했다. 잔사에 초산에틸을 첨가하고 생성되는 분말을 건조시키고 트리플루오로초산 10㎖에 용해시켰다. 이 용액을 40분간 방치하고, 트리플루오로초산을 감압하에서 유거하고, 잔사를 빙초산 30㎖ 용해시켰다. Pd블랙을 촉매로 사용하여 16시간동안 접촉환원을 행했다.The insolubles were filtered off and the DMF was distilled off under reduced pressure. Ethyl acetate was added to the residue, and the resulting powder was dried and dissolved in 10 ml of trifluoroacetic acid. The solution was left to stand for 40 minutes, trifluoroacetic acid was distilled off under reduced pressure, and the residue was dissolved in 30 ml of glacial acetic acid. Catalytic reduction was carried out for 16 hours using Pd black as a catalyst.

촉매를 여거하고 여액을 감압하에서 건고시킨 다음 물 10㎖에 용해시켰다. 암벌라이트 IRA-410으로 이온 교환을 행한 후에, 소량의 불용물을 여거하고, 이 여액을 카아복시메틸-셀룰로오즈(2.2×30㎝)컬럼에 통과시켰다. 0.005M 및 0.2M 초산암모늄 수용액(각 800㎖)으로 경사용출을 행하여, 820∼1,180㎖의 용출분획을 모아서 동결 건조했다. 이 방법으로 백색 우모상 물질 670㎎을 얻었다.The catalyst was filtered off and the filtrate was dried under reduced pressure and then dissolved in 10 ml of water. After ion exchange with Amberlite IRA-410, a small amount of insoluble material was filtered off and the filtrate was passed through a carboxymethyl-cellulose (2.2 x 30 cm) column. The solution was decanted with an aqueous solution of 0.005 M and 0.2 M ammonium acetate (800 ml each), and 820-1,180 ml of elution fractions were collected and freeze-dried. This method yielded 670 mg of a white, feathery material.

아미노산분석 : Lys, 1.02; Arg, 0.98; Thr, 0.96; Pro, 2.04; Ala, 1.00; Tyr, 0.87; Phe, 2.02; β-Ala, 1.05(펩티드 함량 : 74%)Amino acid analysis: Lys, 1.02; Arg, 0.98; Thr, 0.96; Pro, 2.04; Ala, 1.00; Tyr, 0.87; Phe, 2.02; β-Ala, 1.05 (peptide content: 74%)

[실시예 17]Example 17

β-Ala-Arg-Gly-Phe-Phe-Tyr-Leu-OH의 제조Preparation of β-Ala-Arg-Gly-Phe-Phe-Tyr-Leu-OH

a) Z-Phe-Phe-Tyr-OEt의 제조a) Preparation of Z-Phe-Phe-Tyr-OEt

에타놀 30㎖에 Z-Phe-Tyr-OEt 3.42g을 용해시키고 Pd블랙을 촉매로 사용하여 2시간동안 접촉환원을 행했다. 촉매를 여거하고 용매를 감압하에서 유거시켰다. 그 잔사를 DMF15㎖에 용해시키고, Z-Phe-OSus2.77g을 첨가했다. 이 혼합물을 10시간동안 교반했다. 이 반응혼합물에 물 80㎖를 첨가하여 생성되는 결정을 여과수집하고 에타놀-초산에틸-에틸에테르로 재침전시켰다. 이 방법으로 융점 185∼186℃의 침상물질 3.72g(83.4%)을 얻었다.3.42 g of Z-Phe-Tyr-OEt was dissolved in 30 ml of ethanol, and catalytic reduction was performed for 2 hours using Pd black as a catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was dissolved in 15 mL of DMF, and 2.77 g of Z-Phe-OSus was added. The mixture was stirred for 10 hours. 80 ml of water was added to the reaction mixture, and the resulting crystals were collected by filtration and reprecipitated with ethanol-ethyl acetate-ethyl ether. In this manner, 3.72 g (83.4%) of acicular material having a melting point of 185 ° C to 186 ° C was obtained.

Figure kpo00056
Figure kpo00056

b) Z-β-Ala-Arg(NO2)-Gly-Phe-Phe-Tyr-OEt의 제조b) Preparation of Z-β-Ala-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-OEt

에타놀 50㎖에 Z-Phe-Phe-Tyr-OEt 2.0g을 현탁시키고, Pd블랙을 촉매로 사용하여 1.5시간동안 촉매환원을 행했다. 촉매를 여거하고, 용매를 감압하에서 유거했다. 그 잔사를 DMF20㎖에 용해시켰다. 이 용액에 빙냉하에 Z-β-Ala-Arg(NO2)-Gly-OH 1.56g, HONB 0.7g 및 DCC 0.8g을 첨가하고 그 혼합물을 12시간동안 교반했다.2.0 g of Z-Phe-Phe-Tyr-OEt was suspended in 50 ml of ethanol, and catalytic reduction was performed for 1.5 hours using Pd black as a catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was dissolved in 20 ml of DMF. To this solution was added 1.56 g of Z-β-Ala-Arg (NO 2 ) -Gly-OH, 0.7 g of HONB, and 0.8 g of DCC under ice-cooling, and the mixture was stirred for 12 hours.

형성된 우레아 유도체를 여거하고 DMF를 감압하에서 유거했다. 그 잔사에 물 60㎖를 첨가하여 생성되는 분말을 여과로 수집한 다음 건조시키고, DMF-초산에틸로 재침전시켰다. 수량 2.58g(82%), 융점 83∼85℃The urea derivative formed was filtered off and the DMF was distilled off under reduced pressure. To the residue was added 60 ml of water, the resulting powder was collected by filtration, dried and reprecipitated with DMF-ethyl acetate. Yield 2.58 g (82%), melting point 83-85 ° C

Figure kpo00057
Figure kpo00057

b) Z-β-Ala-Arg(NO2)-Gly-Phe-Phe-Tyr-OH의 제조b) Preparation of Z-β-Ala-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-OH

아세톤 30㎖에 Z-β-Ala-Arg(NO2)-Gly-Phe-Phe-Tyr-OEt 2.00g을 현탁시키고, 빙냉하에, 1N수산화나트륨 수용액 6.3㎖을 첨가했다. 그 다음에 실온에서, 이 혼합물을 1시간동안 교반했다. 1N염산 3㎖를 첨가한 다음에, 아세톤을 감압하에서 유거했다. 소량의 불용물을 여거한 다음 1N염산 3.8㎖를 첨가했다. 생성되는 침전물을 여과하여 수집하고 냉수로 양호하게 세척한 다음 건조시켰다. 수량 1.96g(98%), 융점70∼73℃,2.00 g of Z-β-Ala-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-OEt was suspended in 30 ml of acetone, and 6.3 ml of 1N aqueous sodium hydroxide solution was added under ice-cooling. Then at room temperature, the mixture was stirred for 1 hour. After adding 3 ml of 1N hydrochloric acid, acetone was distilled off under reduced pressure. A small amount of insoluble matter was filtered off and 3.8 ml of 1N hydrochloric acid was added. The resulting precipitate was collected by filtration, washed well with cold water and dried. Yield 1.96 g (98%), melting point 70-73 ° C,

Figure kpo00058
Figure kpo00058

d) Z-β-Ala-Arg(NO2)-Gly-Phe-Phe-Tyr-Leu-OBzl의 제조d) Preparation of Z-β-Ala-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-Leu-OBzl

DMF 5㎖에 H-Leu-OBzl-P-톨루엔술포네이트 275㎎을 용해시키고 이 용액을 10% N-에틸모르폴린-DMF 0.9㎖로 중화시켰다. -10℃로 냉각하여 Z-β-Ala-Arg(NO2)-Gly-Phe-Phe-Tyr-OH 670㎎, HONB 251㎎ 및 DCC 289㎎을 첨가했다. 이 혼합물을 12시간동안 교반하여 형성된 DC우레아를 여거했다. DMF를 감압하에서 유거하고 그 잔사에 물 30㎖를 첨가했다. 생성되는 침전물을 여과 수집하고 뜨거운 메타놀로 세척한 다음 건조시켰다. 수량 703㎎(87.9%), 융점 178∼181℃,275 mg of H-Leu-OBzl-P-toluenesulfonate was dissolved in 5 ml of DMF and the solution was neutralized with 0.9 ml of 10% N-ethylmorpholine-DMF. After cooling to −10 ° C., 670 mg of Z-β-Ala-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-OH, 251 mg of HONB, and 289 mg of DCC were added. The mixture was stirred for 12 hours to filter out DC urea formed. DMF was distilled off under reduced pressure and 30 ml of water was added to the residue. The resulting precipitate was collected by filtration, washed with hot methanol and dried. Yield 703mg (87.9%), melting point 178-181 degreeC,

Figure kpo00059
Figure kpo00059

Figure kpo00060
Figure kpo00060

e) β-Ala-Arg-Gly-Phe-Phe-Tyr-Leu-OH의 제조e) Preparation of β-Ala-Arg-Gly-Phe-Phe-Tyr-Leu-OH

초산 30㎖에 Z-β-Ala-Arg(NO2)-Gly-Phe-Phe-Tyr-Leu-OBzl 500㎎을 용해시키고 Pd블랙을 촉매로 사용하여 8시간동안 접촉환원을 행했다. 촉매를 여거하고 용매를 감압하에서 유거시켰다. 그잔사를 물 5㎖에 용해시키고 이 용액을 카아복시메틸-셀룰로오즈의 컬럼(2.6×18㎝)에 통과시켰다. 0.005M 초산암모늄 수용액(700㎖)과 0.2M 초산암모늄 수용액(700㎖)을 사용하여 선형구배 경사법(linear gradient method)으로 용출을 행하여 상기의 화합물을 370∼720㎖의 분획으로 용출시켰다. 이 분획을 모아서 동결 건조했다. 수량 277㎎(64.2%).500 mg of Z-β-Ala-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-Leu-OBzl was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 8 hours using Pd black as a catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was dissolved in 5 ml of water and the solution passed through a column of carboxymethyl-cellulose (2.6 x 18 cm). Elution was carried out using a linear gradient method using 0.005 M aqueous ammonium acetate solution (700 ml) and 0.2 M aqueous ammonium acetate solution (700 ml) to elute the compound in fractions of 370 to 720 ml. The fractions were combined and lyophilized. Yield 277 mg (64.2%).

Figure kpo00061
Figure kpo00062
Figure kpo00061
Figure kpo00062

[실시예 18]Example 18

β-Ala-Arg-Gly-Phe-Phe-Tyr-Ala-NH2의 제조Preparation of β-Ala-Arg-Gly-Phe-Phe-Tyr-Ala-NH 2

H-Leu-OBzl-P-톨루엔술포네이트 대신에 H-Ala-NH2염산염을 사용하여 실시예 17-d) 및-e)에 기재한 방법을 반복하여, β-Ala-Arg-Gly-Phe-Phe-Tyr-Ala-NH2·2 초산염 (수량 216㎎)을 얻었다.Repeating the method described in Examples 17-d) and -e) using H-Ala-NH 2 hydrochloride instead of H-Leu-OBzl-P-toluenesulfonate, β-Ala-Arg-Gly-Phe -Phe-Tyr-Ala-NH 2 .2 acetate (quantity 216 mg) was obtained.

아미노산 분석 : Arg, 1.01; Gly, 1.00; Ala, 1.02; Phe, 2.00; Tyr, 0.89, β-Ala, 1.12(펩티드 함량 : 82.4%).Amino acid analysis: Arg, 1.01; Gly, 1.00; Ala, 1.02; Phe, 2.00; Tyr, 0.89, β-Ala, 1.12 (peptide content: 82.4%).

[실시예 19]Example 19

β-Ala-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-OH의 제조Preparation of β-Ala-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-OH

a) Z-Phe-Phe-Tyr-Thr-Pro-OtBu의 제조Preparation of a) Z-Phe-Phe- Tyr-Thr-Pro-O t Bu

메타놀 30㎖에 Z-Thr-Pro-OtBu 1.80g을 용해시키고 Pd블랙을 촉매로 하여 5시간동안 접촉환원을 행했다. 촉매를 여거하고 용매를 감압하에서 유거했다. 잔사를 DMF 20㎖에 용해시키고, 이 용액을 -10℃로 냉각한 후에, Z-Phe-Phe-Tyr-OH 2.70g, HONB 1.59g 및 DCC 1.37g을 첨가했다. 이 혼합물을 18시간동안 교반하여 형성된 우레아 유도체를 여거하고 물100㎖를 첨가했다. 생성되는 침전물을 여과수집하여 건조시키고 초산에틸 100㎖에 용해시켰다. 이 용액을 물 50㎖로 2회 세척하고 황산나트륨으로 건조시켰다. 용매를 유거한 다음에 초산에틸을 상기 간사에 첨가했다. 생성되는 분말을 여과 수집한 다음 건조시켰다. 수량 2.51g(89.8%), 융점 137∼139℃Dissolving Z-Thr-Pro-O t Bu 1.80g 30㎖ in methanol and subjected to catalytic reduction for 5 hours to the Pd black as the catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was dissolved in 20 mL of DMF, and after cooling the solution to -10 ° C, 2.70 g of Z-Phe-Phe-Tyr-OH, 1.59 g of HONB, and 1.37 g of DCC were added. The mixture was stirred for 18 hours to remove urea derivative formed and 100 ml of water was added. The resulting precipitate was collected by filtration, dried, and dissolved in 100 ml of ethyl acetate. The solution was washed twice with 50 ml of water and dried over sodium sulfate. After distilling off the solvent, ethyl acetate was added to the secretary. The resulting powder was collected by filtration and then dried. Yield 2.51 g (89.8%), melting point 137-139 ° C

Figure kpo00063
Figure kpo00063

b) Z-β-Ala-Arg(NO2)-Gly-Phe-Phe-Tyr-Thr-Pro-OtBu의 제조Preparation of b) Z-β-Ala- Arg (NO 2) -Gly-Phe-Phe-Tyr-Thr-Pro-O t Bu

메타놀 20㎖에 Z-Phe-Phe-Tyr-Thr-Pro-OtBu 1.50g을 용해시키고 Pd블랙을 촉매로 사용하여 수소기류하에서 4시간동안 접촉환원을 행했다. 촉매를 여거하고 용매를 감압하에서 유거시켰다.Dissolving Z-Phe-Phe-Tyr- Thr-Pro-O t Bu 1.50g in methanol 20㎖ and using Pd black as the catalyst was subjected to catalytic reduction for 4 hours in a hydrogen stream. The catalyst was filtered off and the solvent was distilled off under reduced pressure.

잔사를 DMF 10㎖에 용해시키는 한편, 이 용액에 빙냉하에 Z-β-Ala-Arg(NO2)-Gly-OH 0.87g, HONB, 0.47g 및 DCC 0.54g을 첨가했다. 이 혼합물을 16시간동안 교반했다. 형성된 DC-우레아를 여거하고 여액에 물 50㎖를 첨가한 다음 겔을 분리시켰다. 침전물을 여과 수집하여 건조시키고, DMF-초산에틸로 재침전시켰다. 이 침전물을 여과 수집한 다음 에타놀로 재침전시켰다. 수량1.04g(67.4%), 융점153∼156℃The residue was dissolved in 10 mL of DMF, while 0.87 g of Z-β-Ala-Arg (NO 2 ) -Gly-OH, HONB, 0.47 g, and 0.54 g of DCC were added to this solution under ice cooling. The mixture was stirred for 16 hours. The formed DC-urea was filtered off and 50 ml of water was added to the filtrate and the gel was separated. The precipitate was collected by filtration, dried and reprecipitated with DMF-ethyl acetate. This precipitate was collected by filtration and then reprecipitated with ethanol. Quantity 1.04 g (67.4%), Melting point 153-156 ° C

Figure kpo00064
Figure kpo00064

c) β-Ala-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-OH의 제조c) Preparation of β-Ala-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-OH

Z-β-Ala-Arg(NO2)-Gly-Phe-Phe-Tyr-Thr-Pro-OtBu 900㎎에 아니졸 0.9㎖를 첨가한 다음, 무수 불화수소 10㎖를 첨가했다. 이 혼합물을 -4℃에서 30분간 교반했다. 불화수소를 감압하에서 유거하고, 그 잔사에 물 30㎖를 첨가했다.A Z-β-Ala-Arg ( NO 2) -Gly-Phe-Phe-Tyr-Thr-Pro-O t Bu was added anisole 0.9㎖ the 900㎎ Next, anhydrous hydrogen fluoride was added 10㎖. The mixture was stirred at -4 ° C for 30 minutes. Hydrogen fluoride was distilled off under reduced pressure, and 30 ml of water was added to the residue.

이 용액을 에틸에테르 30㎖로 추출하고 수용액층을 암벌라이트 IRA-410(초산형)의 컬럼(1.0×10.0㎝)에 통과시킨 다음 이것을 물로 세척하고 세척액을 유출액과 합하여 이것을 동결건조했다. 이 제품을 물10㎖에 용해시키고, 이 용액을 카아복시메틸-셀룰로오즈의 컬럼(2.2×21㎝)의 컬럼에 통과시켰다. 0.005M 초산암모늄 수용액 (700㎖)과 0.3M 초산암모늄 수용액 (700㎖)으로 경사용출을 행하여 235∼385㎖의 용출분획을 모아 동결건조했다. 수량 476㎎(57.0%)The solution was extracted with 30 ml of ethyl ether, and the aqueous layer was passed through a column of Ambolite IRA-410 (acetic acid type) (1.0 × 10.0 cm), which was then washed with water, and the washing solution was combined with the effluent and lyophilized. This product was dissolved in 10 ml of water and the solution passed through a column of carboxymethyl-cellulose column (2.2 x 21 cm). The solution was decanted with 0.005 M aqueous ammonium acetate solution (700 mL) and 0.3 M aqueous ammonium acetate solution (700 mL), and 235-385 mL elution fractions were collected and lyophilized. Yield 476mg (57.0%)

Figure kpo00065
Figure kpo00065

Figure kpo00066
Figure kpo00066

[실시예 20]Example 20

ε-Acap-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-OH의 제조Preparation of ε-Acap-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-OH

a) Z-ε-Acap-Arg(NO2)-Gly-OEt의 제조a) Preparation of Z-ε-Acap-Arg (NO 2 ) -Gly-OEt

Z-Arg(NO2)-Gly-OEt 24.1g에 25% HBr-초산 12㎖를 첨가하고, 이 혼합물을 실온에서 40분간 진탕시켰다. 이 용액에 에틸에테르를 첨가하여 생성되는 침전물을 여과 수집한 다음 수산화나트륨으로 건조시켰다.12 ml of 25% HBr-acetic acid was added to 24.1 g of Z-Arg (NO 2 ) -Gly-OEt, and the mixture was shaken at room temperature for 40 minutes. The precipitate produced by adding ethyl ether to this solution was collected by filtration and dried over sodium hydroxide.

한편, Z-ε-Acap-OH 1.33g 및 HONB 0.99g을 테트라하이드로푸란 5㎖에 용해시키고, 빙냉하에 DCC 1.14g을 첨가했다. 이 혼합물을 4시간동안 교반하여 형성된 디사이클로헥실우레아를 여거했다. 상기의 아민성분을 DMF 10㎖에 용해시키고, 이 용액을 트리에틸아민으로 중화시킨 후에, 상기 활성 에스테르용액을 첨가했다. 이 혼합물을 철야 교반했다. 용매를 감압하에서 유거하고 잔사를 초산에틸 50㎖에 용해시켰다. 이 용액을 물로 세척한 다음에 탄산수소나트륨의 포화수용액(50㎖×2)으로 세척했다. 물로 세척하고 무수 황산나트륨으로 건조시켰다. 용매를 감압하에서 유거하고 잔사에 석유 벤진을 첨가했다. 생성되는 결정을 물-에타놀-초산에틸로부터 재결정시켰다. 수량 2.1g(76%), 융점 85∼87℃,On the other hand, 1.33 g of Z-ε-Acap-OH and 0.99 g of HONB were dissolved in 5 ml of tetrahydrofuran, and 1.14 g of DCC was added under ice cooling. The mixture was stirred for 4 hours, and the dicyclohexylurea formed was filtered off. The amine component was dissolved in 10 ml of DMF, and the solution was neutralized with triethylamine, and then the active ester solution was added. The mixture was stirred overnight. The solvent was distilled off under reduced pressure and the residue was dissolved in 50 ml of ethyl acetate. The solution was washed with water and then with a saturated aqueous solution of sodium hydrogen carbonate (50 mL × 2). Washed with water and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure and petroleum benzine was added to the residue. The resulting crystals were recrystallized from water-ethanol-ethyl acetate. Yield 2.1g (76%), Melting Point 85 ~ 87 ℃,

Figure kpo00067
Figure kpo00067

Figure kpo00068
Figure kpo00068

b) Z-ε-Acap-Arg(NO2)-Gly-OH의 제조b) Preparation of Z-ε-Acap-Arg (NO 2 ) -Gly-OH

아세톤 10㎖에 Z-ε-Acap-Arg(NO2)-Gly-OEt 1.8g을 용해시키고, 빙냉한 후에, 2N산화나트륨 2.9㎖을 가했다. 실온에서, 이 혼합물을 2시간동안 교반하고, 이 혼합물에 1N염산 2.5㎖를 가한 다음 아세톤을 유거했다. 잔사에 물 10㎖를 가하고, 불용물을 여거한 후, 이 용액을 1N염산을 사용하여 산성으로 변화시켰다. 생성되는 결정을 여과하여 수집했다. 수량 1.59g(93%), 융점 97.5∼99℃.1.8 g of Z-ε-Acap-Arg (NO 2 ) -Gly-OEt was dissolved in 10 ml of acetone, and after cooling with ice, 2.9 ml of 2N sodium oxide was added. At room temperature, the mixture was stirred for 2 hours, 2.5 ml of 1N hydrochloric acid was added to the mixture, and then acetone was distilled off. 10 ml of water was added to the residue, and the insoluble was filtered off, and then the solution was changed to acidic with 1N hydrochloric acid. The resulting crystals were collected by filtration. Yield 1.59 g (93%), melting point 97.5-99 degreeC.

Figure kpo00069
Figure kpo00069

c) ε-Acap-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-OH의 제조c) Preparation of ε-Acap-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-OH

실시예 19-b)의 방법에 있어서, Z-ε-Ala-Arg(NO2)-Gly-OH를 Z-ε-Acap-Arg(NO2)-Gly-OH로 대체하여, 실시예 19-b) 및 c)에 기재한 것과 동일한 방법으로 반복하여 표제의 목적물 428㎎을 얻었다.In the method of Example 19-b), Z-ε-Ala-Arg (NO 2 ) -Gly-OH is replaced with Z-ε-Acap-Arg (NO 2 ) -Gly-OH, and Example 19- The same procedure as described in b) and c) was repeated to obtain 428 mg of the title product.

Figure kpo00070
Figure kpo00070

Figure kpo00071
Figure kpo00071

[실시예 21]Example 21

Lys-Arg-Gly-Phe-Phe-Tyr-Phr-Pro-OH의 제조Preparation of Lys-Arg-Gly-Phe-Phe-Tyr-Phr-Pro-OH

a) di-Z-Lys-Arg(NO2)-Gly-OEt의 제조a) Preparation of di-Z-Lys-Arg (NO 2 ) -Gly-OEt

di-Z-Lys-OH 2.07g을 사용하여, 실시예 20-a)와 동일한 방법으로 하여 상기의 목적물을 겔로서 수득했다. 이 겔 물질을 물-에타놀-초산에틸로 재침전시켰다. 수량 2.57g(73%), 융점 161∼162℃.Using 2.07 g of di-Z-Lys-OH, the target product was obtained as a gel in the same manner as in Example 20-a). This gel material was reprecipitated with water-ethanol-ethyl acetate. Yield 2.57 g (73%), melting | fusing point 161-162 degreeC.

Figure kpo00072
Figure kpo00072

b) di-Z-Lys-Arg(NO2)-Gly-OH의 제조b) Preparation of di-Z-Lys-Arg (NO 2 ) -Gly-OH

아세톤 10㎖에 di-Z-Lys-Arg(NO2)-Gly-OEt 2.0g을 용해시키고, 빙냉하에 2N수산화나트륨 2.1㎖를 첨가했다. 그 다음에, 실온에서 이 혼합물을 2시간동안 교반했다. 1N염산 1.4㎖를 첨가한 후에 아세톤을 감압하에서 유거하고 잔사에 물 10㎖를 첨가했다.2.0 g of di-Z-Lys-Arg (NO 2 ) -Gly-OEt was dissolved in 10 ml of acetone, and 2.1 ml of 2N sodium hydroxide was added under ice-cooling. Then, the mixture was stirred at room temperature for 2 hours. After adding 1.4 mL of 1N hydrochloric acid, acetone was distilled off under reduced pressure, and 10 mL of water was added to the residue.

불용물을 여거하고, 이 여액을 1N염산으로 산성으로Filter off the insoluble matter and acidify the filtrate with 1N hydrochloric acid.

했다. 생성되는 겔을 여과하여 수집했다. 수량 1.78g (93%), 융점 131∼132.5℃,did. The resulting gel was collected by filtration. Yield 1.78g (93%), Melting Point 131-132.5 ℃,

Figure kpo00073
Figure kpo00073

c) Lys-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-OH의 제조c) Preparation of Lys-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-OH

Z-β-Ala-Arg(NO2)-Gly-OH 대신에 di-Z-Lys-Arg(NO2)-Gly-OH를 사용하여 실시예 19-b)의 방법을 반복하여 상기의 목적물 452㎎을 얻었다.Z-β-Ala-Arg ( NO 2) -Gly-OH in place of di-Z-Lys-Arg ( NO 2) -Gly-OH Example 19-b) how the target product 452 was repeated using the Mg was obtained.

Figure kpo00074
Figure kpo00074

Figure kpo00075
Figure kpo00075

Figure kpo00076
Figure kpo00076

[실시예 22]Example 22

β-Ala-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Ala-OH의 제조Preparation of β-Ala-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Ala-OH

a) Z-Lys(BOC)-Ala-OtBu의 제조Preparation of a) Z-Lys (BOC) -Ala-O t Bu

메타놀 300㎖에 Z-Ala-OtBu 14g을 용해시키고, Pd 블랙을 촉매로 사용하여 2시간 동안 접촉 환원을 행한다. 촉매를 여거하고, 메타놀을 유거했다.In methanol 300㎖ dissolved Z-Ala-O t Bu 14g , catalytic reduction is carried out for 2 hours using Pd black as the catalyst. The catalyst was filtered off and the methanol was distilled off.

잔사를 테트라하이드로푸탄 50㎖에 용해시켰다. 한편. Z-Lys(BOC)-OH, 디사이클로헥실아민염 28.1g을 초산에틸 300㎖에 현탁시키고, 0.5N 황산 200㎖로 3회 세척했다. 물로 세척한 후에 이것을 무수 황산나트륨으로 건조시켰다.The residue was dissolved in 50 ml of tetrahydroputane. Meanwhile. 28.1 g of Z-Lys (BOC) -OH and dicyclohexylamine salt were suspended in 300 ml of ethyl acetate and washed three times with 200 ml of 0.5 N sulfuric acid. After washing with water it was dried over anhydrous sodium sulfate.

초산에틸을 약 150㎖에 용적으로 부분적으로 유거하였다. 잔사를 상기 테트라하이드로푸탄 용액에 첨가한 다음에 HONB 10g을 첨가했다. 빙냉하에 DCC 11.3g을 첨가하고, 이 혼합물을 16시간 동안 교반했다. 형성된 DC-우레아를 여거하고, 여액을 건고시켰다. 잔사를 초산에틸 500㎖에 용해시키고, 0.5N 황산과 4% 탄산수소나트륨 수용액으로 세척했다. 물로 양호하게 세척한 후, 초산에틸층을 무수 황산나트륨으로 건조시켰다. 용매를 감압하에서 유거하고 석유 엔진을 첨가하여 결정을 분리했다. 이들 결정을 여과수집하고, 초산에틸-석유 벤진으로 재침전시켰다. 수량 21.9g (87%). 융점 55∼57℃.Ethyl acetate was partially distilled off in about 150 ml. The residue was added to the tetrahydrobutane solution followed by 10 g of HONB. 11.3 g of DCC were added under ice cooling, and the mixture was stirred for 16 hours. The DC-urea formed was filtered off and the filtrate was dried. The residue was dissolved in 500 ml of ethyl acetate and washed with 0.5 N sulfuric acid and 4% aqueous sodium hydrogen carbonate solution. After washing well with water, the ethyl acetate layer was dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure and crystals were separated by addition of a petroleum engine. These crystals were collected by filtration and reprecipitated with ethyl acetate-petroleum benzine. Quantity 21.9 g (87%). Melting point 55-57 degreeC.

Figure kpo00077
Figure kpo00077

b) Z-Pro-Lys(BOC)-Ala-OtBu의 제조Preparation of b) Z-Pro-Lys ( BOC) -Ala-O t Bu

메타놀 40mI에 Z-Lys(BOC)-Ala-OtBu 2.5g을 용해시키고 Pd 블랙을 촉매로 사용하여 2시간 동안 접촉환원을 행했다. 촉매를 여거하고, 여액을 감압하에서 건고했다. 잔사를 초산에틸 20㎖에 용해시키고, 이 용액에 Z-Pro-ONB 2.45g을 첨가한 다음에, 이 혼합물을 실온에서 18시간 동안 교반했다. 이 용액에 초산에틸 200㎖를 첨가하고, 이 혼합물을 0.5N 황산과 4% 탄산수소나트륨 수용액으로 세척한 다음에, 물로 3회 세척하고 무수 황산나트륨으로 건조시킨 다음 감압하에서 건고했다. 그 잔사를 석유 벤진을 첨가하여 생성되는 결정을 여과 수집하고 초산에틸-석유 벤진의 혼합물로 재침전시켰다. 수량 2.53g (85%).Dissolving Z-Lys (BOC) -Ala- O t Bu 2.5g 40mI in methanol and subjected to catalytic reduction for 2 hours by using Pd black as the catalyst. The catalyst was filtered off and the filtrate was dried under reduced pressure. The residue was dissolved in 20 ml of ethyl acetate, and 2.45 g of Z-Pro-ONB was added to this solution, and then the mixture was stirred at room temperature for 18 hours. 200 ml of ethyl acetate was added to the solution, and the mixture was washed with 0.5N sulfuric acid and 4% aqueous sodium hydrogen carbonate solution, washed three times with water, dried over anhydrous sodium sulfate, and dried under reduced pressure. The residue was collected by petroleum benzine and the resulting crystals were collected by filtration and reprecipitated with a mixture of ethyl acetate-petroleum benzine. Quantity 2.53 g (85%).

Figure kpo00078
Figure kpo00078

c) Z-Thr-Pro-Lys(BOC)-Ala-OtBu의 제조Preparation of c) Z-Thr-Pro- Lys (BOC) -Ala-O t Bu

메타놀 40㎖에 Z-Pro-Lys(BOC)-Ala-OtBu 2.12g을 용해시키고, Pd블랙을 촉매로 사용하여 3시간 동안 접촉환원을 행했다. 이 촉매를 여거하고 용매를 감압하에서 유거했다.Dissolving Z-Pro-Lys (BOC) -Ala-O t Bu 2.12g 40㎖ in methanol and was subjected to catalytic reduction for 3 hours using Pd black as the catalyst. This catalyst was filtered off and the solvent was distilled off under reduced pressure.

잔사를 디옥산 20㎖에 용해시켰다. 한편. Z-Thr-OH 977㎎과 HONB 806㎎을 초산에틸-디옥산(1 : 1)10㎖에 용해시키고, 빙냉하에 DCC800㎎을 첨가했다. 이 혼합물을 6시간 동안 교반하여 형성된 DC-우레아를 여거하고, 이 여액을 상기 디옥산 용액에 첨가했다. 이 혼합물을 16시간 동안 교반했다. 용매를 감압하에서 유거하고, 잔류물을 초산에틸 150㎖에 용해시켰다. 이 용액을 0.5N 황산과 4% 탄산수소나트륨 수용액으로 세척했다. 물로 세척한 후에, 무수 황산나트륨으로 건조시키고 용매를 감압하에서 유거했다. 잔사에 석유 벤진을 첨가하여 생성되는 분말을 수집했다. 수량 2.3g.(93%). 융점 64∼67℃.The residue was dissolved in 20 ml of dioxane. Meanwhile. 977 mg of Z-Thr-OH and 806 mg of HONB were dissolved in 10 ml of ethyl acetate-dioxane (1: 1), and DCC800 mg was added under ice-cooling. The mixture was stirred for 6 hours to filter off the DC-urea formed and this filtrate was added to the dioxane solution. This mixture was stirred for 16 hours. The solvent was distilled off under reduced pressure, and the residue was dissolved in 150 ml of ethyl acetate. The solution was washed with 0.5N sulfuric acid and 4% aqueous sodium hydrogen carbonate solution. After washing with water, it was dried over anhydrous sodium sulfate and the solvent was distilled off under reduced pressure. The resulting powder was collected by adding petroleum benzine to the residue. Yield 2.3 g. (93%). Melting point 64-67 degreeC.

Figure kpo00079
Figure kpo00079

d) Z-Phe-Phe-Tyrr-Thr-Pro-Lys(BOC)-Ala-OtBu의 제조Preparation of d) Z-Phe-Phe- Tyrr-Thr-Pro-Lys (BOC) -Ala-O t Bu

메타놀 70㎖에 Z-Thr-Pro-Lys(BOC)-Ala-OtBu 1.41g을 용해시키고, Pd블랙을 촉매로 사용하여 2시간 동안 접촉환원을 행했다. 촉매를 여거하고 용매를 감압하에서 유거했다. 이 잔사를 DMF10㎖에 용해시키고. 그 다음에 Z-Phe-Phe-OH 1.1g과 HONB 720㎎을 첨가했다. 빙냉하에, DCC 618㎎을 첨가하고, 이 혼합물을 20시간 교반했다. 용매를 감압하에서 유거하고 이 잔사를 초산에틸-에테르(1 : 1)로 처리했다. 생성되는 분말을 여과수집하고 에타놀로부터 결정시켰다. 수량 2.1g (100%). 융점 160∼163.5℃,Dissolving Z-Thr-Pro-Lys ( BOC) -Ala-O t Bu 1.41g in methanol 70㎖ and, using Pd black as the catalyst was subjected to catalytic reduction for 2 hours. The catalyst was filtered off and the solvent was distilled off under reduced pressure. This residue was dissolved in 10 ml of DMF. Then 1.1 g of Z-Phe-Phe-OH and 720 mg of HONB were added. Under ice-cooling, 618 mg of DCC was added, and the mixture was stirred for 20 hours. The solvent was distilled off under reduced pressure and the residue was treated with ethyl acetate-ether (1: 1). The resulting powder was collected by filtration and determined from ethanol. Quantity 2.1g (100%). Melting point 160 ~ 163.5 ℃,

Figure kpo00080
Figure kpo00080

e) Z-Arg(NO2)-Gly-Phe-Phe-Tyr-Thr-Pro-Lys(BOC)-Ala-OtBu의 제조 e) Z-Arg (NO 2 ) Preparation of -Gly-Phe-Phe-Tyr- Thr-Pro-Lys (BOC) -Ala-O t Bu

메타놀 30㎖에 Z-Phe-Phe-Thr-Pro-Lys(BOC)-Ala-OtBu 2.32g을 용해시키고 Pd블랙을 촉매로 사용하여 3시간 동안 접촉환원을 행했다. 촉매를 여거하고, 메타놀을 유거했다. 잔사를 DMF 5㎖에 용해시키고. 이 용액에 Z-Aly(NO2)-Gly-ONB 1.26g을 첨가한 다음. 이 혼합물을 실온에서 20시간 교반했다. DMF를 감압하에서 유거하고, 그 잔사에 물 50㎖를 첨가했다. 생성되는 분말을 여과 수집하고. DMF-물로 2회 재침전시켰다. 수량 2.5g (88%). 융점 138∼141℃ (분해).Dissolving Z-Phe-Phe-Thr- Pro-Lys (BOC) -Ala-O t Bu 2.32g 30㎖ in methanol and subjected to catalytic reduction for 3 hours using Pd black as the catalyst. The catalyst was filtered off and the methanol was distilled off. The residue was dissolved in 5 ml of DMF. To this solution was added 1.26 g of Z-Aly (NO 2 ) -Gly-ONB. This mixture was stirred at room temperature for 20 hours. DMF was distilled off under reduced pressure, and 50 ml of water was added to the residue. The resulting powder is collected by filtration. Reprecipitated twice with DMF-water. Quantity 2.5g (88%). Melting point 138-141 degreeC (decomposition).

Figure kpo00081
Figure kpo00081

f) β-Ala-Arg-Gly-Phe-Phe-Tyr-Pro-Lys-Ala-OH의 제조f) Preparation of β-Ala-Arg-Gly-Phe-Phe-Tyr-Pro-Lys-Ala-OH

메타놀 및 빙초산(2 : 1)과의 혼합물 30㎖에 Z-Arg(NO2)-Gly-Phe-Phe-Tur-Thr-Pro-Lys(BOC)-Ala-OtBu 710㎎을 용해시키고, Pd 블랙을 촉매로 사용하여 8시간 동안 접촉환원을 행했다. 촉매를 여가하고 여액을 감압하에서 건고했다. 그 잔사를 물 10㎖에 용해시키고, 이 용액을 카아복시메틸-셀룰로오즈의 컬럼(130㎖)에 통과시켰다. 0.005M 초산암모늄 수용액(800㎖)과 0.2M 초산암모늄 수용액(800㎖)으로 경사용출을 행했다. 913㎖ 내지 1,190㎖의 분획을 모아서 동결 건조하여 백색 우모상 물질 350㎎을 얻었다.Methanol and glacial acetic acid (2: 1) mixture and 30㎖ Z-Arg (NO 2) -Gly-Phe-Phe-Tur-Thr-Pro-Lys (BOC) was dissolved -Ala-O t Bu 710㎎ in, Catalytic reduction was performed for 8 hours using Pd black as a catalyst. The catalyst was allowed to rest and the filtrate was dried under reduced pressure. The residue was dissolved in 10 mL of water and the solution was passed through a column of carboxymethyl-cellulose (130 mL). The solution was decanted with 0.005 M aqueous ammonium acetate solution (800 mL) and 0.2 M aqueous ammonium acetate solution (800 mL). Fractions of 913 mL to 1190 mL were collected and freeze-dried to obtain 350 mg of white feathery material.

이 분말을 DMF 8㎖에 용해시키고, 여기에 p-톨루엔술폰산모노하이드레이트 41㎎을 첨가했다. 그 다음에 BOC-β-Ala-ONB 82㎎을 첨가하고 이 혼합물을 16시간 동안 교반했다. DMF를 감압하에서 유거하고 그 잔사에 트리플루오로초산 3㎖를 첨가했다. 이 혼합물을 30분간 진탕시키고 트리플루오로초산을 유거했다. 잔사를 물 10㎖에 용해시키고 암벌라이트 IRA-410 (초산형)의 컬럼(1.0×10㎝)에 통과시켜 이 화합물을 초산염으로 전환시켰다. 용출물을 동결 건조하고 카아복시메틸-셀룰로오즈의 컬럼(2.2×17㎝)에 통과시켰다. 0.005M 초산암모늄 수용액(500㎖)과 0.2M 초산암모늄 수용액(500㎖)으로 경사용출을 행했다. 430∼500㎖의 분휙을 모아 동결 건조하여 백색우모상 물질 250㎖을 얻었다.This powder was dissolved in 8 ml of DMF, and 41 mg of p-toluenesulfonic acid monohydrate was added thereto. Then 82 mg BOC-β-Ala-ONB was added and the mixture was stirred for 16 h. DMF was distilled off under reduced pressure and 3 ml of trifluoroacetic acid was added to the residue. The mixture was shaken for 30 minutes and the trifluoroacetic acid was distilled off. The residue was dissolved in 10 ml of water and passed through a column (1.0 × 10 cm) of Amberlite IRA-410 (acetic acid type) to convert this compound to acetate. The eluate was lyophilized and passed through a column of carboxymethyl-cellulose (2.2 × 17 cm). The solution was decanted with 0.005 M aqueous ammonium acetate solution (500 mL) and 0.2 M aqueous ammonium acetate solution (500 mL). 430-500 ml of powder was collected and freeze-dried to obtain 250 ml of white wool.

Figure kpo00082
Figure kpo00082

Figure kpo00083
Figure kpo00083

[실시예 23]Example 23

Gly-rg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Ala-OH의 제조 BCC-β-Ala-ONB를 BOC-Gly-ONB로 대체하고 실시예 22-f)의 방법을 반복하여 백색 우모상 물질로서 상기의 목적물 214㎎을 얻었다.Preparation of Gly-rg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Ala-OH Replace BCC-β-Ala-ONB with BOC-Gly-ONB and repeat the method of Example 22-f) 214 mg of the target substance was obtained as a white feathery substance.

Figure kpo00084
Figure kpo00084

Figure kpo00085
Figure kpo00085

[실시예 24]Example 24

Leu-Arg-Gly-Phe-Phe-Tyr-Gly-NH2의 제조Preparation of Leu-Arg-Gly-Phe-Phe-Tyr-Gly-NH 2

a) Z-Leu-Arg(Tos)Gly-Phe-Phe-Tyr(Bzl)-Gly-수지의 제조a) Preparation of Z-Leu-Arg (Tos) Gly-Phe-Phe-Tyr (Bzl) -Gly-resin

고상 펩티드 합성장치(시마즈 APS 800)의 반응조에 BOC-Gly-수지(1.75m㏖의 Gly함유)4.04g을 넣고 디클로로메탄으로 20시간동안 팽윤시켰다. 그 후에 메리피일드법에 의하여, BOC-Tyr(Bzl)-OH, BOC-Phe-OH, BOC-Phe-OH, BOC-Gly-OH, Aoc-Arg(Tos)-OH 및 Z-Leu-OH를 소정의 순서에 따라 도입했다. 축합제로서 DCC를 사용하고, 각 아미노산을 4당량으로 사용하고 트리플루오로초산-디클로로메탄(1 : 1)으로 BOC기를 제거했다. 수지를 반응용기로부터 취하여, 디클로로메탄, DMF, 메타놀 및 초산으로 세척한 다음 건조시켰다. 이 방법으로 상기 수지 5.07g을 얻었다.4.04 g of BOC-Gly-resin (containing 1.75 mmol of Gly) was added to a reaction vessel of a solid-phase peptide synthesizer (Shimadzu APS 800), followed by swelling with dichloromethane for 20 hours. Then, by the Mary Feild method, BOC-Tyr (Bzl) -OH, BOC-Phe-OH, BOC-Phe-OH, BOC-Gly-OH, Aoc-Arg (Tos) -OH and Z-Leu-OH Was introduced in a predetermined order. DCC was used as a condensing agent, and each amino acid was used in 4 equivalents, and the BOC group was removed by trifluoroacetic acid-dichloromethane (1: 1). The resin was taken from the reaction vessel, washed with dichloromethane, DMF, methanol and acetic acid and then dried. In this way, 5.07 g of the resin was obtained.

b) Z-Leu-Arg(Tos)-Gly-Phe-Tyr(Bzl)-Gly-NH2의 제조b) Preparation of Z-Leu-Arg (Tos) -Gly-Phe-Tyr (Bzl) -Gly-NH 2

17% 암모니아-메타놀 50㎖에 상기 a)에서 제조한 수지 4.41g을 현탁시키고 밀폐시킨 다음, 이 현탁액을 실온에서 48시간 교반했다. 이 수지를 여거하고, DMF로 충분히 세척했다. 이 세척액과 여액을 모아서 용매를 감압하에서 유거했다. 유상 잔사에 에틸에테르를 가하여 생성되는 분말을 여과수집하고 에테르로 충분히 세척했다. 수량 950㎎.4.41 g of the resin prepared in a) was suspended and sealed in 50 ml of 17% ammonia-methanol, and the suspension was stirred for 48 hours at room temperature. This resin was filtered off and washed sufficiently with DMF. The washing solution and the filtrate were collected and the solvent was distilled off under reduced pressure. Ethyl ether was added to the oily residue, and the resulting powder was collected by filtration and washed sufficiently with ether. Yield 950 mg.

c) Leu-Arg-Gly-Phe-Phe-Tyr-Gly-NH2의 제조c) preparation of Leu-Arg-Gly-Phe-Phe-Tyr-Gly-NH 2

무수 불화수소 10ml에 상기 b)에서 제조한 보호펩티드-아미드 조품 500㎎과 아니졸 0.5㎖를 용해시킨 용액을 0℃에서 60분간 교반했다. 불화수소를 유거하고 잔사를 물 50㎖에 용해시켰다. 이 용액을 에틸에테르 20㎖로 2회 추출하여 수용액층을 암벌라이드 IRA-410(초산형)의 컬럼(2×10㎝)에 통과시켜 동결 건조했다. 이 제품을 카아복시메틸-셀룰로오즈의 컬럼(2.3×17㎝)에 통과시키고 0.005M 초산암모늄 수용액(400㎖)과 0.2M 초산암모늄 수용액(400㎖)으로 경사용출을 행했다. 490∼550㎖의 분획을 모아 동결 건조했다. 이 방법으로 백색 우모상 물질로서 상기의 목적물 167㎎을 얻었다.A solution obtained by dissolving 500 mg of the protective peptide-amide preparation prepared in b) and 0.5 ml of anisole in 10 ml of anhydrous hydrogen fluoride was stirred at 0 ° C. for 60 minutes. Hydrogen fluoride was distilled off and the residue was dissolved in 50 ml of water. The solution was extracted twice with 20 ml of ethyl ether, and the aqueous layer was passed through a column (2 × 10 cm) of Amberide IRA-410 (acetic acid type) and lyophilized. This product was passed through a column of carboxymethyl-cellulose (2.3 x 17 cm) and eluted with 0.005 M aqueous ammonium acetate solution (400 mL) and 0.2 M aqueous ammonium acetate solution (400 mL). Fractions of 490-550 ml were combined and lyophilized. In this manner, 167 mg of the target product was obtained as a white, feathery material.

아미노산분석 : Arg, 1.02; Gly, 2.00 : Leu, 1.03; Tyr, 0.89; Phe, 2.08 (펩티드 함량 : 84%)Amino acid analysis: Arg, 1.02; Gly, 2.00: Leu, 1.03; Tyr, 0.89; Phe, 2.08 (peptide content: 84%)

[실시예 25]Example 25

β-Ala-Arg-Gly-Phe-Phe-Tyr-Ala-Gly-NH2의 제조Preparation of β-Ala-Arg-Gly-Phe-Phe-Tyr-Ala-Gly-NH 2

a) Z-β-Ala-Arg(Tos)-Gly-Phe-Phe-Tyr(Bzl)-Ala-Gly-수지의 제조a) Preparation of Z-β-Ala-Arg (Tos) -Gly-Phe-Phe-Tyr (Bzl) -Ala-Gly-resin

시마즈 APS-800합성 장치의 반응조에 BOC-Gly-수지 (Gly함유량 1.32mM) 3.03g을 넣고, 그 다음에 디클로로메탄으로 팽윤시켰다. 그 다음에, 대칭 무수물법 (symmetric anhydride process) [Hoppe-Seyle-r's, Z. Physiol. Chem. 353. 1973(1972)참조]에 의하여 BOC-Ala-OH, BOC-Tyr(Bzl)-OH, BOC-Phe-OH, AOC-Arg(Tos)-OH 및 Z-β-Ala-OH를 순서에 따라 도입했다. 각 단계에서 BOC의 제거는 50% 트리플루오로초산-디클로로메탄으로 행했다.3.03 g of BOC-Gly-resin (Gly content 1.32 mM) was placed in a reactor of a Shimadzu APS-800 synthesis apparatus, followed by swelling with dichloromethane. Then, a symmetric anhydride process [Hoppe-Seyle-r's, Z. Physiol. Chem. 353. See 1973 (1972) in which BOC-Ala-OH, BOC-Tyr (Bzl) -OH, BOC-Phe-OH, AOC-Arg (Tos) -OH and Z-β-Ala-OH Introduced along. Removal of BOC at each step was done with 50% trifluoroacetic acid-dichloromethane.

또한 각 단계에 있어서, 미반응 아미노기를 초산 무수물로 아세틸화했다. 모든 아미노산을 도입한 후, 이 수지를 에타놀, DMF, 디클로로메탄, 초산 및 메타놀로 세척한 다음에 감압하에서 건조시켰다. 이 방법으로 펩티드 수지 3.70g을 얻었다.In each step, the unreacted amino group was acetylated with acetic anhydride. After introduction of all amino acids, the resin was washed with ethanol, DMF, dichloromethane, acetic acid and methanolol and then dried under reduced pressure. This method yielded 3.70 g of peptide resin.

b) Z-β-Ala-Arg(Tos)-Gly-Phe-Phe-Tyr(Bzl)-Ala-Gly-N2의 제조b) Preparation of Z-β-Ala-Arg (Tos) -Gly-Phe-Phe-Tyr (Bzl) -Ala-Gly-N 2

17% 암모니아-메타놀 50㎖에 상기 a)에서 제조한 펩티드 수지 3.28g을 현탁시키고 밀폐한 다음. 이 현탁액을 실온에서 40시간 교반했다. 수지를 여거하고 DMF 50㎖로 세척했다. 여액과 세척물을 모아서 감압하에 건고했다. 잔사에 에테르를 첨가하여 생성되는 분말을 여과 수집하고 건조시켰다. 이 방법으로 보호 펩티드-아미드 조품 433㎎을 얻었다.Suspend and seal 3.28 g of the peptide resin prepared in a) in 50 ml of 17% ammonia-methanol. This suspension was stirred for 40 hours at room temperature. The resin was filtered off and washed with 50 mL of DMF. The filtrate and washings were combined and dried under reduced pressure. The powder produced by adding ether to the residue was collected by filtration and dried. In this way, 433 mg of crude peptide-amide was obtained.

c) β-Ala-Arg-Gly-Phe-Phe-Tyr-Ala-Gly-NH2의 제조c) Preparation of β-Ala-Arg-Gly-Phe-Phe-Tyr-Ala-Gly-NH 2

불화수소 무수물 8㎖와 아니졸 0.3㎖와의 혼합물에 상기의 b)에서 제조한 보호 펩티드-아미드 310㎎을 용해시키고. 이 용액을 0℃에서 60분간 교반했다.In a mixture of 8 ml of hydrogen fluoride anhydride and 0.3 ml of anisol, 310 mg of the protective peptide-amide prepared in b) above was dissolved. This solution was stirred at 0 ° C. for 60 minutes.

불화수소를 감압하에서 유거하고, 그 잔사를 물 50㎖에 용해시켰다. 이 용액을 에테르 10㎖로 2희 추출했다. 수용액층을 암벌라이트 IRA-410 (초산형)의 컬럼 (1×10㎝)에 통과시키고, 이것을 물로 세척했다. 용출물과 세척액을 화합하여 이것을 동결 건조했다. 생성물을 물 10㎖에 용해시키고 이 용액을 카아복시메틸-셀룰로오즈의 컬럼(2.3×17㎝)에 통과시켰다. 0.005M 및 0.2M 초산 암모늄의 수용액(각 400㎖)으로 경사용출을 행했다. 495∼540㎖의 분류물을 모아 동결 건조하여 상기의 목적물 134㎎을 얻었다.Hydrogen fluoride was distilled off under reduced pressure, and the residue was dissolved in 50 ml of water. This solution was extracted two times with 10 ml of ether. The aqueous layer was passed through a column (1 × 10 cm) of Amberlite IRA-410 (acetic acid type), which was washed with water. The eluate and wash were combined and lyophilized. The product was dissolved in 10 ml of water and the solution passed through a column of carboxymethyl-cellulose (2.3 x 17 cm). The solution was decanted with an aqueous solution of 0.005 M and 0.2 M ammonium acetate (400 mL each). 495-540 ml of the fractions were collected and freeze-dried to obtain 134 mg of the target substance.

Figure kpo00086
Figure kpo00086

Figure kpo00087
Figure kpo00087

Figure kpo00088
Figure kpo00088

[실시예 26]Example 26

α,γ-Dab-Arg-Gly-Phe-Phe-Tyr-Ala-Gly-NH2의 제조Preparation of α, γ-Dab-Arg-Gly-Phe-Phe-Tyr-Ala-Gly-NH 2

최종적으로 도입하고자 하는 아미노산으로서, Z,β-Ala-OH 대신에 di-Z-α,γ-Abu-OH를 사용하여 실시예 25의 방법을 반복하였다. 이 방법으로 백색 우모상 물질로서 상기의 목적물을 얻었다.The method of Example 25 was repeated using di-Z-α, γ-Abu-OH instead of Z, β-Ala-OH as the amino acid to be finally introduced. In this manner, the target product was obtained as a white, feathery material.

Figure kpo00089
Figure kpo00089

Figure kpo00090
Figure kpo00090

[실시예 27]Example 27

Gly-Arg-Gly-Phe-Phe-NH2의 제조Preparation of Gly-Arg-Gly-Phe-Phe-NH 2

a) Z-Gly-Arg(NO2)-Gly-Phe-Phe-NH2의 제조a) Preparation of Z-Gly-Arg (NO 2 ) -Gly-Phe-Phe-NH 2

Z-Arg(NO2)-Gly-Phe-Phe-NH20.80g에 25% HBr 초산 8㎖를 첨가하고 이 혼합물을 실온에서 45분간 충분히 진탕시켰다. 이 반응 혼합물에 에테르 100㎖를 가하여 생성되는 분말을 여과수집하고 감압하에서 2일간 건조기 중에서 수산화나트륨 과립으로 건조시켰다. 건조물은 DMF 10㎖에 용해시키고 용액을 트리에틸아민으로 중화시켰다. 이용액에 Z-Gly-ONB 0.43g을 가하고 이 혼합물을 10시간 동안 교반했다.To 0.80 g of Z-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 , 8 ml of 25% HBr acetic acid was added and the mixture was sufficiently shaken at room temperature for 45 minutes. 100 ml of ether was added to the reaction mixture, and the resulting powder was collected by filtration and dried in a dryer for 2 days under reduced pressure with sodium hydroxide granules. The dryness was dissolved in 10 mL of DMF and the solution was neutralized with triethylamine. 0.43 g of Z-Gly-ONB was added to the solution, and the mixture was stirred for 10 hours.

이 용액에 물 7㎖를 가하여 오일을 분리했다. 경사하여 상층액을 제거한 후에, 물 50㎖를 첨가했다. 생성되는 분말을 여과 수집한 다음 건조시켰다. 이 생정물을 DMF-초산에틸로 재침전시켜 정제했다. 수량 0.66g (77%).7 ml of water was added to this solution to separate the oil. After decantation and removal of the supernatant, 50 ml of water was added. The resulting powder was collected by filtration and then dried. This crude product was purified by reprecipitation with DMF-ethyl acetate. Quantity 0.66g (77%).

Figure kpo00091
Figure kpo00091

b) Gly-Arg-Gly-Phe-Phe-NH2의 제조b) Preparation of Gly-Arg-Gly-Phe-Phe-NH 2

초산 30㎖에 Z-Gly-Arg(NO2)-Gly-Phe-Phe-NH2500㎎을 용해시키고, 수소기류 중에서 Pd 블랙을 촉매로 사용하여 7시간 동안 촉매환원을 행했다. 촉매를 여거하고, 초산을 감압하에서 유거했다. 잔사를 물10㎖에 용해시키고 이 용액을 카아복시메틸-셀룰로오즈의 컬럼(1.8×10㎝)에 통과시켰다.500 mg of Z-Gly-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 7 hours using Pd black as a catalyst in a hydrogen stream. The catalyst was filtered off and acetic acid was distilled off under reduced pressure. The residue was dissolved in 10 ml of water and the solution passed through a column of carboxymethyl-cellulose (1.8 × 10 cm).

0.1M 초산암모늄 수용액(700㎖)과 1M초산암모늄 수용액(700㎖)을 사용하여 선형 구배 경사법으로 용출을 행했다. 410∼515㎖의 분획을 모아 동결 건조하여 백색 우모상 물질 307㎎ (65%)을 얻었다.Elution was performed by the linear gradient gradient method using 0.1 M aqueous ammonium acetate solution (700 ml) and 1 M ammonium acetate aqueous solution (700 ml). Fractions of 410-515 mL were collected and freeze-dried to give 307 mg (65%) of white feathery material.

Figure kpo00092
Figure kpo00092

[실시예 28]Example 28

D-Ala-Arg-Gly-Phe-Phe-NH2의 제조Preparation of D-Ala-Arg-Gly-Phe-Phe-NH 2

a) Z-D-Ala-Arg(NO2)-Gly-Phe-Phe-NH2의 제조a) Preparation of ZD-Ala-Arg (NO 2 ) -Gly-Phe-Phe-NH 2

25% HBr 초산 8㎖에 Z-Arg(NO2)-Gly-Phe-Phe-NH20.80g을 용해시키고, 이 용액을 실온에서 40분간 진탕시켰다. 이 혼합물에 에틸에테르 100㎖를 가하여 침전물을 형성했다. 이 침전물을 여과 수집하고, 에테르로 세척한 다음 건조했다. 건조된 생성물을 DMF 10㎖에 용해시키고, 이 용액을 트리에틸아민으로 중화시킨 다음에, Z-D-Ala-ONB 0.51g을 가했다. 이 혼합물을 8시간 동안 교반했다. DMF를 감압하에서 유거하고 그 잔사에 물 50㎖를 가했다.0.80 g of Z-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 was dissolved in 8 ml of 25% HBr acetic acid, and the solution was shaken at room temperature for 40 minutes. 100 ml of ethyl ether was added to this mixture to form a precipitate. This precipitate was collected by filtration, washed with ether and dried. The dried product was dissolved in 10 mL of DMF, the solution was neutralized with triethylamine, and then 0.51 g of ZD-Ala-ONB was added. This mixture was stirred for 8 hours. DMF was distilled off under reduced pressure and 50 ml of water was added to the residue.

생성되는 분말을 여과 수집하여 건조시킨 후에, 이 분말을 뜨거운 초산에틸로 세척하고, 이어서 DMF-초산에틸로 재침전시켰다. 수량 0.799g (92%). 융점 223∼225℃,After the resulting powder was collected by filtration and dried, the powder was washed with hot ethyl acetate and then reprecipitated with DMF-ethyl acetate. Yield 0.799 g (92%). Melting point 223-225 캜,

Figure kpo00093
Figure kpo00093

b) D-Ala-Arg-Gly-Phe-Phe-NH2의 제조b) Preparation of D-Ala-Arg-Gly-Phe-Phe-NH 2

초산 30㎖에 Z-D-Ala-Arg(NO2)-Gly-Phe-Phe-NH2600㎎을 용해시키고 Pd블랙을 촉매로 사용하기 7시간 동안 접촉 환원을 행했다. 촉매를 여거하고 용매를 감압하에서 유거했다. 그 잔사를 물 10㎖에 용해시키고, 이 용액을 카아복시메틸-세파덱스의 컬럼(1.8×11㎝)에 통과시켰다.600 mg of ZD-Ala-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 was dissolved in 30 ml of acetic acid and catalytic reduction was performed for 7 hours using P d black as a catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was dissolved in 10 ml of water, and the solution was passed through a column of carboxymethyl-sefadex (1.8 x 11 cm).

0.1M 초산암모늄 수용액(700㎖)과 1M 초산암모늄 수용액(700㎖)으로 선형 구배 용출을 행하여 350∼450㎖의 용출 분획을 모아서 동결건조했다 이 방법으로 백색 우모상 물질 400㎖ (73%)을 생성했다.Linear gradient elution was performed with 0.1 M aqueous ammonium acetate solution (700 ml) and 1 M aqueous ammonium acetate solution (700 ml) to collect 350-450 ml of the elution fractions and lyophilized. 400 ml (73%) of white feathery material was obtained by this method. Created.

Figure kpo00094
Figure kpo00094

[실시예 29]Example 29

Phe-Arg-Gly-Phe-Phe-NH2의 제조Preparation of Phe-Arg-Gly-Phe-Phe-NH 2

a) Z-Phe-Arg(NO2)-Gly-Phe-Phe-NH2의 제조a) Preparation of Z-Phe-Arg (NO 2 ) -Gly-Phe-Phe-NH 2

25% HBr-초산 10㎖에 Z-Arg(NO2)-Gly-Phe-Phe-NH2800㎎을 용해시키고, 이 용액을 50분간 진탕시켰다. 이 용액에 에테르 80㎖를 첨가하고 생성되는 침전물을 여과 수집하고, 건조시킨 다음 DMF 10㎖에 용해시켰다. 이 용액을 트리에틸아민으로 중화시킨 다음에, Z-Phe-OPCP(펜타클로로페닐에스테르) 700㎎을 첨가했다. 이 혼합물을 10시간 동안 교반하고, 여기에 1N 암모니아 수용액 50m1를 첨가했다. 유충을 경사에 의하여 취해서 이 유상물질에 물을 가했다. 생성되는 분말을 여과수집한 다음 건조시켰다. 이 분말에 초산에틸 50㎖를 가하여, 이 혼합물을 가열한 다음 분말을 뜨거운 조건하에서 여과수집했다. 분말을 DMF-초산에틸로 재침전시켜 정제했다. 수량 805㎎ (92%).800 mg of Z-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 was dissolved in 10 ml of 25% HBr-acetic acid, and the solution was shaken for 50 minutes. 80 ml of ether was added to the solution and the resulting precipitate was collected by filtration, dried and dissolved in 10 ml of DMF. After neutralizing this solution with triethylamine, 700 mg of Z-Phe-OPCP (pentachlorophenyl ester) was added. The mixture was stirred for 10 hours, and 50 ml of 1N aqueous ammonia solution was added thereto. The larvae were taken by tilt and water was added to this oily substance. The resulting powder was collected by filtration and then dried. 50 ml of ethyl acetate was added to the powder, and the mixture was heated, and the powder was collected by filtration under hot conditions. The powder was purified by reprecipitation with DMF-ethyl acetate. Yield 805 mg (92%).

Figure kpo00095
Figure kpo00095

b) Phe-Ag-Gly-Phe-Phe-NH2의 제조b) preparation of Phe-Ag-Gly-Phe-Phe-NH 2

무수 불화수소 6ml에, Z-Phe-Arg(NO2)-Gly-Phe-Phe-NH2500㎎을 용해시켜 이 용액을 -10℃에서 40분간 교반했다. 불화수소를 유거하고 잔사를 물 10㎖에 용해시켰다. 이 용액을 암벌라이트-lRA-410(초산형)의 컬럼(0.9×15㎝)을 통과시켜 이것을 물로 세척했다. 이 방법으로 상기의 목적물 402㎎을 수득했다.500 mg of Z-Phe-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 was dissolved in 6 ml of anhydrous hydrogen fluoride, and the solution was stirred at −10 ° C. for 40 minutes. Hydrogen fluoride was distilled off and the residue was dissolved in 10 ml of water. This solution was passed through a column of Amberlite-lRA-410 (acetic acid type) (0.9 × 15 cm) and washed with water. In this way, 402 mg of the target product was obtained.

아미노산 분석 : Arg, 1.01; Gly, 0.98; Phe, 2.94 (펩티드 함량 : 86.2%)Amino acid analysis: Arg, 1.01; Gly, 0.98; Phe, 2.94 (peptide content: 86.2%)

[실시예 30]Example 30

Leu-Arg-Gly-Phe-Phe-Tyr-NH2의 제조Preparation of Leu-Arg-Gly-Phe-Phe-Tyr-NH 2

a) Z-Arg(NO2)-Gly-Phe-Phe-Tyr-NH2의 제조a) Preparation of Z-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-NH 2

DMF100㎖에 Z-Phe-Phe-Tyr-NH212.2g을 용해시키고 Pd 블랙을 촉매로 사용하여 5시간 동안 접촉환원을 행했다. 촉매를 여거하고 여기에 Z-Arg(NO2)-Gly-OH 8.6g과 HONB 4.3g을 가했다.12.2 g of Z-Phe-Phe-Tyr-NH 2 was dissolved in 100 mL of DMF, and catalytic reduction was performed for 5 hours using Pd black as a catalyst. The catalyst was filtered off, and 8.6 g of Z-Arg (NO 2 ) -Gly-OH and 4.3 g of HONB were added thereto.

빙냉하에. DCC4.95g을 가하여, 이 혼합물을 12시간동안 교반했다. 형성된 DC-우레아를 여거하고, 물 1ℓ를 여액에 첨가하여 생성되는 겔을 여과수집한 다음 메타놀과 물로재침전시켰다. 수량 16.25g(91.8%),Under ice cooling. 4.95 g of DCC were added and the mixture was stirred for 12 hours. The formed DC-urea was filtered off, and 1 liter of water was added to the filtrate, and the resulting gel was collected by filtration and then reprecipitated with methanol and water. 16.25 g (91.8%),

Figure kpo00096
Figure kpo00096

b) Arg-Gly-Phe-Phe-Tyr-NH2의 제조b) Preparation of Arg-Gly-Phe-Phe-Tyr-NH 2

초산 30㎖에 Z-Arg(NO2)-Gly-Phe-Phe-Tyr-NH2600㎎을 용해시키고, Pd 블랙을 촉매로 사용하여 9시간 동안 접촉 환원을 행했다. 촉매를 여거하고, 용매를 감압하에서 유거했다. 이 잔사를 물 15㎖에 용해시키고 그 다음에 카아복시메틸세파덱스의 컬럼(1.3×11㎝)에 의하여 정제시켰다. 0.1M 초산암모늄 수용액(500㎖)과 1M 초산암모늄 수용액(500㎖)으로 선형 구배 경사용출을 행했다. 250∼420㎖의 분획을 모아서 동결 건조했다. 수량 416㎎ (72.5%).600 mg of Z-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-NH 2 was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 9 hours using Pd black as a catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. This residue was dissolved in 15 ml of water and then purified by column of carboxymethyl sepadex (1.3 x 11 cm). Linear gradient gradient elution was performed with 0.1 M aqueous ammonium acetate solution (500 mL) and 1 M aqueous ammonium acetate solution (500 mL). 250-420 mL of fractions were combined and lyophilized. Yield 416 mg (72.5%).

Figure kpo00097
Figure kpo00097

c) Z-Leu-Arg(NO2)-Gly-Phe-Phe-Tyr-NH2의 제조c) Preparation of Z-Leu-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-NH 2

Z-Arg(NO2)-Gly-Phe-Phe-Tyr-NH2700㎎에 아니졸 0.2㎖를 가한 다음에 25% HBr-초산 7㎖를 가했다. 이 혼합물을 실온에서 40분간 진탕시킨 다음에 에틸에테르 100㎖를 가했다. 생성되는 침전물을 여과수집하고, DMF 100㎖에 용해시켰다. 이 용액을 트리에틸아민으로 중화시킨 다음에 Z-Leu-Sou (N-하이드록시숙신아미드에스테르) 344㎎을 가했다. 이 혼합물을 12시간 동안 교반했다. DMF를 감압하에서 유거하고 그 잔사에 물 50㎖를 가했다. 생성되는 분말을 여과하여 수집하고 메타놀 및 물로 재침 전시켜 정제했다. 수량 560㎎(70.9%). 융점 193∼195℃To 700 mg of Z-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-NH 2 was added 0.2 ml of anizole and then 7 ml of 25% HBr-acetic acid. The mixture was shaken at room temperature for 40 minutes and then 100 ml of ethyl ether was added. The resulting precipitate was collected by filtration and dissolved in 100 ml of DMF. The solution was neutralized with triethylamine and then 344 mg of Z-Leu-Sou (N-hydroxysuccinamide ester) was added. This mixture was stirred for 12 hours. DMF was distilled off under reduced pressure and 50 ml of water was added to the residue. The resulting powder was collected by filtration and purified by reprecipitation with methanol and water. Yield 560 mg (70.9%). Melting Point 193 ~ 195 ℃

Figure kpo00098
Figure kpo00098

d) Leu-Arg-Gly-Phe-Phe-Tyr-NH2의 제조d) preparation of Leu-Arg-Gly-Phe-Phe-Tyr-NH 2

초산30㎖에 Z-Leu-Arg(NO2)-Gly-Phe-Phe-Tyr-NH2400㎎을 용해시키고, Pd블랙을 촉매로 사용하여 10시간 동안 접촉 환원을 행했다. 촉매를 여거하고 용매를 감압하에서 유거했다. 잔사를 물 50㎖에 용해시킨 다음. 그 용액을 카아복시메틸-셀룰로오즈의 컬럼(2.6×22㎝)에 통과시켰다.400 mg of Z-Leu-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-NH 2 was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 10 hours using Pd black as a catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was dissolved in 50 ml of water. The solution was passed through a column of carboxymethyl-cellulose (2.6 x 22 cm).

0.005M 초산암모늄 수용액 (700㎖)과 0.2M 초산암모늄 수용액 (700㎖)으로 경사용출을 행하고, 830∼910㎖의 분획을 모아 동결 건조했다. 수량 217㎎ (55.5%).The solution was decanted with 0.005 M aqueous ammonium acetate solution (700 mL) and 0.2 M aqueous ammonium acetate solution (700 mL), and 830-910 mL fractions were collected and freeze-dried. Yield 217 mg (55.5%).

Figure kpo00099
Figure kpo00099

[실시예 31]Example 31

α-Abu-Arg-Gly-Phe-Phe-Tyr-NH2의 제조Preparation of α-Abu-Arg-Gly-Phe-Phe-Tyr-NH 2

Z-Leu 대신에 Z-α-Abu를 사용하여 실시예 30의 방법을 반복하여 상기의 목적물을 얻었다.The target of the above was obtained by repeating the method of Example 30 using Z-α-Abu instead of Z-Leu.

Figure kpo00100
Figure kpo00100

[실시예 32]Example 32

Nle-Arg-Gly-Phe-Phe-Tyr-NH2의 제조Preparation of Nle-Arg-Gly-Phe-Phe-Tyr-NH 2

Z-Leu 대신에 Z-Nle을 사용하여 실시예 30의 방법을 반복하여 상기의 목적물을 얻었다.The target of the above was obtained by repeating the method of Example 30 using Z-Nle instead of Z-Leu.

Figure kpo00101
Figure kpo00101

[실시예 33]Example 33

Val-Arg-Gly-Phe-Phe-Tyr-NH2의 제조Preparation of Val-Arg-Gly-Phe-Phe-Tyr-NH 2

DMF 10㎖에 실시예 30-b)에서 제조한 Arg-Gly-Phe-Tyr-NH2·2 초산염 400㎎을 용해시킨 다음에 Z-Val-ONB 300㎎을 가했다. 이 용액을 트리에틸아민으로 중화시켜 10시간 동안 교반했다. 이 용액에 에테르 50㎖를 가하여 생성되는 침전물을 여과수집하고 초산에틸로 세척한 다음 건조시켰다. 이 생성물을 초산-물(1 : 1)30㎖에 용해시키고, Pd 블랙을 촉매로 사용하여 4시간 동안 촉매환원을 행했다. 촉매를 여거하고 이 여액을 견고시켰다. 잔사를 물 10㎖에 용해시키고 실시예 30-c)에 기술한 것과 동일한 방법으로 크로마토그라피하여 정제했다. 수량 360㎎,

Figure kpo00102
-13.7°(c=0.5, 물)400 mg of Arg-Gly-Phe-Tyr-NH 2 .2 acetate prepared in Example 30-b) was dissolved in 10 ml of DMF, followed by addition of 300 mg of Z-Val-ONB. The solution was neutralized with triethylamine and stirred for 10 hours. 50 ml of ether was added to the solution, and the resulting precipitate was collected by filtration, washed with ethyl acetate and dried. This product was dissolved in 30 ml of acetic acid-water (1: 1) and catalytic reduction was carried out for 4 hours using Pd black as a catalyst. The catalyst was filtered off and the filtrate was solidified. The residue was dissolved in 10 ml of water and purified by chromatography in the same manner as described in Example 30-c). 360 mg,
Figure kpo00102
-13.7 ° (c = 0.5, water)

아미노산분석 : Arg, 1.02; Gly, 1.00 Val, 0.97; Phe, 2.04; Tyr, 0.97(펩티드 함량 : 86.2%)Amino acid analysis: Arg, 1.02; Gly, 1.00 Val, 0.97; Phe, 2.04; Tyr, 0.97 (peptide content: 86.2%)

[실시예 34]Example 34

β-Ala-Arg-Gly-Phe-Phe-NH2의 제조Preparation of β-Ala-Arg-Gly-Phe-Phe-NH 2

a) Z-Arg(NO2)Gly-OEt의 제조a) Preparation of Z-Arg (NO 2 ) Gly-OEt

테트라하이드로푸란 200㎖에 Z-Arg(NO2)-OH 70.7g을 용해시키고 빙냉하에 2.4-디니트로페놀 40.5g 및 DCC45.4g을 가하여 이 혼합물을 4시간 동안 교반했다. 한편, Gly-OEt HC1 30.7g을 테트라하이드로푸란 200㎖에 현탁시키고, 빙냉하에 이 현탁액을 트리에틸아민 30.8㎖로 중화시켰다. 형성된 디사이클로헥실우레아를 여거하고, 상기와 같이 제조한 활성 에스테르 용액을 이 여액에 가한 다음에 철야 교반했다. 용액을 농축하여 잔사를 초산에틸 500㎖에 용해시켰다. 이 용액을 탄산수소나트륨의 포화수용액(200㎖×3), 1N 염산(200㎖×3), 염화나트륨의 포화수용액(200㎖×3)의 순서로 세척한 다음, 무수 황산나트륨으로 건조시켰다. 이 용액을 농축하고 초산에틸-석유벤진으로 결정시켰다. 결정을 여과하여 다시 회수한 뒤 초산에틸-석유벤진으로 재결정했다. 수량 70.0g(79.8%), 융점 109∼110℃.

Figure kpo00103
Figure kpo00104
70.7 g of Z-Arg (NO 2 ) -OH was dissolved in 200 mL of tetrahydrofuran, 40.5 g of 2.4-dinitrophenol and 45.4 g of DCC were added under ice-cooling, and the mixture was stirred for 4 hours. On the other hand, 30.7 g of Gly-OEt HC1 was suspended in 200 ml of tetrahydrofuran, and the suspension was neutralized with 30.8 ml of triethylamine under ice cooling. The dicyclohexyl urea formed was filtered off, the active ester solution prepared as mentioned above was added to this filtrate, and it stirred overnight. The solution was concentrated to dissolve the residue in 500 ml of ethyl acetate. The solution was washed in the order of a saturated aqueous solution of sodium bicarbonate (200 mL x 3), 1N hydrochloric acid (200 mL x 3), and a saturated aqueous solution of sodium chloride (200 mL x 3), followed by drying over anhydrous sodium sulfate. This solution was concentrated and determined with ethyl acetate-petroleum benzine. The crystals were collected by filtration and recrystallized with ethyl acetate-petroleum benzine. Yield 70.0 g (79.8%), melting | fusing point 109-110 degreeC.
Figure kpo00103
Figure kpo00104

Figure kpo00105
Figure kpo00105

b) Z-Arg(NO2)-Gly-OH의 제조b) Preparation of Z-Arg (NO 2 ) -Gly-OH

아세톤 100㎖에 Z-Arg(NO2)-Gly-OEt 20.0g을 현탁시키고, 빙냉하에 1N 수산화나트륨 수용액 64㎖를 가했다. 이 혼합물을 실온에서 2시간 동안 교반했다.20.0 g of Z-Arg (NO 2 ) -Gly-OEt was suspended in 100 ml of acetone, and 64 ml of 1N aqueous sodium hydroxide solution was added under ice-cooling. The mixture was stirred at rt for 2 h.

과잉의 알칼리를 염산으로 중화시킨 후에, 이 용액을 감압하에서 농축하고 그 잔사에 물 100㎖를 가했다. 불용물을 여거하고, 이 여액을 염산으로 산성으로 하고 생성되는 결정을 여과하여 회수했다. 수량18.3g(93.7%), 융점 103∼105℃,

Figure kpo00106
After neutralizing excess alkali with hydrochloric acid, the solution was concentrated under reduced pressure and 100 ml of water was added to the residue. The insolubles were filtered off, the filtrate was made acidic with hydrochloric acid and the resulting crystals were collected by filtration. Quantity 18.3 g (93.7%), Melting point 103-105 degreeC,
Figure kpo00106

Figure kpo00107
Figure kpo00107

c) Z-Arg(NO2)-Gly-Phe-Phe-NH2의 제조c) Preparation of Z-Arg (NO 2 ) -Gly-Phe-Phe-NH 2

DMF 60㎖와 메타놀 40㎖와의 혼합물에 Z-Phe-Phe-NH28.91g을 용해시키고 Pd 블랙 존재하에 14시간동안 접촉 수첨반응은 행했다. 촉매를 여거하고 용매를 감압하에서 유거했다. 잔사를 DMF30㎖에 용해시켰다. 한편, Z-Arg(NO2)-Gly-OH 6.80g을 테트라하이드로푸란 50㎖에 가하고, 빙냉하에 HONB3.23g과 DCC3.71g을 가한 다음에 5시간 동안 교반시켰다. 형성된 디사이클로헥실우레아를 여거하고 상기의 아민성분(H-Phe- Phe-NH2)을 이 여액에 가했다. 혼합물을 철야 교반하고 용매를 감압하에서 유거한 후에 잔사에 물 100㎖를 가하여 생성되는 분말을 여과수집했다.8.91 g of Z-Phe-Phe-NH 2 was dissolved in a mixture of 60 ml of DMF and 40 ml of methanol, and contact hydrogenation was carried out for 14 hours in the presence of Pd black. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was dissolved in 30 ml of DMF. Meanwhile, 6.80 g of Z-Arg (NO 2 ) -Gly-OH was added to 50 mL of tetrahydrofuran, and HOB3.23 g and DCC3.71 g were added under ice cooling, followed by stirring for 5 hours. The formed dicyclohexyl urea was filtered out and the amine component (H-Phe-Phe-NH 2 ) was added to the filtrate. The mixture was stirred overnight, the solvent was distilled off under reduced pressure, and 100 ml of water was added to the residue, and the resulting powder was collected by filtration.

건조시킨 후에, 생성물을 초산에틸로 세척하고 에타놀-초산에틸로 재결정시켰다. 수량 8.34g(72.7%), 융점 112∼113℃,

Figure kpo00108
After drying, the product was washed with ethyl acetate and recrystallized with ethanol-ethyl acetate. Yield 8.34 g (72.7%), melting point 112-113 ° C,
Figure kpo00108

Figure kpo00109
Figure kpo00109

d) Z-β-Ala-ONB의 제조d) preparation of Z-β-Ala-ONB

테트라하이드로푸란 40㎖에 Z-β-Ala-OH 3.35g과 HONB 3.23g을 용해하여, 빙냉시킨 후에 DCC3.71g을 가했다. 이 혼합물을 철야 교반하여 형성된 디사이클로헥실우레아를 여거했다. 용매를 감압하에서 유거하고 여기에 석유 엔진을 가했다. 생성되는 결정을 여과하여 회수하고 아세토니트릴로부터 재결정시켰다. 수량 3.83g (66.4%), 융점 125∼126℃.3.35 g of Z-β-Ala-OH and 3.23 g of HONB were dissolved in 40 mL of tetrahydrofuran, and after cooling with ice, DCC3.71 g was added. The mixture was stirred overnight to dicyclohexylurea formed. The solvent was distilled off under reduced pressure and a petroleum engine was added thereto. The resulting crystals were collected by filtration and recrystallized from acetonitrile. Yield 3.83 g (66.4%), melting point 125-126 degreeC.

Figure kpo00110
Figure kpo00110

e) Z-β-Ala-Arg)NO2)-Gly-Phe-Phe-NH2의 제조e) Preparation of Z-β-Ala-Arg) NO 2 ) -Gly-Phe-Phe-NH 2

Z-Arg(NO2)-Gly-Phe-Phe-NH21.06g에 25% HBr-초산 10㎖를 가하고, 실온에서 40분간 진탕시킨 후에, 여기에 에틸에테르를 첨가했다. 생성되는 침전물을 여과 회수하고, 데시케이터 중의 감압하에서 수산화나트륨으로 건조시킨 다음, DMF 10㎖에 용해시켰다. 냉각 후에, 이 용액을 트리에틸아민 0.84㎖로 중화시킨 다음에 여기에 Z-β-Ala-ONB 0.69g을 가했다. 이 혼합물을 철야 교반하고 용매를 감압하에서 유거한 다음 물 50㎖를 가했다. 생성되는 분말을 건조시키고, 초산에틸로 세척하고, 물-디옥산-초산에틸로 재침전시켰다. 수량 0.98g(83.3%)융점 161∼163℃,

Figure kpo00111
10 ml of 25% HBr-acetic acid was added to 1.06 g of Z-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 , shaken at room temperature for 40 minutes, and ethyl ether was added thereto. The resulting precipitate was collected by filtration, dried over sodium hydroxide under reduced pressure in a desiccator, and then dissolved in 10 ml of DMF. After cooling, the solution was neutralized with 0.84 mL of triethylamine, and then 0.69 g of Z-β-Ala-ONB was added thereto. The mixture was stirred overnight, the solvent was distilled off under reduced pressure, and 50 ml of water was added thereto. The resulting powder was dried, washed with ethyl acetate and reprecipitated with water-dioxane-ethyl acetate. 0.98 g (83.3%) Melting Point 161-163 deg.
Figure kpo00111

Figure kpo00112
Figure kpo00112

f) β-Ala-Arg-Gly-Phe-Phe-NH2의 제조f) Preparation of β-Ala-Arg-Gly-Phe-Phe-NH 2

초산 40㎖에 Z-β-Ala-Arg(NO2)-Gly-Phe-Phe-NH2를 촉매로서 팔라듐과 함께 용해시키고 14시간동안 접촉환원을 시켰다. 촉매를 여거하고 용매를 감압하에서 유거했다. 잔류물을 카아복시메틸-세파덱스의 컬럼(2.5㎝×9㎝)에 통과시키고 선형 구배 경사법에 의하여 0.01N 초산암모늄 수용액(700㎖)으로부터 1N 초산암모늄 수용액(700㎖)을 통하여 용출을 행했다. 780∼990㎖에 분획을 모아 동결 건조했다. 수량 500㎎(66%),In 40 ml of acetic acid, Z-β-Ala-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 was dissolved with palladium as a catalyst and subjected to catalytic reduction for 14 hours. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was passed through a column of carboxymethyl-sefadex (2.5 cm x 9 cm) and eluted from a 0.01 N aqueous ammonium acetate solution (700 mL) through a 1 N aqueous ammonium acetate solution (700 mL) by linear gradient gradient method. . The fractions were collected in 780-990 ml and lyophilized. Yield 500 mg (66%),

Figure kpo00113
Figure kpo00113

Figure kpo00114
Figure kpo00114

[괄호 안의 숫자는 이론치를 나타내는데, 이하 동일하게 적용한다]. (펩티드 함량 : 76%)[Numbers in parentheses indicate theoretical values, the same applies hereafter]. (Peptide Content: 76%)

[실시예 35]Example 35

γ-Abu-Arg-Gly-Phe-Phe-NH2의 제조Preparation of γ-Abu-Arg-Gly-Phe-Phe-NH 2

a) Z-7-Abu-ONB의 제조a) Preparation of Z-7-Abu-ONB

테트라하이드로푸란 40㎖에 Z-γ-Abu-OH4.75g과 HONB 3.94g을 용해시키고, 빙냉한 후에, 여기에 DCC3.94g을 용해시키고, 빙냉한 후에. 여기에 DCC 4.54g을 가했다. 혼합물을 6시간 동안 교반하여 형성된 디사이클로헥실우레아를 여거했다. 용매를 감압하에서 유거한 다음에 에틸에테르 30㎖를 잔사에 가하고, 이어서 소량의 물을 가했다. 생성되는 결정을 여과하여 수집했다. 수량 6.0g(75.3%), 융점 66∼69℃After dissolving 4.75 g of Z-γ-Abu-OH and 3.94 g of HONB in 40 ml of tetrahydrofuran, and after ice-cooling, after dissolving DCC 3.94 g and ice-cooling thereto. To this was added 4.54 g of DCC. The mixture was stirred for 6 hours to filter out dicyclohexylurea formed. The solvent was distilled off under reduced pressure, and then 30 ml of ethyl ether was added to the residue, followed by addition of a small amount of water. The resulting crystals were collected by filtration. Quantity 6.0 g (75.3%), melting point 66-69 degrees Celsius

Figure kpo00115
Figure kpo00115

b) Z-γ-Abu-Arg(NO2)-Gly-Phe-Phe-NH2의 제조b) Preparation of Z-γ-Abu-Arg (NO 2 ) -Gly-Phe-Phe-NH 2

실시예 34-e)에서 기재한 것과 동일한 방법에 따라 Z-Arg(NO2)-Gly-Phe-Phe- NH20.53g을 HBr-초산으로 처리하여 DMF 15㎖에 용해시켰다. 이 용액을 트리에틸아민으로 중화시킨후에, Z-γ-Abu-ONB 0.44g을 가했다. 이 혼합물을 철야 교반하고 용매를 강압하에서 유거한 다음 물을 가했다. 생성되는 분말을 여과 회수하고 충분히 건조시켰다.0.53 g of Z-Arg (NO 2 ) -Gly-Phe-Phe- NH 2 was treated with HBr-acetic acid and dissolved in 15 ml of DMF according to the same method as described in Example 34-e). After neutralizing this solution with triethylamine, 0.44 g of Z-γ-Abu-ONB was added. The mixture was stirred overnight and the solvent was distilled off under reduced pressure and water was added. The resulting powder was collected by filtration and dried sufficiently.

초산에틸로 세척하고 에타놀-물로부터 재침전시켰다. 수량 0.38g(65%), 융점 167∼170℃,

Figure kpo00116
Figure kpo00117
Washed with ethyl acetate and reprecipitated from ethanol-water. 0.38 g (65%), Melting point 167-170 degreeC,
Figure kpo00116
Figure kpo00117

Figure kpo00118
Figure kpo00118

c) γ-Abu-Arg-Gly-Phe-Phe-NH2의 제조c) Preparation of γ-Abu-Arg-Gly-Phe-Phe-NH 2

초산 30㎖에 Z-γ-Abu-Arg(NO2)-Gly-Phe-Phe-300mg을 용해시키고, Pd를 촉매 로 하여 6시간 동안 접촉환원을 행했다. 촉매를 여거한 후에 용매를 감압하에서 유거하고 그 잔사를 카아복시메틸-세파덱스의 컬럼(1.8㎝×10㎝)에 통과시켰다. 그 다음에 선형 구배경사법에 의하여 0.005N 초산암모늄 수용액(350㎖)으로부터 1N 초산암모늄 수용액(350㎖)을 통과시켜 용출을 행하고, 290∼340㎖의 분획을 모아 동결시켰다. 수량 180㎎(63%),

Figure kpo00119
Z-γ-Abu-Arg (NO 2 ) -Gly-Phe-Phe-300 mg was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 6 hours using Pd as a catalyst. After the catalyst was filtered off, the solvent was distilled off under reduced pressure and the residue was passed through a column of carboxymethyl-sefadex (1.8 cm x 10 cm). Then, eluting was carried out by passing 1 N ammonium acetate solution (350 mL) from 0.005 N ammonium acetate solution (350 mL) by linear background method, and 290-340 mL fractions were collected and frozen. 180 mg (63%)
Figure kpo00119

Figure kpo00120
Figure kpo00120

[실시예 36]Example 36

δ-AvaI-Arg-Gly-Phe-Phe-NH2의 제조Preparation of δ-AvaI-Arg-Gly-Phe-Phe-NH 2

a) Z-δ-Aval-Arg(NO2)-Gly-Phe-Phe-NH2의 제조a) Preparation of Z-δ-Aval-Arg (NO 2 ) -Gly-Phe-Phe-NH 2

실시예 34-e)와 동일한 방법으로, Z-Arg(NO2)-Gly-Phe-Phe-NH20.80g을 HBr-초산으로 처리하여 DMF 10㎖에 용해시켰다. 이 용액을 트리에틸아민으로 중화시켰다. 한편, Z-δ-AvaI-OH0.30g과 HONB 0.24g을 테트라하이드로푸란 5㎖에 용해시켰다. 빙냉시키면서, 여기에 DCC 0.27g을 가하고, 그 혼합물을 30분간 교반했다. 디사이클로헥실우레 아를 여거하고 이 여액을 상기의 아민성분[H-δ-Aval-Arg(NO2)-Gly-Phe-Phe-NH2]에 가한 다음에 철야 교반했다. 용매를 감압하에서 유거하고 물을 가했다. 생성되는 분말을 여과하여 회수하고 충분히 건조시켰다. 초산에틸로 세척하고 DMF-초산에틸로 재침전시켰다. 수량 0.62g(70%), 융점 154∼157℃.

Figure kpo00121
In the same manner as in Example 34-e), 0.80 g of Z-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 was treated with HBr-acetic acid and dissolved in 10 ml of DMF. This solution was neutralized with triethylamine. On the other hand, 0.30 g of Z-δ-AvaI-OH and 0.24 g of HONB were dissolved in 5 ml of tetrahydrofuran. While cooling with ice, 0.27 g of DCC was added thereto, and the mixture was stirred for 30 minutes. The dicyclohexyl urea was removed and the filtrate was added to the amine component [H-δ-Aval-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 ], followed by stirring overnight. The solvent was distilled off under reduced pressure and water was added. The resulting powder was collected by filtration and dried sufficiently. Washed with ethyl acetate and reprecipitated with DMF-ethyl acetate. Yield 0.62 g (70%), melting point 154-157 degreeC.
Figure kpo00121

Figure kpo00122
Figure kpo00122

b) δ-Aval-Arg-Gly-Phe-Phe-NH2의 제조b) Preparation of δ-Aval-Arg-Gly-Phe-Phe-NH 2

초산 30㎖에 Z-Aval-Arg(NO2)-Gly-Phe-Phe-NH2500㎎을 용해시키고 촉매로서 Pd를 사용하여 5시간동안 접촉 환원을 행했다. 촉매를 여거한 후에, 용매를 감압하에서 유거했다. 잔사를 카아복시메틸-세파덱스(1.8㎝×9㎝)의 컬럼에 통과시키고 선형 구배 경사법이 의하여 0.1N 초산암모늄수용액(500㎖)으로부터 1N 초산암모늄 수용액(500㎖)을 통과시켜 용출을 행했다. 290∼370㎖의 분획을 모아 동경건조했다. 수량 290㎎(61%,

Figure kpo00123
500 mg of Z-Aval-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 5 hours using Pd as a catalyst. After filtering off the catalyst, the solvent was distilled off under reduced pressure. The residue was passed through a column of carboxymethyl-sepadex (1.8 cm x 9 cm) and eluted by passing a 1 N ammonium acetate solution (500 ml) from a 0.1 N ammonium acetate solution (500 ml) by a linear gradient gradient method. . Fractions of 290-370 ml were collected and dried in Tokyo. Quantity 290 mg (61%,
Figure kpo00123

Figure kpo00124
Figure kpo00124

(2), 펩티드 함량 : 81.4%(2), peptide content: 81.4%

[실시예 37]Example 37

ε-Acap-Arg-Gly-Phe-Phe-NH2의 제조Preparation of ε-Acap-Arg-Gly-Phe-Phe-NH 2

a) Z-ε-Acap-Arg(NO2)-Gly-Phe-Phe-NH2의 제조a) Preparation of Z-ε-Acap-Arg (NO 2 ) -Gly-Phe-Phe-NH 2

실시예 34-e)와 동일한 방법으, Z-Arg(NO2)-Gly-Phe-Phe-NH20.80g을 HBr-초산으로 처리하여 DMF10㎖에 용해시켰다. 이 용액을 트리에틸아민으로 중화시켰다. 한편, Z-ε-Acap-OH0.32g과 HONB 0.24g을 테트라하이드로푸란 5㎖에 용해시키고, 빙냉하에 DCC 0.27g을 가했다. 혼합물을 3시간 동안 교반하여 형성된 디사이클로 헥실우레아를 여거하고 이 여액을 상기 아민 성분[H-Arg(NO2)-Gly-Phe-Phe-NH2]에 가했다. 이 혼합물을 철야 교반했다. 용매를 감압하에서 유거하고 물을 가했다. 생성되는 분말을 여과희수하고 충분히 건조시켰다. 그 다음에 초산에틸로 세척하고, DMF-초산에틸로 재결정시켰다. 수량 0.49g(55%), 융점 102∼104℃

Figure kpo00125
In the same manner as in Example 34-e), 0.80 g of Z-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 was treated with HBr-acetic acid and dissolved in 10 ml of DMF. This solution was neutralized with triethylamine. On the other hand, 0.32 g of Z-ε-Acap-OH and 0.24 g of HONB were dissolved in 5 ml of tetrahydrofuran, and 0.27 g of DCC was added under ice cooling. The mixture was stirred for 3 hours to distill off the dicyclo hexylurea formed and add this filtrate to the amine component [H-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 ]. The mixture was stirred overnight. The solvent was distilled off under reduced pressure and water was added. The resulting powder was filtered off and dried sufficiently. Then washed with ethyl acetate and recrystallized with DMF-ethyl acetate. 0.49 g (55%), melting point 102-104 ° C
Figure kpo00125

Figure kpo00126
Figure kpo00126

b) ε-Acap-Arg-Gly-Phe-Phe-NH2의 제조b) Preparation of ε-Acap-Arg-Gly-Phe-Phe-NH 2

초산 30㎖에 Z-ε-Acap-Arg(NO2)-Gly-Phe-Phe-NH2400㎎을 용해시키고, 촉매 로서 Pd를 사용하여 7시간 동안 접촉환원을 행했다. 촉매를 여거하고 용매를 감압하에서 유거했다. 이 잔사를 카아복시메틸-세파덱스의 컬럼(1.8㎝×10㎝)에 통과시킨 다음 선형 구배 경사법에 의하여 0.1N 초산암모늄 수용액(500㎖)으로부터 1N 초산암모늄 수용액(500㎖)을 통과시켜 용출을 행했다. 250∼330㎖의 분획을 모아 동결건조시켰다. 수량 200㎎(51%),

Figure kpo00127
400 mg of Z-ε-Acap-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 7 hours using Pd as a catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. This residue was passed through a column of carboxymethyl-sefadex (1.8 cm × 10 cm), and then eluted by passing a 1 N ammonium acetate solution (500 mL) from a 0.1 N ammonium acetate solution (500 mL) by a linear gradient gradient method. Done. 250-330 ml of fractions were combined and lyophilized. 200 mg (51%)
Figure kpo00127

Figure kpo00128
Figure kpo00128

[실시예 38]Example 38

Lys-Arg-Gly-Phe-Phe-NH2의 제조Preparation of Lys-Arg-Gly-Phe-Phe-NH 2

a) Di-Z-Lys-Arg(NO2)-Gly-Phe-Phe-NH2의 제조a) Preparation of Di-Z-Lys-Arg (NO 2 ) -Gly-Phe-Phe-NH 2

실시예 34-e)와 동일한 방법으로, Z-Arg(NO2)-Gly-Phe-Phe-NH20.80g을 HBr-초산으로 처리하여 DMF10㎖에 용해시켰다. 이 용액을 트리에틸아민으로 중화시켰다.In the same manner as in Example 34-e), 0.80 g of Z-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 was treated with HBr-acetic acid and dissolved in 10 ml of DMF. This solution was neutralized with triethylamine.

한편, di-Z-Lys-OH 0.54g과 HONB 0.26g을 테트라하이드로푸란 5㎖에 용해시키고, 빙냉하면서 DCC0.30g을 가했다. 이 혼합물을 4시간 동안 교반하고 생성되는 디사이클로헥실우레아를 여거했다. 여액을 상기 아민성분[H-Arg(NO2)-Gly-Phe-Phe-NH2]에 첨가한 다음 철야 교반했다. 용매를 감압하에서 유거하고, 그 잔사에 물을 가했다. 생성되는 분말을 여과회수하고 충분히 건조시켰다. 그 다음에 초산에틸로 세척하고, 이어서 DMF-초산에틸로 재침전시켰다. 수량 0.82g(77%), 융점 200∼204℃(분해),On the other hand, 0.54 g of di-Z-Lys-OH and 0.26 g of HONB were dissolved in 5 ml of tetrahydrofuran, and 0.30 g of DCC was added while cooling with ice. The mixture was stirred for 4 hours and the resulting dicyclohexylurea was filtered off. The filtrate was added to the amine component [H-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 ] and then stirred overnight. The solvent was distilled off under reduced pressure, and water was added to the residue. The resulting powder was collected by filtration and dried sufficiently. It was then washed with ethyl acetate and then reprecipitated with DMF-ethyl acetate. Yield 0.82 g (77%), melting point 200-204 ° C (decomposition),

Figure kpo00129
Figure kpo00129

b) Lys-Arg-Gly-Phe-Phe-NH2의 제조b) Preparation of Lys-Arg-Gly-Phe-Phe-NH 2

초산 30㎖에 di-Z-Lys-Arg(NO2)-Gly-Phe-Phe-NH2600㎎을 용해시키고, 촉매 로서 Pd를 사용하여, 6시간 동안 접촉환원을 행했다. 촉매를 여거하고 용매를 감압하에서 유거했다. 잔사를 카아복시메틸 세파덱스의 컬럼(1.5㎝×11㎝)에 통과시키고 선형 구배 경사법에 의해 0.1N 초산 암모늄 수용액(700㎖)으로부터 1N 초산암모늄 수용액(700㎖)을 통과시켜 용출을 행했다. 650∼760㎖의 분획을 모아 동결건조했다. 수량 280㎎(52%),

Figure kpo00130
600 mg of di-Z-Lys-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 6 hours using Pd as a catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was passed through a column of carboxymethyl sefadex (1.5 cm x 11 cm) and eluted by passing a 1 N ammonium acetate solution (700 mL) from a 0.1 N ammonium acetate solution (700 mL) by a linear gradient gradient method. 650-760 mL of fractions were combined and lyophilized. Yield 280 mg (52%),
Figure kpo00130

Figure kpo00131
Figure kpo00131

[실시예 39]Example 39

α,γ-Dab-Arg-Gly-Phe-Phe-NH2의 제조Preparation of α, γ-Dab-Arg-Gly-Phe-Phe-NH 2

a) di-A-Dab-Arg(NO2)-Gly-Phe-Phe-NH2의 제조a) Preparation of di-A-Dab-Arg (NO 2 ) -Gly-Phe-Phe-NH 2

실시예 34-e)와 동일한 방법으로, Z-Arg(NO2)-Gly-Phe-Phe-NH20.80g을 HBr-초꺼으로 처리하여 DMF10㎎에 용해시켰다. 이 용액을 트리에틸아민으로 중화시겼다. 한편 di-Z-α,γ-Dab-OH0.50g 및 HONB0.26g을 테트라하이드로푸탄 5㎎에 용해시키고, 빙냉시키면서, DCC0.30g을 가했다. 이 혼합물을 4시간동안 교반하고 형성된 디사이클로헥실우레아를 여거했다.In the same manner as in Example 34-e), 0.80 g of Z-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 was treated with HBr-dissolved to dissolve in DMF10 mg. This solution was neutralized with triethylamine. On the other hand, 0.50 g of di-Z-α, γ-Dab-OH and 0.26 g of HONB were dissolved in 5 mg of tetrahydrobutane, and 0.30 g of DCC was added while ice-cooling. The mixture was stirred for 4 hours and the dicyclohexylurea formed was filtered off.

여액을 상기 아민성분 H-Arg(NO2)-Gly-Phe-Phe-NH2에 가하여 이 혼합물을 철야 교반했다. 용매를 감압하에서 유거하고 잔사에 물을 가했다. 생성되는 분말을 여과 회수하고 충분히 건조시켰다. 이 분말을 초산에틸로 세척하고 DMF-초산에틸로 재침전시켰다. 수량 0.82g(78%), 융점 184∼188℃.The filtrate was added to the amine component H-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 , and the mixture was stirred overnight. The solvent was distilled off under reduced pressure and water was added to the residue. The resulting powder was collected by filtration and dried sufficiently. The powder was washed with ethyl acetate and reprecipitated with DMF-ethyl acetate. Yield 0.82 g (78%), melting point 184-188 degreeC.

Figure kpo00132
Figure kpo00132

b) α,γ-Dab-Arg-Gly-Phe-Phe-NH2의 제조b) Preparation of α, γ-Dab-Arg-Gly-Phe-Phe-NH 2

초산 30㎖에 Di-Z-α,γ-Dab-Arg(NO2)-Gly-Phe-Phe-NH2600㎎을 용해시키고, 촉매로서 Pd를 사용하여 6시간 동안 접촉환원을 행했다. 촉매를 여거하고 용매를 감압하에서 유거했다. 이 잔사를 카아복시메틸-세파덱스의 컬럼(1.5㎝×13㎝)에 통과시키고, 선형 구배 경사법에 의하여 0.1N 초산암모늄 수용액(700㎖)으로부터 1N 초산암모늄 수용액(700㎖)을 통과시켜 용출을 행했다. 610∼680㎖의 분획을 모아 동결건조했다. 수량 255㎎(46%),

Figure kpo00133
600 mg of Di-Z-α, γ-Dab-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 6 hours using Pd as a catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was passed through a column of carboxymethyl-sefadex (1.5 cm x 13 cm) and eluted by passing 1 N ammonium acetate solution (700 mL) from 0.1 N ammonium acetate solution (700 mL) by linear gradient gradient method. Done. 610-680 mL of fractions were combined and lyophilized. Yield 255 mg (46%),
Figure kpo00133

Figure kpo00134
Figure kpo00134

[실시예 40]Example 40

Arg-Arg-Gly-Phe-Phe-NH2의 제조Preparation of Arg-Arg-Gly-Phe-Phe-NH 2

a) Z-Arg(NO2)-Arg(NO2)-Gly-Phe-Phe-NH2의 제조a) Preparation of Z-Arg (NO 2 ) -Arg (NO 2 ) -Gly-Phe-Phe-NH 2

실시예 34-e)와 동일한 방법으로, Z-Arg(NO2)-Gly-Phe-Phe-NH20.80g을 HBr-초산으로 처리하여 DMF10㎖에 용해시켰다. 이 용액을 트리에틸아민으로 중화시켰다. 이 용액을 트리에틸아민으로 중화시켰다. 한편 Z-Arg(NO2)-OH 0.39g과 2,4-디니트로페놀 0.22g을 테트라하이드로푸란 5㎖에 용해시키고 빙냉시키면서, DCC 0.25g을 가했다. 이 혼합물을 2시간 동안 교반하고 형성된 디사이클로헥실우레아를 여거했다. 이 여액을 상기의 아민성분[H-Arg(NO2)-Gly-Phe-Phe-NH2]에 가한 다음에 철야 교반했다. 용매를 감압하에 유거 하고 잔사에 물을 가했다. 유상 생성물로 충분히 세척하고, DMF-초산에틸로 재침전시켰다. 수량 0.90g(89%), 융점 89∼92℃,

Figure kpo00135
In the same manner as in Example 34-e), 0.80 g of Z-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 was treated with HBr-acetic acid and dissolved in 10 ml of DMF. This solution was neutralized with triethylamine. This solution was neutralized with triethylamine. On the other hand, 0.39 g of Z-Arg (NO 2 ) -OH and 0.22 g of 2,4-dinitrophenol were dissolved in 5 ml of tetrahydrofuran, and 0.25 g of DCC was added while ice-cooling. The mixture was stirred for 2 hours and the dicyclohexylurea formed was filtered off. This filtrate was added to the amine component [H-Arg (NO 2 ) -Gly-Phe-Phe-NH 2 ], followed by stirring overnight. The solvent was distilled off under reduced pressure and water was added to the residue. Washed sufficiently with oily product and reprecipitated with DMF-ethyl acetate. 0.90 g (89%), melting point 89-92 deg.
Figure kpo00135

Figure kpo00136
Figure kpo00136

b) Arg-Arg-Gly-Phe-Phe-NH2의 제조b) Preparation of Arg-Arg-Gly-Phe-Phe-NH 2

초산 40㎖에 Z-Arg(NO2)-Arg(NO2)-Gly-Phe-Phe-NH2700㎎을 용해시키고, 촉매로서 Pd를 사용하여 9시간 동안 촉매환원을 행했다. 촉매를 여거하고 용매를 감압하에서 유거했다. 잔사를 카아복시메틸-셀룰로오즈의 컬럼(3㎝×18㎝)에 통과시키고 0.005N 초산암모늄 수용액(1ℓ)으로부터 0.3N 초산암모늄수용액(1ℓ)을 통과시켜 용출을 행했다. 890∼1,410㎖의 용출 분획을 모아 동결건조시켰다. 수량 380㎎(45%),

Figure kpo00137
700 mg of Z-Arg (NO 2 ) -Arg (NO 2 ) -Gly-Phe-Phe-NH 2 was dissolved in 40 ml of acetic acid, and catalytic reduction was performed for 9 hours using Pd as a catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was passed through a column of carboxymethyl-cellulose (3 cm x 18 cm) and eluted by passing 0.3 N ammonium acetate aqueous solution (1 L) from 0.005 N aqueous ammonium acetate solution (1 L). Elution fractions of 890-1,410 ml were collected and lyophilized. Yield 380 mg (45%),
Figure kpo00137

Figure kpo00138
Figure kpo00138

[실시예 41]Example 41

β-Ala-Arg-Gly-Phe-Phe-Tyr-NH2의 제조Preparation of β-Ala-Arg-Gly-Phe-Phe-Tyr-NH 2

a) Z-β-Ala-Arg(NO2)-Gly-OEt의 제조a) Preparation of Z-β-Ala-Arg (NO 2 ) -Gly-OEt

Z-Arg(NO2)-Gly-OEt 26.3g에 25% HBr-초산 130㎖를 가하고 실온에서 60분간 교반한후에, 에틸에테르를 가했다. 이 침전물을 여과 회수하고 수산화나트륨으로 건조시켰다. 그 다음에 건조된 침전물을 DMF150㎖에 용해시켜서 빙냉시킨 후에 이 용액을 트리에틸아민으로 중화시켰다. 그 후에 Z-β-Ala-ONB 23.1g을 가하고, 이 혼합물을 철야 교반했다. 용매를 감압하에서 유거하고 이 잔사를 소량의 n-부타놀을 함유하는 초산에틸 300㎖에 용해시켰다. 이 용액을 물, 탄산수소나트륨의 포화수용액(100㎖×3) 및 염화나트륨의 포화 수용액(100㎖×3)으로 세척한 다음에 무수 황산나트륨으로 건조시켰다. 용매를 감압하에서 유거하고 에틸에테르를 가했다. 생성되는 분말을 여과회수하고 에타놀-초산에틸로부터 재결정시켰다. 수량22.9g(75%), 융점 97∼99℃,

Figure kpo00139
130 ml of 25% HBr-acetic acid was added to 26.3 g of Z-Arg (NO 2 ) -Gly-OEt, and stirred at room temperature for 60 minutes, followed by ethyl ether. This precipitate was collected by filtration and dried over sodium hydroxide. The dried precipitate was then dissolved in 150 ml of DMF and ice cooled before neutralizing the solution with triethylamine. Thereafter, 23.1 g of Z-β-Ala-ONB was added, and the mixture was stirred overnight. The solvent was distilled off under reduced pressure and the residue was dissolved in 300 ml of ethyl acetate containing a small amount of n-butanol. The solution was washed with water, a saturated aqueous solution of sodium bicarbonate (100 mL x 3) and a saturated aqueous solution of sodium chloride (100 mL x 3), and then dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure and ethyl ether was added. The resulting powder was recovered by filtration and recrystallized from ethanol-ethyl acetate. Yield 22.9 g (75%), melting point 97-99 ℃
Figure kpo00139

Figure kpo00140
Figure kpo00140

b) Z-β-Ala-Arg(NO2)-Gly-OH의 제조b) Preparation of Z-β-Ala-Arg (NO 2 ) -Gly-OH

아세톤 50㎖와 물 25㎖와의 혼합물에 Z-β-Ala-Arg(NO2)-Gly-OEt 12.1g을 용해시키고, 빙냉하에 염화나트륨 1N 수산화나트륨 수용액 27.8㎖를 30분에 걸쳐 적가했다. 이 혼합물을 동일한 조건하에서 1시간 동안 교반하고 실온에서 2시간 더 교반한 후, 1N 염산 3.8㎖를 가하고, 아세톤을 감압하에 유거했다. 잔사에 물 50㎖를 가하고 이 혼합물을 6N 염산으로 산성화하여 즉시 고화되는 유상 물질을 얻었다.12.1 g of Z-β-Ala-Arg (NO 2 ) -Gly-OEt was dissolved in a mixture of 50 ml of acetone and 25 ml of water, and 27.8 ml of an aqueous sodium chloride 1N sodium hydroxide solution was added dropwise over 30 minutes under ice-cooling. The mixture was stirred under the same conditions for 1 hour and further stirred at room temperature for 2 hours, and then 3.8 ml of 1N hydrochloric acid was added, and acetone was distilled off under reduced pressure. 50 ml of water was added to the residue, and the mixture was acidified with 6N hydrochloric acid to obtain an oily substance which immediately solidified.

이와같이하여 얻은 고체물질을 여과 수집했다. 수랑 10.3g(86.0%), 융점 101∼103℃,

Figure kpo00141
Figure kpo00142
The solid material thus obtained was collected by filtration. 10.3 g (86.0%) of water, melting point 101-103 deg.
Figure kpo00141
Figure kpo00142

Figure kpo00143
Figure kpo00143

c) Z-Ph-Tyr-OMe의 제조c) preparation of Z-Ph-Tyr-OMe

테트라하이드로푸란 100㎖에 Tyr-OMe HCl 5.10g을 현탁시켜 빙냉시킨 후에, 이 현탁액을 트리에틸아민 3.08㎖로 중화시켰다. 여기에 Z-Phe-OH 5.99g, HONB 3.94g 및DCC 4.54g을 가하고 이 혼합물을 철야 교반했다. 형성된 디사이클로헥실우레아를 여거하고, 용매를 감압하에서 증발시켜 유거했다. 잔사를 초산에틸 200㎖에 용해시키고, 이 용액을 탄산수소나트륨의 포화 수용액(100㎖×3), 1N 염산(100㎖×3) 및 물로 세척한 다음, 무수 황산나트륨으로 건조시켰다. 초산에틸을 감압하에서 유거하고, 석유벤진을 가하여 젤라틴성 잔사를 얻고, 이것을 여과회수하고 초산에틸-석유벤젠으로부터 재침전시켰다. 수량 6.00g(63%), 융점 132∼133℃,

Figure kpo00144
After suspension of ice-cooled by suspending 5.10 g of Tyr-OMe HCl in 100 mL of tetrahydrofuran, the suspension was neutralized with 3.08 mL of triethylamine. 5.99 g of Z-Phe-OH, 3.94 g of HONB, and 4.54 g of DCC were added thereto, and the mixture was stirred overnight. The formed dicyclohexyl urea was filtered off and the solvent was distilled off by evaporation under reduced pressure. The residue was dissolved in 200 ml of ethyl acetate, and the solution was washed with a saturated aqueous solution of sodium hydrogen carbonate (100 ml x 3), 1N hydrochloric acid (100 ml x 3) and water, and then dried over anhydrous sodium sulfate. Ethyl acetate was distilled off under reduced pressure, petroleum benzine was added to obtain a gelatinous residue, which was recovered by filtration and reprecipitated from ethyl acetate-petroleum benzene. Quantity 6.00 g (63%), Melting point 132-133 ° C,
Figure kpo00144

Figure kpo00145
Figure kpo00145

d) Z-Phe-Tyr-NH2의 제조d) preparation of Z-Phe-Tyr-NH 2

암모니아로 포화시킨 메타놀 40㎖에 Z-Phe-Tyr-OMe 3.0g을 용해시켜, 이 용액을 1주일간 밀폐용기 내에 저장하여 침상형 물질을 분리했다. 용매를 감압하에서 증발시킨 후, 에틸에테르를 가하고 생성되는 결정을 여과하여 회수하고 에타놀-물로부터 재결정시켰다. 수량 2.61g(90%), 융점 217∼218℃,Z-Phe-Tyr-OMe 3.0g was dissolved in 40 ml of methanol, saturated with ammonia, and the solution was stored in a closed container for 1 week to separate needle-like material. After evaporation of the solvent under reduced pressure, ethyl ether was added and the resulting crystals were collected by filtration and recrystallized from ethanol-water. Yield 2.61 g (90%), melting point 217-218 ° C,

Figure kpo00146
Figure kpo00146

e) Z-Phe-Phe-Tyr-NH2의 제조e) preparation of Z-Phe-Phe-Tyr-NH 2

Z-Phe-Tyr-NH21.15g에 소량의 아니졸을 가한 다음에 25% HBr-초산 11㎖를 가했다. 실온에서 40분간 교반한 후에, 에틸에테르를 가했다. 생성되는 침전물을 여과회수하고 수산화나트륨으로 건조시켰다. 한편, Z-Phe-OH 0.67g과 HONB 0.45g을 테트라하이드로푸란 5㎖에 용해시키면서 DCC 0.52g을 가했다. 혼합물을 4시간 동안 교반하고 생성되는 디사이클로헥실우레아를 여거했다.A small amount of anisol was added to 1.15 g of Z-Phe-Tyr-NH 2 followed by 11 ml of 25% HBr-acetic acid. After stirring for 40 minutes at room temperature, ethyl ether was added. The resulting precipitate was filtered off and dried over sodium hydroxide. On the other hand, DCC 0.52g was added dissolving 0.67 g of Z-Phe-OH and 0.45 g of HONB in 5 ml of tetrahydrofuran. The mixture was stirred for 4 hours and the resulting dicyclohexylurea was filtered off.

상기 아민 성분[H-Phe-Tyr-NH2]을 DMF 10㎖에 용해시키고 이 용액을 트리에틸아민으로 중화시켰다.The amine component [H-Phe-Tyr-NH 2 ] was dissolved in 10 mL of DMF and the solution was neutralized with triethylamine.

이 용액에 상기 에스테르 용액을 가하고 이 혼합물을 철야 교반했다. 용매를 감압하에서 유거한 다음 여기에 물을 가했다. 생성되는 결정을 여과하여 회수하여 초산에틸로 추출하고 DMF-초산에틸로 재결정했다. 수량 1.01g(74%), 융점 218∼221℃(분해),

Figure kpo00147
The ester solution was added to this solution, and the mixture was stirred overnight. The solvent was distilled off under reduced pressure and then water was added thereto. The resulting crystals were collected by filtration, extracted with ethyl acetate and recrystallized with DMF-ethyl acetate. Yield 1.01 g (74%), melting point 218-221 ° C (decomposition),
Figure kpo00147

Figure kpo00148
Figure kpo00148

f) Z-β-Ala-Arg(NO2)-Gly-Phe-Phe-Tyr-NH2의 제조f) Preparation of Z-β-Ala-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-NH 2

메타놀 30㎖와 DMF 20㎖와의 혼합물에 Z-Phe-Phe-Tyr-NH20.91g을 현탁시키고 7시간 동안 촉매환원을 행했다. 메타놀을 감압하에서 유거했다. 한편, Z-β-Ala-Arg-(NO2)-Gly-OH 0.72g과 HONB 0.32g을 DMF 5㎖에 용해시키고, 빙냉하면서 DCC 0.37g을 가했다. 이 혼합물을 6시간 동안 교반하여 생생된 디사이클로헥실우레아를 여거했다. 이 여액을 상기 아민 성분 [H-Phe-Phe-Tyr-NH2]에 가한 다음 철야 교반했다. 용매를 감압하에서 유거하여 고체물질을 얻고 이것을 물로 적정했다. 생성되는 분말을 여과 회수하고 DMF-초산에틸로부터 재침전시켰다.0.91 g of Z-Phe-Phe-Tyr-NH 2 was suspended in a mixture of 30 ml of methanol and 20 ml of DMF, followed by catalytic reduction for 7 hours. Methanol was distilled off under reduced pressure. On the other hand, 0.72 g of Z-β-Ala-Arg- (NO 2 ) -Gly-OH and 0.32 g of HONB were dissolved in 5 ml of DMF, and 0.37 g of DCC was added while ice-cooling. The mixture was stirred for 6 hours to remove vivid dicyclohexylurea. This filtrate was added to the amine component [H-Phe-Phe-Tyr-NH 2 ], followed by stirring overnight. The solvent was distilled off under reduced pressure to obtain a solid material which was titrated with water. The resulting powder was collected by filtration and reprecipitated from DMF-ethyl acetate.

수량 0.88g(62%), 융점 174∼177℃,

Figure kpo00149
Yield 0.88 g (62%), melting point 174-177 degreeC,
Figure kpo00149

Figure kpo00150
Figure kpo00150

g) β-Ala-Arg-Gly-Phe-Phe-Tyr-NH2의 제조g) Preparation of β-Ala-Arg-Gly-Phe-Phe-Tyr-NH 2

초산 30㎖에 Z-β-Ala-Arg(NO2)-Gly-Phe-Phe-Tyr-NH2740㎎을 용해시키고 촉매로서 Pd를 사용하여 7시간 동안 접촉환원을 행했다. 촉매를 여거하고, 용매를 감압하에서 유거했다. 잔사를 카아복시메틸-세파덱스의 컬럼(1.6㎝×15㎝)에 통과시키고 선형 구배 경사법에 의하여 0.005N 초산 암모늄의 수용액(700㎖)으로부터 1N 초산암모늄의 수용액(700㎖)을 통과시켜 용출을 행했다. 580∼790㎖의 용출 분획을 모아서 동결건조했다. 수량 540㎎(75%),

Figure kpo00151
740 mg of Z-β-Ala-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-NH 2 was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 7 hours using Pd as a catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was passed through a column of carboxymethyl-sepadex (1.6 cm x 15 cm) and eluted by passing through an aqueous solution of 1 N ammonium acetate (700 mL) from an aqueous solution of 0.005 N ammonium acetate (700 mL) by linear gradient gradient method. Done. Elution fractions of 580-790 mL were collected and lyophilized. 540 mg (75%),
Figure kpo00151

Figure kpo00152
Figure kpo00152

h) β-Ala-Arg-Gly-Phe-Phe-Tyr-NH2의 제조h) Preparation of β-Ala-Arg-Gly-Phe-Phe-Tyr-NH 2

β-Ala-Arg-Gly-Phe-Phe-Tyr-NH2·2 초산염 트리하이드레이트(9.33g)를 물 20㎖에 용해시키고, 이 용액에 구연산 모노하이드레이트 2.2g을 교반하면서 가했다. 생성된 결정질 침전물을 여과 수집하고 소량의 냉수로 세척하여 대응하는 2구연산염 10.4g을 얻었다.

Figure kpo00153
β-Ala-Arg-Gly- Phe-Phe-Tyr-NH 2 · 2 was dissolved nitrate trihydrate (9.33g) in water 20㎖, was added with stirring to 2.2g of citric acid monohydrate to the solution. The resulting crystalline precipitate was collected by filtration and washed with a small amount of cold water to obtain 10.4 g of the corresponding dicitramate.
Figure kpo00153

Figure kpo00154
Figure kpo00154

[실시예 42]Example 42

γ-Abu-Arg-Gly-Phe-Phe-Tyr-NH2의 제조Preparation of γ-Abu-Arg-Gly-Phe-Phe-Tyr-NH 2

a) Z-γ-Abu-Arg(NO2)-Gly-OEt의 제조a) Preparation of Z-γ-Abu-Arg (NO 2 ) -Gly-OEt

Z-Arg(NO2)-Gly-OEt 4.38g에 25% HBr-초산 40㎖를 가하고, 실온에서 30분간 교반한 후에, 에틸 에테르를 가했다. 생성되는 침전을 여과회수한 다음 수산화나트륨으로 건조시켰다.40 ml of 25% HBr-acetic acid was added to 4.38 g of Z-Arg (NO 2 ) -Gly-OEt, and stirred at room temperature for 30 minutes, followed by ethyl ether. The resulting precipitate was filtered off and dried over sodium hydroxide.

그 다음에, DMF 30㎖를 가하여 빙냉시킨 후에, 이 용액을 트리에틸아민으로 중화시켰다.Then, 30 ml of DMF was added thereto, followed by ice cooling, and the solution was neutralized with triethylamine.

이 용액에 Z-γ-Abu-ONB 4.16g을 가하고 이 혼합물을 철야 교반했다. 용매를 감압하에서 유가하고, 물을 이 잔사에 가했다. 물을 경사법에 의하여 제거하고, 에틸에테르를 잔사에 가하여 잔사를 고화시켰다.4.16 g of Z-γ-Abu-ONB was added to this solution, and the mixture was stirred overnight. The solvent was fed under reduced pressure, and water was added to this residue. Water was removed by decantation and ethyl ether was added to the residue to solidify the residue.

그 다음에, 이것을 여과회수하고 아세토니트릴로부터 재침전시켰다.This was then filtered off and reprecipitated from acetonitrile.

수량 2.5g(48%), 융점 60∼62℃,

Figure kpo00155
Yield 2.5 g (48%), melting point 60-62 ° C,
Figure kpo00155

Figure kpo00156
Figure kpo00156

b) Z-γ-Abu-Arg(NO2)-Gly-OH의 제조b) Preparation of Z-γ-Abu-Arg (NO 2 ) -Gly-OH

아세톤 20㎖에 Z-γ-Abu-Arg(NO2)-Gly-OEt 2.0g을 용해시키고, 빙냉하면서, 1N 수산화나트륨의 수용액 5.7㎖를 가했다. 이 혼합물을 실온에서 2시간 동안 교반한 다음에 1N 염산 6㎖를 가하고, 이어서 아세톤을 감압하에서 유거했다. 생성되는 결정을 여과회수하고 에타놀-물로 부터 재결정시켰다.2.0 g of Z-γ-Abu-Arg (NO 2 ) -Gly-OEt was dissolved in 20 ml of acetone, and 5.7 ml of an aqueous solution of 1N sodium hydroxide was added while cooling with ice. The mixture was stirred at room temperature for 2 hours, then 6 ml of 1N hydrochloric acid was added, and then the acetone was distilled off under reduced pressure. The resulting crystals were filtered off and recrystallized from ethanol-water.

수량 1.86g(98%), 융점 113∼115℃,

Figure kpo00157
Yield 1.86 g (98%), melting point 113-115 ° C,
Figure kpo00157

Figure kpo00158
Figure kpo00158

c) Z-γ-Abu-Arg(NO2)-Gly-Phe-Phe-Tyr-NH2의 제조c) Preparation of Z-γ-Abu-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-NH 2

Z-Phe-Phe-Tyr-NH21.34g에 소량의 아니졸을 가한 다음에 25% HBr-초산 13㎖를 가했다.A small amount of anisol was added to 1.34 g of Z-Phe-Phe-Tyr-NH 2 followed by 13 ml of 25% HBr-acetic acid.

실온에서 45분간 진탕시킨 후에, 에틸에테르를 가하고 생성되는 침전을 여과희수하고 수산화나트륨으로 건조시켰다. 한편, Z-γ-Abu-Arg(NO2)-Gly-OH 0.99g과 HONB 0.43g을 DMF 5㎖에 용해시키고, 빙냉하에 DCC 0.50g을 가했다. 이 혼합물을 6시간 동안 교반하고 디사이클로헥실 우레아를 여거했다. 상기 아민 성분 [H-Phe-Phe-Tyr-NH2]을 DMF 10㎖에 용해시키고 이 용액을 트리에틸아민으로 중화시켰다.After shaking for 45 minutes at room temperature, ethyl ether was added and the resulting precipitate was filtered off and dried over sodium hydroxide. On the other hand, 0.99 g of Z-γ-Abu-Arg (NO 2 ) -Gly-OH and 0.43 g of HONB were dissolved in 5 mL of DMF, and 0.50 g of DCC was added under ice-cooling. The mixture was stirred for 6 hours and the dicyclohexyl urea was filtered off. The amine component [H-Phe-Phe-Tyr-NH 2 ] was dissolved in 10 mL of DMF and the solution was neutralized with triethylamine.

이 용액에 상기의 활성에스테르 용액을 가하고 이 혼합물을 제거했다. 생성되는 분말을 여과회수하여 초산에틸로 세척하고, DMF-초산에틸로 재침전시켰다.The above active ester solution was added to this solution to remove this mixture. The resulting powder was collected by filtration, washed with ethyl acetate and reprecipitated with DMF-ethyl acetate.

수량 1.12g(58%), 융점 139.5∼141℃,

Figure kpo00159
Yield 1.12 g (58%), melting point 139.5-141 ° C,
Figure kpo00159

Figure kpo00160
Figure kpo00160

Figure kpo00161
Figure kpo00161

d) γ-Abu-Arg-Gly-Phe-Phe-Tyr-NH2의 제조d) preparation of γ-Abu-Arg-Gly-Phe-Phe-Tyr-NH 2

초산 30㎖에 Z-γ-Abu-Arg(NO2)-Gly-Phe-Phe-Tyr-NH2800㎎을 용해시키고, 촉매로서 Pd를 사용하여 14시간 동안 접촉환원을 행했다. 촉매를 여거하고 용매를 감압하에서 유거했다. 자사를 카아복시메틸-세파덱스의 컬럼(1.5㎝×10㎝)에 통과시키고 경사 용출법에 의하여 0.1N 초산암모늄의 수용액(700㎖)으로부터 1N 초산암모늄의 수용액(700㎖)을 통과시켜 용출을 행했다. 410∼600㎖의 용출분획을 모아서 동결 건조시켰다. 수량 412㎖ (52%),

Figure kpo00162
800 mg of Z-γ-Abu-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-NH 2 was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 14 hours using Pd as a catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The solution was passed through a column of carboxymethyl-sefadex (1.5 cm × 10 cm) and passed through an aqueous solution of 1 N ammonium acetate (700 ml) from an aqueous solution of 0.1 N ammonium acetate (700 ml) by a gradient elution method. Done. Elution fractions of 410-600 ml were collected and freeze-dried. Water volume 412ml (52%),
Figure kpo00162

Figure kpo00163
Figure kpo00163

[실시예 43]Example 43

ε-Acap-Arg-Gly-Phe-Phe-Tyr-NH2의 제조Preparation of ε-Acap-Arg-Gly-Phe-Phe-Tyr-NH 2

a) Z-ε-Acap-Arg(NO2)-Gly-OEta) Z-ε-Acap-Arg (NO 2 ) -Gly-OEt

2-Arg(NO2)-GIX-OEt 2.41g에 25% HBr-초산 12㎖를 가하고 실온에서 40분간 진탕시킨후에, 에틸에테르를 가했다. 생성되는 침전물을 여과회수하고 수산화나트륨으로 건조시켰다.To 2.41 g of 2-Arg (NO 2 ) -GIX-OEt, 12 ml of 25% HBr-acetic acid was added and shaken at room temperature for 40 minutes, followed by ethyl ether. The resulting precipitate was filtered off and dried over sodium hydroxide.

한편, Z-ε-Acap-OH 1.33g과 HONB 0.99g을 테트라하이드로푸란 5㎖에 용해시킨 다음 빙냉하면서 DCC1.14g을 가했다.Meanwhile, 1.33 g of Z-ε-Acap-OH and 0.99 g of HONB were dissolved in 5 ml of tetrahydrofuran, and then 1.14 g of DCC was added while cooling with ice.

이 혼합물을 4시간 동안 교반하고 형성된 디사이클로 헥실우레아를 여거했다.The mixture was stirred for 4 hours and the dicyclo hexylurea formed was filtered off.

상기 아민성분을 DMF 10㎖에 용해시키고, 용액을 트리에틸아민으로 중화시킨후에 상기의 활성 에스테르 용액을 가했다. 이 혼합물을 철야교반하고, 용매를 감압하에서 유거했다. 잔사를 초산에틸 50㎖에 용해시키고 이 용액을 물, 탄산수소나트륨의 포화수용액(50㎖×2) 및 물로 세척한 다음, 무수탄산나트륨으로 건조시켰다. 용매를 감압하에서 유거하고 여기에 석유벤진을 가했다. 생성되는 결정을 물-에타놀-초산에틸로 재결정시켰다.The amine component was dissolved in 10 ml of DMF, the solution was neutralized with triethylamine, and then the active ester solution was added. The mixture was stirred overnight and the solvent was distilled off under reduced pressure. The residue was dissolved in 50 ml of ethyl acetate and the solution was washed with water, a saturated aqueous solution of sodium bicarbonate (50 ml x 2) and water, and then dried over anhydrous sodium carbonate. The solvent was distilled off under reduced pressure and petroleum benzine was added thereto. The resulting crystals were recrystallized from water-ethanol-ethyl acetate.

Figure kpo00164
Figure kpo00164

b) Z-ε-Acap-Arg(NO2)-Gly-OH의 제조b) Preparation of Z-ε-Acap-Arg (NO 2 ) -Gly-OH

아세톤 10㎖에 Z-ε-Acap-Arg(NO2)-Gly-OEt 1.8g을 용해시키고, 빙냉하면서 2N 수산화나트륨의 수용액 2.9㎖를 가했다. 이 혼합물을 실온에서 2시간 동안 교반했다.1.8 g of Z-ε-Acap-Arg (NO 2 ) -Gly-OEt was dissolved in 10 ml of acetone, and 2.9 ml of an aqueous solution of 2N sodium hydroxide was added with ice cooling. The mixture was stirred at rt for 2 h.

1N 염산 2.5㎖를 부가한 다음에 아세톤을 감압하에서 유거했다. 잔사에 물 10㎖를 가하고 불용물을 여거했다. 이 여액을 1N 염산으로 산성으로 하여 생성되는 결정을 제거했다. 이들 결정을 여과회수했다.2.5 ml of 1N hydrochloric acid was added, and then acetone was distilled off under reduced pressure. 10 ml of water was added to the residue, and the insoluble matter was filtered off. The filtrate was acidified with 1N hydrochloric acid to remove crystals formed. These crystals were recovered by filtration.

Figure kpo00165
Figure kpo00165

Figure kpo00166
Figure kpo00166

c) Z-ε-Acap-Arg(NO2)-Gly-Phe-Phe-Tyr-NH2의 제조c) Preparation of Z-ε-Acap-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-NH 2

Z-Phe-Phe-Tyr-NH21.22g에 소량의 아니졸을 가하고 이어서 25% HBr-초산 10㎖를 가했다. 이 혼합물을 실온에서 40분간 진탕시키고, 여기에 에틸에테르를 가했다. 침전물을 여과 회수하고 수산화나트륨으로 건조시켰다. 한편, Z-ε-Acap-Arg(NO2)-Gly-OH 1.05g과 HONB 0.36g을 DMF 10㎖에 용해시키고, 물로 냉각하면서, 여기에 DCC 0.42g을 가했다. 이 혼합물을 6시간 동안 교반하여 부산물인 디사이클로헥실우레아를 여거했다.A small amount of anisole was added to 1.22 g of Z-Phe-Phe-Tyr-NH 2 followed by 10 ml of 25% HBr-acetic acid. The mixture was shaken for 40 minutes at room temperature, and ethyl ether was added thereto. The precipitate was collected by filtration and dried over sodium hydroxide. On the other hand, 1.05 g of Z-ε-Acap-Arg (NO 2 ) -Gly-OH and 0.36 g of HONB were dissolved in 10 ml of DMF, and 0.42 g of DCC was added thereto while cooling with water. The mixture was stirred for 6 hours to filter off byproduct dicyclohexylurea.

상기 아민성분을 DMF 10㎖에 용해시켜 이 용액을 트리에틸아민으로 중화시켰다.The amine component was dissolved in 10 ml of DMF to neutralize this solution with triethylamine.

이 용액에 상기 활성 에스테르 용액을 가하고 이 혼합물을 철야 교반했다. 용매를 감압하에서 유거하고 물을 가했다. 생성되는 분말을 여과회수하여 초산에틸로 세척하고, DMF-초산에틸로 재침전시켰다.The active ester solution was added to this solution, and the mixture was stirred overnight. The solvent was distilled off under reduced pressure and water was added. The resulting powder was collected by filtration, washed with ethyl acetate and reprecipitated with DMF-ethyl acetate.

Figure kpo00167
Figure kpo00167

d) ε-Acap-Arg-Gly-Phe-Phe-Tyr-NH2의 제조d) Preparation of ε-Acap-Arg-Gly-Phe-Phe-Tyr-NH 2

초산 40㎖에 Z-ε-Acap-Arg(NO2)-Gly-Phe-Phe-Tyr-NH2700㎖을 용해시키고 촉매로서 Pd를 사용하여 14시간 동안 접촉환원을 행했다. 촉매를 여거하고 용매를 감압하에서 유거했다. 잔사를 카아복시메틸-세파덱스(1.8㎝×12㎝)의 컬럼에 통과시키고 선형 구배 경사법에 의하여 0.1N 초산암모늄의 수용액(700㎖)으로부터 1N초산 암모늄의 수용액(700㎖)을 통과시켜 용출을 행하여 430∼550㎖을 용출분획을 모아서 동결건조시켰다. 수량 430㎎ (62%),

Figure kpo00168
700 ml of Z-ε-Acap-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-NH 2 was dissolved in 40 ml of acetic acid, and catalytic reduction was performed for 14 hours using Pd as a catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was passed through a column of carboxymethyl-sepadex (1.8 cm x 12 cm) and eluted by passing through an aqueous solution of ammonium acetate (700 mL) from an aqueous solution of 0.1 N ammonium acetate (700 mL) by linear gradient gradient method. 430-550 ml of the elution fractions were collected and lyophilized. 430 mg (62%),
Figure kpo00168

Figure kpo00169
Figure kpo00169

[실시예 44]Example 44

Lys-Arg-Gly-Phe-Phe-Tyr-NH2의 제조Preparation of Lys-Arg-Gly-Phe-Phe-Tyr-NH 2

a) di-Z-Lys-Arg(NO2)-Gly-OEt의 제조a) Preparation of di-Z-Lys-Arg (NO 2 ) -Gly-OEt

di-Z-Lys-OH 2.07g을 사용하여, 실시예 43-a)와 정확히 동일한 방법을 행하여 겔상의 목적물을 얻었다. 물-에타놀-초산에틸로 재침전시켜 목적물 2.57g(73%)을 얻었다.Using 2.07 g of di-Z-Lys-OH, the same procedure as in Example 43-a) was carried out to obtain a gel target product. Reprecipitation with water-ethanol-ethyl acetate gave 2.57 g (73%) of the title compound.

Figure kpo00170
Figure kpo00170

b) di-Z-Lys-Arg(NO2)-Gly-OH의 제조b) Preparation of di-Z-Lys-Arg (NO 2 ) -Gly-OH

아세톤 10㎖에 di-Z-Lys-Arg(NO2)-Gly-OEt 2.0g을 용해시키고, 빙냉시키면서, 2N 수산화나트륨의 수용액 2.1㎖를 가했다. 이 혼합물을 실온에서 2시간동안 교반했다. 1N 염산 1.4㎖를 가한 다음에, 아세톤을 감압하에서 유거했다. 잔류물을 물 10㎖로 희석하고 불용물을 유거했다. 그 다음에, 이 용액을 1N 염산으로 산성으로 하고 생성되는 젤라틴성 침전물을 여과회수했다.2.0 g of di-Z-Lys-Arg (NO 2 ) -Gly-OEt was dissolved in 10 ml of acetone, and 2.1 ml of an aqueous solution of 2N sodium hydroxide was added while cooling with ice. The mixture was stirred at rt for 2 h. 1.4 ml of 1N hydrochloric acid was added, and then acetone was distilled off under reduced pressure. The residue was diluted with 10 mL of water and the insolubles were distilled off. Then, the solution was made acidic with 1N hydrochloric acid, and the resulting gelatinous precipitate was collected by filtration.

Figure kpo00171
Figure kpo00171

c) di-Z-Lys-Arg(NO2)-Gly-Phe-Phe-Tyr-NH2의 제조c) Preparation of di-Z-Lys-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-NH 2

di-Z-Lys-Arg(NO2)-Gly-OH 1.21g을 사용하여, 실시예 43-c)와 정확히 동일한 방법을 사용하여 겔상의 목적물을 얻었다. 수량.1.21g (58%), 융점 199∼203℃,

Figure kpo00172
Using the same method as Example 43-c), using 1.21 g of di-Z-Lys-Arg (NO 2 ) -Gly-OH, the gelled target product was obtained. Yield 1.21 g (58%), Melting Point 199-203 ° C,
Figure kpo00172

Figure kpo00173
Figure kpo00173

d) Lys-Arg-Gly-Phe-Phe-Tyr-NH2의 제조d) preparation of Lys-Arg-Gly-Phe-Phe-Tyr-NH 2

초산 30㎖에 di-Z-Lys-Arg(NO)2-Gly-Phe-Phe-Tyr-NH21.00g을 용해시키고, 촉매로서 Pd를 사용하여 20시간 동안 접촉환원을 행했다. 촉매를 여거하고 용매를 감압하에서 유거했다. 잔사를 카아복시메틸 세파덱스 컬럼(1.8㎝×10㎝)에 통과시켰다. 선형 구배 경사법에 의하여 0.1N 초산암모늄의 수용액(500㎖)으로부터 1N 초산암모늄의 수용액(500㎖)을 통과시켜 용출을 행하고 650∼890㎖의 용출분획을 모아 동결 건조시켰다. 수량 468㎎ (50%),

Figure kpo00174
1.00 g of di-Z-Lys-Arg (NO) 2 -Gly-Phe-Phe-Tyr-NH 2 was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 20 hours using Pd as a catalyst. The catalyst was filtered off and the solvent was distilled off under reduced pressure. The residue was passed through a carboxymethyl Sephadex column (1.8 cm x 10 cm). Elution was carried out by passing an aqueous solution of 1N ammonium acetate (500 mL) from an aqueous solution of 0.1 N ammonium acetate (500 mL) by a linear gradient gradient method, and the elution fractions of 650-890 mL were collected and freeze-dried. 468 mg (50%),
Figure kpo00174

Figure kpo00175
Figure kpo00175

Figure kpo00176
Figure kpo00176

[실시예 45]Example 45

α,γ-Dab-Arg-Gly-Phe-Phe-Tyr-NH2의 제조Preparation of α, γ-Dab-Arg-Gly-Phe-Phe-Tyr-NH 2

a) di-Z-α,γ-Dab-Arg(NO2)-Gly-OEt 의 제조a) Preparation of di-Z-α, γ-Dab-Arg (NO 2 ) -Gly-OEt

에틸에테르 40㎖에 di-Z-α,γ-Dab-OH·("DCHA"는 디사이클로헥실아민의 약칭임)를 현탁시키고, 이 현탁액을 그 따음에 0.5N 황산으로 흔들어 주었다. 에테르층을 물로 세척하고 무수 황산나트륨으로 건조시켰다. 용매를 유거하고, 실시예 43-a)와 정확히 동일한 방법을 사용하여 겔상의 목적물을 얻었다. 이것을 물-에타놀-초산에틸로부터 재침전시켰다.In 40 ml of ethyl ether, di-Z-α, γ-Dab-OH. ("DCHA" is short for dicyclohexylamine) was suspended. The suspension was then shaken with 0.5 N sulfuric acid. The ether layer was washed with water and dried over anhydrous sodium sulfate. The solvent was distilled off, and the gel target product was obtained using the exact same method as in Example 43-a). This was reprecipitated from water-ethanol-ethyl acetate.

수량 2.36g (70%), 융점 153∼156℃,

Figure kpo00177
Yield 2.36g (70%), Melting Point 153 ~ 156 ℃,
Figure kpo00177

Figure kpo00178
Figure kpo00178

b) di-Z-α,γ-Dab-Arg(NO2)-Gly-OH의 제조b) Preparation of di-Z-α, γ-Dab-Arg (NO 2 ) -Gly-OH

아세톤 30㎖에 di-Z-α,γ-Dab-Arg(NO2)-Gly-OEt 2.0g을 용해시키고 빙냉하에 여기에 2N 수산화나트륨의 수용액 2.97㎖를 적가했다. 이 혼합물을 동일한 조건하에서 1시간 동안 교반하고 1N염산 3㎖를 가했다. 아세톤을 강압하에서 유거하고, 물 10㎖를 가했다. 불용물을 여거하고 여액을 1N 염산으로 산성으로했다. 생성되는 젤라틴성 침전물을 여과회수했다.2.0 g of di-Z-α, γ-Dab-Arg (NO 2 ) -Gly-OEt was dissolved in 30 ml of acetone, and 2.97 ml of an aqueous solution of 2N sodium hydroxide was added dropwise thereto under ice cooling. The mixture was stirred for 1 hour under the same conditions, and 3 ml of 1N hydrochloric acid was added. Acetone was distilled off under reduced pressure, and 10 ml of water was added thereto. The insolubles were filtered off and the filtrate was acidified with 1N hydrochloric acid. The resulting gelatinous precipitate was filtered off.

Figure kpo00179
Figure kpo00179

Figure kpo00180
Figure kpo00180

c) di-Z-α,γ-Dab-Arg(NO2)-Gly-Phe-Phe-Tyr-NH2의 제조c) Preparation of di-Z-α, γ-Dab-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-NH 2

di-Z-α,γ-Dab-Arg(NO2)-Gly-OH 1.12g을 사용하여, 실시예 43-c)와 정확히 동일한 방법을 사용하여 겔상의 목적물을 얻었다. 수량 1.02g (51%), 융점 191∼195℃,

Figure kpo00181
Using 1.12 g of di-Z-α, γ-Dab-Arg (NO 2 ) -Gly-OH, a gelled target product was obtained using the exact same method as in Example 43-c). Yield 1.02g (51%), Melting Point 191-195 ℃,
Figure kpo00181

Figure kpo00182
Figure kpo00182

d) α,γ-Dab-Arg-Gly-Phe-Phe-Tyr-NH2의 제조d) Preparation of α, γ-Dab-Arg-Gly-Phe-Phe-Tyr-NH 2

초산 30㎖에 di-Z-α,γ-Dab-Arg(NO2)-Gly-Phe-Phe-Tyr-NH2600㎎을 용해시키고, 촉매로서 Pd를 사용하여 12시간 동안 접촉환원을 행했다. 촉매를 여가하고 용매를 감압하에서 증발시켜 제거했다. 잔사를 카아복시메틸-세파덱스의 컬럼(1.8㎝×10㎝)에 통과시키고, 선형 구배경사법에 의하여 0.1N초산암모늄의 수용액(500㎖)으로부터 1N 초산암모늄의 수용액(500㎖)을 통과시켜 용출을 행했다. 490∼620㎖의 분획을 모아서 동결건조시켰다.600 mg of di-Z-α, γ-Dab-Arg (NO 2 ) -Gly-Phe-Phe-Tyr-NH 2 was dissolved in 30 ml of acetic acid, and catalytic reduction was performed for 12 hours using Pd as a catalyst. The catalyst was quenched and the solvent was removed by evaporation under reduced pressure. The residue was passed through a column of carboxymethyl-sepadex (1.8 cm × 10 cm), and then passed through an aqueous solution of 0.1 N ammonium acetate (500 mL) by a linear background method (500 mL). Elution was performed. Fractions of 490-620 ml were collected and lyophilized.

Figure kpo00183
Figure kpo00183

아미노산 분석 : Arg, 1.00(1), Dab, 1.04(1), Gly, 1.09(1), Tyr, 1.02(1), Phe, 2.13(2) : 펩티드 함량 : 79%.Amino acid analysis: Arg, 1.00 (1), Dab, 1.04 (1), Gly, 1.09 (1), Tyr, 1.02 (1), Phe, 2.13 (2): Peptide content: 79%.

이하에 본 발명의 실시예에서 본 발명의 폴리펩티드의 치환기 및 아미노산 또는 펩티드 구조식을 기재한다.In the following Examples of the present invention, substituents and amino acid or peptide structural formulas of the polypeptides of the present invention are described.

[실시예의 목록][List of Examples]

R1-Arg-R2-Phe-Phe-R3 R 1 -Arg-R 2 -Phe-Phe-R 3

Figure kpo00184
Figure kpo00184

Figure kpo00185
Figure kpo00185

Figure kpo00186
Figure kpo00186

Figure kpo00187
Figure kpo00187

Claims (1)

하기 일반식(Ⅰ)의 폴리펩티드를 제조함에 있어서, R1에 해당하는 아미노산 자체 또는 R1이 수소인 아르기닌, 또는 N-말단 아미노산으로서 아미노산 잔기 R1자체이거나 또는 N-말단 아미노산으로서, R1이 수소인 아르기닐기를 갖는 폴리펩티드(Ⅰ)의 어느 단편을 폴리펩티드(Ⅰ)의 잔여 단편과 펩티드 축합시키고, 그 축합생성물이 보호기를 갖는 경우에는 그것을 탈리시킴을 특징으로하는 하기 일반식(Ⅰ)로 나타내는 폴리펩티드의 제조법.To this in preparing a polypeptide of formula (Ⅰ), the amino acid corresponding to R 1 itself, or R 1 is a hydrogen arginine, or N- terminal amino acid or amino acid residue R 1 itself or as N- terminal amino acid, R 1 A fragment of the polypeptide (I) having an arginyl group which is hydrogen is peptide condensed with the remaining fragment of the polypeptide (I), and when the condensation product has a protecting group, it is represented by the following general formula (I) Preparation of Polypeptides.
Figure kpo00188
Figure kpo00188
상기 식에 있어서,In the above formula, R1은 수소 또는 염기성 또는 중성인 아미노산 잔기,R 1 is hydrogen or an amino acid residue that is basic or neutral, R2는 중성 아미노산 잔기,R 2 is a neutral amino acid residue, R3은 NH2·Tyr-NH2또는 1∼5개의 아미노산 잔기로 구성된 티로실 펩티드 잔기 또는 그의 티로실 펩티드의 아미드 잔기를 나타내는데, 상기 R1이 수소인 경우에, R2는 Pro이다.R 3 represents NH 2 · Tyr-NH 2 or a tyrosyl peptide residue consisting of 1 to 5 amino acid residues or an amide residue of a tyrosyl peptide thereof, wherein when R 1 is hydrogen, R 2 is Pro.
KR7500656A 1975-03-28 1975-03-28 Process for the preparation of polypeptides KR800000076B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR7500656A KR800000076B1 (en) 1975-03-28 1975-03-28 Process for the preparation of polypeptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR7500656A KR800000076B1 (en) 1975-03-28 1975-03-28 Process for the preparation of polypeptides

Publications (1)

Publication Number Publication Date
KR800000076B1 true KR800000076B1 (en) 1980-01-30

Family

ID=19201067

Family Applications (1)

Application Number Title Priority Date Filing Date
KR7500656A KR800000076B1 (en) 1975-03-28 1975-03-28 Process for the preparation of polypeptides

Country Status (1)

Country Link
KR (1) KR800000076B1 (en)

Similar Documents

Publication Publication Date Title
US4008209A (en) Nonapeptide amide analogs of luteinizing releasing hormone
US3972859A (en) Novel decapeptide amide analogs of leuteinizing hormone-releasing hormone
FI60553B (en) FOERFARANDE FOER FRAMSTAELLNING AV OVULATIONSFRAMKALLANDE NONAPEPTIDAMIDDERIVAT
US4350627A (en) Biologically active peptides
CA1065856A (en) Derivatives of salmon calcitonin
US4277394A (en) Tetrapeptidehydrazide derivatives
JPS62129297A (en) Calcitonin gene related peptide derivative
EP0270376B1 (en) Calcitonin gene-related peptide derivatives
US4237046A (en) Polypeptides and methods of preparation
RU2067000C1 (en) Peptide and a method of its synthesis
DE3780000T2 (en) PEPTIDE COMPOUNDS.
US4001199A (en) Novel polypeptides useful for treating diabetes and hypercholesteremia
DE2112553C3 (en) 1-alpha-aminolsobutyric acid corticotropin peptides, their derivatives, acid addition salts and complexes, and medicinal products
US4559324A (en) Polypeptide-diesters, their production and use
KR800000076B1 (en) Process for the preparation of polypeptides
JPH051798B2 (en)
US4073890A (en) Novel polypeptides
US4358440A (en) Polypeptide and its production and use
US4018754A (en) Novel polypeptides having ACTH-like action
EP0005248B1 (en) Tetrapeptidehydrazide derivatives and process for their preparation
US4159979A (en) Protected amino acids or peptides
DE2534086A1 (en) POLYPEPTIDES WITH EFFECTS SIMILAR TO ACTH, THEIR SALTS AND COMPLEX METHODS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
JPS6136298A (en) Tripeptideamides
US3417072A (en) Intermediates in the synthesis of secretin
FI68245B (en) FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT AKTIVA POLYPEPTIDDERIVAT ELLER SYRAADDITIONSSALTER DAERAV